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Abstract  
Snakebite is a massive global burden and is a neglected area of tropical diseases. Snake venom 
neurotoxins have been the subject of intense research efforts, albeit significantly less is known about 
coagulotoxins. Venoms can deleteriously affect any physiological system reachable by the 
bloodstream, including being able to directly interfere with the coagulation cascade. Such 
coagulopathic toxins may be either anticoagulant or procoagulant and snake venoms are unique in 
their use of procoagulant toxins for predatory purposes. Our limited knowledge into the mechanisms 
of action of snake venom hinders our understanding of the clinical pathologies and also restricts our 
use of these powerful natural products as lead compounds in drug design and development. Two 
snake families which exhibit coagulant properties and lead to a range of clinical pathologies are 
vipers, Viperidae, and non-front-fanged snakes, Colubridae. The primary focus of this thesis was to 
investigate and compare the coagulotoxicity effects and mechanisms of various species of known 
venomous snakes that effect coagulation. Species chosen for this investigation have had limited 
previous research conducted, thus a knowledge gap in the literature remains. These coagulant 
properties were investigated through a multi-disciplinary approach, highlighting key results from both 
families.  
Data chapters 2 and 3 explore venom from the boomslang (Dispholidus typus) and the twig snakes 
(Thelotornis species) - iconic African snakes belonging to the family Colubridae. Both species 
produce strikingly similar lethal procoagulant pathologies. Despite these similarities, antivenom is 
only produced for treating bites by D. typus, and the mechanisms of action of both venoms have been 
understudied. We found that T. mossambicanus produced a significantly stronger coagulation 
response compared to D. typus, governed by strong prothrombin activation through PIII-SVMPs. 
Despite similarities in symptoms and clinical manifestations, venom composition differs widely 
between the two species, recovered from a combined approach of venomics and transcriptomics. The 
neutralising capability of the available boomslang antivenom was also investigated on both species, 
with it being 11.3 times more effective upon D. typus venom than T. mossambicanus.  
Envenomation by Crotalinae such as Asian pit vipers can induce multiple clinical complications 
resulting from coagulopathic and neuropathic effects. Data chapters 4 - 8 investigate the Asian Pit 
Viper clade. While intense research has been undertaken for some species, such as Calloselasma 
rhodostoma, functional coagulopathic effects have been neglected. As these species’ venoms affect 
the blood coagulation cascade and are known to produce haemorrhagic shock in envenomed patients, 
we investigated their effects upon coagulation using venoms of 33 species from the Asian pit viper 
clade including Azemiops, Calloselasma, Deinagkistrodon, Gloydius, Hypnale, Protobothrops, 
Trimeresurus and Tropidolaemus. Fibrinogen was the main coagulation target among these species 
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with many varying coagulotoxic effects exhibited. Various species including Calloselasma 
rhodostoma, Deinagkistrodon acutus, Hypnale hypnale, Protobothrops mangshanensis, Ovophis 
okinavensis and some Trimeresurus species produced net anticoagulant effects through pseudo-
procoagulant clotting of fibrinogen, resulting in weak, unstable, transient fibrin clots. Protobothrops 
flavoviridis, P. tokarensis, Gloydius brevicaudus, G. saxatilis, G. ussuriensis and various 
Trimeresurus species exhibited a strong anticoagulant activity through the destructive cleavage of 
fibrinogen (at varying rates) directly resulting in an overall anticoagulant effect. Tropidolaemus 
wagleri was only weakly pseudo-procoagulant, clotting fibrinogen with only a negligible net 
anticoagulant effect.  Azemiops feae and Tropidolaemus subannulatus did not affect clotting and T. 
subannulatus was investigated for its alternatively derived neurotoxicity effects, sharing Waglerin’s 
peptide propeptide region. Other clotting factors, such as FX(a), thrombin, FIX(a) and FXI(a), were 
only mildly affected with minimal inhibition found from varying species. Cross neutralisation of the 
Green Pit Viper monovalent antivenom ‘Thai Red Cross Green Pit Viper antivenin’ was also 
investigated among the Trimeresurus species, with T. gumprechti, T. hageni and T. mcgregori being 
unaffected. These results indicate that anticoagulation mediated by pseudo-procoagulant cleavage of 
fibrinogen is the basal state among Asian pit vipers, while anticoagulation produced by destructive 
cleavage of fibrinogen, such as that found in Protobothrops, is the derived state. This is the first in 
depth study of its kind highlighting extreme enzymatic variability, functional diversification and 
clotting diversification within one clade (Asian pit vipers) surrounding one target site, governed by 
variability in co-factor dependency. This study is also the first to examine in a phylogenetic context 
the coagulotoxic effects of related genera of Asiatic pit vipers.  
The results of these various chapters reveal substantial variation between sister genera, providing 
crucial information about clinical effects and implications for antivenom cross-reactivity among 
venomous snake species. This study increases our understanding of not only the biodiscovery 
potential of these medically important species but also increases our knowledge of the pathological 
relationship between venom and the human coagulation cascade. These results add to the body of 
knowledge necessary to inform clinical management of the envenomed patient, and detail the 
diversity of components and characteristics which enable venom research to be such a biodiscovery 
treasure trove in unlimited diversity, leading to novel drug design surrounding this field.  
iv 
 
Declaration by author 
This thesis is composed of my original work, and contains no material previously published or written 
by another person except where due reference has been made in the text. I have clearly stated the 
contribution by others to jointly-authored works that I have included in my thesis. 
I have clearly stated the contribution of others to my thesis as a whole, including statistical assistance, 
survey design, data analysis, significant technical procedures, professional editorial advice, financial 
support and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my higher degree by research 
candidature and does not include a substantial part of work that has been submitted to qualify for the 
award of any other degree or diploma in any university or other tertiary institution. I have clearly 
stated which parts of my thesis, if any, have been submitted to qualify for another award. 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the policy and procedures of The University of Queensland, the thesis be made available 
for research and study in accordance with the Copyright Act 1968 unless a period of embargo has 
been approved by the Dean of the Graduate School.  
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the copyright 
holder to reproduce material in this thesis and have sought permission from co-authors for any jointly 
authored works included in the thesis. 
 
v 
 
Publications included in this thesis 
Most chapters of this thesis comprise of manuscripts recently accepted for publication or published 
in peer-reviewed journals. I am the lead author of these papers and am responsible for the 
development of ideas and analyses of data.  
 
Incorporated as Chapter 2: 
Debono, J., Casewell, N.R., Bin, L., Kwok, H.F., Fry, B.G. 2017. Coagulating colubrids: 
Evolutionary, pathophysiological and biodiscovery implications of variations between boomslang 
(Dispholidus typus) and twig snake (Thelotornis mossambicanus) venoms. Toxins, 9(5), p.171. 
Contributor Statement of contribution 
Debono, J. Concept and Design (80%) 
Performed experiments (100%) 
Analysis and Interpretation (100%) 
Drafting and Production (100%) 
Edited paper (10%) 
Casewell, N.R. Edited paper (15%) 
Bin, L. Edited paper (5%) 
Kwok, H.F. Edited paper (10%) 
Fry, B.G. Concept and Design (20%) 
Edited paper (60%) 
 
Incorporated as Chapter 3:  
Debono, J., Dashvesky, D., Nouwens, A., Fry, B.G. 2020. The sweet side of venom: glycosylated 
prothrombin activating metalloproteases from Dispholidus typus (boomslang) and Thelotornis 
mossambicanus (twig snake). Comparative Biochemistry and Physiology Part C: Toxicology & 
Pharmacology, 277, p. 108625.  
Contributor Statement of contribution 
Debono, J. Concept and Design (80%) 
Performed experiments (85%) 
Analysis and Interpretation (65%) 
Drafting and Production (100%) 
Edited paper (40%) 
Dashvesky, D. Analysis and Interpretation (25%) 
Performed experiments (10%)  
Edited paper (30%) 
Nouwens, A. Analysis and Interpretation (5%) 
Performed experiments (5%) 
Fry, B. Analysis and Interpretation (5%) 
Concept and Design (20%) 
Edited paper (30%) 
 
 
 
vi 
 
Incorporated as Chapter 4: 
Debono, J., Bos, M.H.A., Coimbra, F., Ge, L., Frank, N., Kwok, H.F., Fry, B.G. 2019. Basal but 
divergent: Clinical implications of differential coagulotoxicity in a clade of Asian vipers. Toxicology 
in Vitro, 58, p.195-206. 
Contributor Statement of contribution 
Debono, J. Concept and Design (80%) 
Performed experiments (100%) 
Analysis and Interpretation (90%) 
Drafting and Production (90%) 
Edited paper (40%) 
Bos, M.H.A. Edited paper (15%) 
Analysis and Interpretation (10%) 
Coimbra, F. Edited paper (5%) 
Analysis and Interpretation (10%) 
Ge, L. Edited paper (5%) 
Frank, N. Production (5%) 
Kwok, H.F. Edited paper (10%) 
Fry, B.G. Drafting and Production (5%) 
Concept and Design (20%) 
Edited paper (25%) 
 
Incorporated as Chapter 5: 
Debono, J., Bos, M.H.A, Nouwens, A., Ge, L., Frank, N., Kwok, H.F., Fry, B.G. 2018. Habu 
coagulotoxicity: Clinical implications of the functional diversification of Protobothrops snake 
venoms upon blood clotting factors. Toxicology in Vitro, 55, p. 62-74. 
Contributor Statement of contribution 
Debono, J. Concept and Design (80%) 
Performed experiments (95%) 
Analysis and Interpretation (90%) 
Drafting and Production (100%) 
Edited paper (30%) 
Bos, M.H.A. Edited paper (15%) 
Analysis and Interpretation (10%) 
Nouwens, A. Performed experiments (5%) 
Ge, L. Edited paper (5%) 
Frank, N. Edited paper (5%) 
Kwok, H.F. Edited paper (15%) 
Fry, B.G. Concept and Design (20%) 
Edited paper (30%) 
 
Incorporated as Chapter 6: 
Debono, J., Bos, M.H.A., Do, M.S., Fry, B.G. 2019. Clinical implications of coagulotoxic variations 
in Mamushi (Viperidae: Gloydius) snake venoms. Comparative Biochemistry and Physiology Part C: 
Toxicology & Pharmacology, 225, p.108567. 
vii 
 
Contributor Statement of contribution 
Debono, J. Concept and Design (65%) 
Performed experiments (100%) 
Analysis and Interpretation (100%) 
Drafting and Production (100%) 
Edited paper (40%) 
Bos, M.H.A. Edited paper (40%) 
Do, M.S. Concept and Design (5%) 
Fry, B. Concept and Design (30%) 
Edited paper (20%) 
 
Incorporated as Chapter 7:  
Debono, J., Bos, M.H.A, Frank, N., Fry, B.G. 2019. Clinical implications of differential antivenom 
efficacy in neutralising coagulotoxicity produced by venoms from species within the arboreal viperid 
snake genus Trimeresurus. Toxicology Letters, 316, p. 35-48.   
Contributor Statement of contribution 
Debono, J. Concept and Design (75%) 
Performed experiments (100%) 
Analysis and Interpretation (100%) 
Drafting and Production (100%) 
Edited paper (40%) 
Bos, M.H.A. Edited paper (40%) 
Frank, N. Concept and Design (5%) 
Fry, B.G. Concept and Design (20%) 
Edited paper (20%) 
 
Incorporated as Chapter 8: 
Debono, J., Xie, B., Violette, A., Fourmy, R., Jaeger, M. and Fry, B.G. 2016. Viper venom botox: 
the molecular origin and evolution of the Waglerin peptides used in anti-wrinkle skin cream. Journal 
of Molecular Evolution, 84, p. 8-11. 
Contributor Statement of contribution 
Debono, J. Concept and Design (50%) 
Performed experiments (100%) 
Analysis and Interpretation (80%) 
Drafting and Production (50%) 
Edited paper (15%) 
Violette, A. Edited paper (15%) 
Fourmy, R. Analysis and Interpretation (10%) 
Edited paper (15%) 
Jaeger, M. Analysis and Interpretation (10%) 
Edited paper (15%) 
Fry, B.G. Concept and Design (50%) 
Edited paper (40%) 
Drafting and Production (50%) 
 
 
viii 
 
Submitted manuscripts included in this thesis  
No manuscripts submitted for publication.  
  
Other publications during candidature 
Peer-reviewed papers  
(*joint first authorship)  
Youngman, N.J., Debono, J., Dobson, J.S., Zdenek, C.N., Harris, R.J., Coimbra, F.C., Naude, A., 
Coster, K., Sundman, E., Braun, R., Hendrikx, I., Fry, B.G. 2019. Venomous landmines: Clinical 
implications of extreme coagulotoxic diversification and differential neutralization by antivenom of 
venoms within the viperid snake genus Bitis. Toxins, 11(7), p.422. 
 
Zdenek, C.N., Hay, C., Arbuckle, K., Jackson, T.N., Bos, M.H.A., Op den Brouw, B., Debono, J., 
Allen, L., Dunstan, N., Morley, T., Herrera, M., Gutiérrez, J.M., Williams, D.J., Fry, B.G. 2019. 
Coagulotoxic effects by brown snake (Pseudonaja) and taipan (Oxyuranus) venoms, and the efficacy 
of a new antivenom. Toxicology in Vitro, 58, p.97-109.  
 
Dashevsky, D.*, Debono, J.*, Rokyta, D., Nouwens, A., Josh, P., Fry, B.G. 2018. Three-Finger toxin 
diversification in the venoms of cat-eye snakes (Colubridae: Boiga). Journal of Molecular Evolution, 
p.1-15. 
 
Coimbra, F.C., Dobson, J., Zdenek, C.N., Op den Brouw, B., Hamilton, B., Debono, J., Masci, P., 
Frank, N., Ge, L., Kwok, H.F., Fry, B.G. 2018. Does size matter? Venom proteomic and functional 
comparison between night adder species (Viperidae: Causus) with short and long venom glands. 
Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 211, p.7-14. 
 
Oulion, B., Dobson, J.S., Zdenek, C.N., Arbuckle, K., Lister, C., Coimbra, F.C., op den Brouw, B., 
Debono, J., Rogalski, A., Violette, A., Fourmy, R., Frank. N., Fry. B.G. 2018. Factor X activating 
Atractaspis snake venoms and the relative coagulotoxicity neutralising efficacy of African 
antivenoms. Toxicology letters, 288, p.119-128. 
 
Goldenberg, J., Cipriani, V., Jackson, T.N., Arbuckle, K., Debono, J., Dashevsky, D., Panagides, N., 
Ikonomopoulou, M.P., Koludarov, I., Li, B., Santana, R.C., Nouwens A., Jones, A., Hay, C., Dunstan, 
N., Allen, L., Bush, B., Milese, J.J., Gen, L., Kwok, H.F., Fry, B.G. 2018. Proteomic and functional 
ix 
 
variation within black snake venoms (Elapidae: Pseudechis). Comparative Biochemistry and 
Physiology Part C: Toxicology & Pharmacology, 205, p.53-61.     
 
Koludarov, I., Jackson, T.N., Dobson, J., Dashevsky, D., Arbuckle, K., Clemente, C.J., Stockdale, 
E.J., Cochran, C., Debono, J., Stephens, C., Panagides, N., Li, B., Manchadi, M. L. R., Violette, A., 
Fourmy, R., Hendrikx, I., Nouwens, A., Clements, J., Martelli, P., Kwok, H. F., Fry, B.G. 2017. Enter 
the Dragon: The dynamic and multifunctional evolution of Anguimorpha lizard venoms. Toxins, 9(8), 
p.242.  
 
Lister, C., Arbuckle, K., Jackson, T.N., Debono, J., Zdenek, C.N., Dashevsky, D., Dunstan, N., Allen, 
L., Hay, C., Bush, B. and Gillett, A., Fry, B.G. 2017. Catch a tiger snake by its tail: Differential 
toxicity, co-factor dependence and antivenom efficacy in a procoagulant clade of Australian 
venomous snakes. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 
202, p.39-54.  
 
Casewell, N.R., Visser, J.C., Baumann, K., Dobson, J., Han, H., Kuruppu, S., Morgan, M., Romilio, 
A., Weisbecker, V., Mardon, K., Ali, S.A., Debono, J., Koludarov, I., Que, I., Bird, G.C., Cooke, G. 
M., Nouwens, A., Hodgson, W. C., Wagstaff, S. C., Cheney, K. L., Vetter, I., der Weerd, L., 
Richardson, M. K. and Fry, B.G. 2017. The evolution of fangs, venom, and mimicry systems in 
blenny fishes. Current Biology, 27(8), p.1184-1191.  
 
Cipriani, V.*, Debono, J.*, Goldenberg, J., Jackson, T.N., Arbuckle, K., Dobson, J., Koludarov, I., 
Li, B., Hay, C., Dunstan, N., Allen, L. 2017. Correlation between ontogenetic dietary shifts and 
venom variation in Australian brown snakes (Pseudonaja). Comparative Biochemistry and 
Physiology Part C: Toxicology & Pharmacology, 197, p.53-60.  
 
Han, H.*, Baumann, K.*, Casewell, N.R.*, Ali, S.A., Dobson, J., Koludarov, I., Debono, J., Cutmore, 
S.C., Rajapakse, N.W., Jackson, T.N. and Jones, R., Hodgson, W.C., Fry, B.G., Kuruppu, S. 2017. 
The cardiovascular and neurotoxic effects of the venoms of six bony and cartilaginous fish species. 
Toxins, 9(2), p.67.  
 
Yang, D.C., Deuis, J.R., Dashevsky, D., Dobson, J., Jackson, T.N., Brust, A., Xie, B., Koludarov, I., 
Debono, J., Hendrikx, I. and Hodgson, W.C., Josh, P., Nouwens, A., Baillie, G.J., Bruxner, T.J.C., 
Alewood, P.F., Lim, K.K.P., Frank, N., Vetter, I., Fry, B.G. 2016. The snake with the Scorpion’s 
x 
 
Sting: Novel Three-Finger toxin sodium channel activators from the venom of the long-glanded blue 
coral snake (Calliophis bivirgatus). Journal of Molecular Evolution, 8(10), p.303.  
 
Debono, J.*, Cochran, C.*, Kuruppu, S., Nouwens, A., Rajapakse, N.W., Kawasaki, M., Wood, K., 
Dobson, J., Baumann, K., Jouiaei, M. and Jackson, T.N., Koludarov, I., Low, D., Ali, S.A., Smith, 
A.I., Barnes, A., Fry, B.G. 2016. Canopy venom: proteomic comparison among new world arboreal 
pit-viper venoms. Toxins, 8(7), p.210.  
  
xi 
 
Conference Abstracts 
26th World Congress of International Society of Thrombosis and Haematology, Berlin Germany 
(2017) - Presented project; Debono, J., Fry, B.G. ‘Differential coagulotoxic effects of Asian pit viper 
snake venoms: Evolutionary, pathophysiology and biodiscovery implications’ (Poster), was 
presented to delegates at the World Congress of International Society of Thrombosis and 
Haematology, Berlin Germany.  
 
Oxford Symposia Venoms, Oxford England (2017) - Presented project; Debono, J., Casewell, 
N.R., Bin, L., Kwok, H.F., Fry, B.G. ‘Coagulating colubrids: Evolutionary, pathophysiological and 
biodiscovery implications of variations between boomslang (Dispholidus typus) and twig snake 
(Thelotornis mossambicanus) venoms’ (Oral presentation), was presented to delegates at the Oxford 
Symposia Venoms, Oxford UK.  
 
19th World Congress of the International Society of Toxinology, Hainan China (2017) - 
Presented project; Debono, J., Casewell, N.R., Bin, L., Kwok, H.F., Fry, B.G. ‘Coagulating 
colubrids: Evolutionary, pathophysiological and biodiscovery implications of variations between 
boomslang (Dispholidus typus) and twig snake (Thelotornis mossambicanus) venoms’ (Oral 
presentation), was presented to delegates at the 19th World Congress of the International Society of 
Toxinology, Hainan China which won ‘Outstanding Student Oral Presentation Award’.  
 
Australian Society of Herpetologists, Brisbane Australia (2018) - Presented project; Debono, J., 
Casewell, N.R., Bin, L., Kwok, H.F., Fry, B.G. ‘Coagulating colubrids: Evolutionary, 
pathophysiological and biodiscovery implications of variations between boomslang (Dispholidus 
typus) and twig snake (Thelotornis mossambicanus) venoms’ (Oral presentation), was presented to 
delegates at the Australian Society of Herpetologists, Brisbane Australia.  
 
27th World Congress of International Society of Thrombosis and Haematology, Melbourne 
Australia (2019) - Presented project; Debono, J., Bos, M.H.A., Fry, B.G. ‘The clinical implications 
of the differential coagulopathic effects of Asian pit viper snake venoms’ (Poster), was presented to 
delegates at the World Congress of International Society of Thrombosis and Haematology, 
Melbourne Australia.  
 
 
 
 
xii 
 
Contributions by others to the thesis  
This thesis would not have been possible without contributions and collaborations from around the 
world. I would firstly like to acknowledge the contribution of the following people to this thesis: I 
acknowledge and thank my supervisory team Associate Professor Bryan Fry as my primary 
supervisor, Dr Irina Vetter and Dr Kevin Arbuckle as my co supervisors. Associate Professor Bryan 
Fry has significantly contributed to the body of this thesis with major contribution in concept and 
design as well as interpretation of data and manuscript editing. I would like to thank my committee 
members for their various roles in support throughout my candidature; Professor Robbie Wilson, Dr 
Eivind Undheim and Dr Vera Weisbecker of the University of Queensland.  
 
The following acknowledgements of contributions are by chapter:  
Chapter 2: Professor Nick Casewell for his contribution to manuscript writing and venom supply of 
Dispholidus typus and Thelotornis mossambicanus. Dr Amanda Nouwens and Peter Josh for their 
LC-MS/MS knowledge, skills and interpretation of data.  
 
Chapter 3: Daniel Dashvesky, for his relentless troubleshooting skills and knowledge of 
transcriptomic analysis, contribution to manuscript writing and significant contribution to data 
interpretation.  
 
Chapter 4 - 7: Dr Mettine Bos for her guidance and expertise surrounding haematology and venom 
effect on fibrinogen as well as significant contribution to manuscript writing.  
 
Chapter 4, 5 & 7: Nathaniel Frank, for his consistent supply of quality venom supplies for a range of 
species.   
 
  
xiii 
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
No works submitted towards another degree have been included in this thesis. 
 
 
Research Involving Human or Animal Subjects  
No animal or human subjects requiring ethics were involved in this research. 
  
xiv 
 
Acknowledgements 
I would first and foremost like to thank my supervisory team, Associate Professor Bryan Fry and Dr 
Irina Vetter for being outstanding supervisors, and in particular granting me a huge amount of 
freedom throughout my candidature to follow my passion around the world. I would also like to thank 
them for their constant encouragement that led to the completion of my thesis. Thank you especially 
to Bryan for his continued support and inspiration throughout my academic career, from the very 
early days when I first began in his lab, he saw something no one else did and believed I could be an 
amazing scientist. Thank you for the countless opportunities you have given me and the insane 
amount of support over the years as colleague, supervisor and friend.   
I would also like to thank my rotating assemblage of committee members; Professor Robbie Wilson, 
Dr Eivind Undheim and Dr Vera Weisbecker for their continued support and advice going through 
each milestone and for stepping in when others were unable to attend. Their advice received at each 
milestone was invaluable, particularly advice about future prospects. I would also like to thank them 
for their continued following of my various additional achievements throughout my candidature. 
A huge thank you to Dr Mettine H. A. Bos, for her expertise and knowledge surrounding haematology 
and venom, and for her continued patience and guidance throughout my candidature. A special thanks 
for her welcome when I spent time visiting her laboratory in Holland, struggling with certain cultural 
differences and for understanding when I needed help. This went above and beyond a scientific 
collaboration and you became a life-long friend, so I thank you for this.   
A very special thanks to my mentor Dr Scott Cutmore, who may not know it but who has been 
instrumental in the completion of not only my PhD but also my academic career to date. He has been 
the shoulder to cry on and the ears and eyes I needed for the past 7 years when discussing projects, 
results, issues with candidature, future prospects about what direction to go in life and an all-round 
amazing friend and colleague – thank you.  
I would also like to give special thanks to past and present members of the Venom Evolution 
Laboratory, particularly Dr Kate Baumann for her everlasting friendship, Dr Timothy Jackson for his 
undeniable wisdom and the six current PhD students – James, Dan, Christina, Bianca, Rich, Francisco 
- who have been the rocks throughout my journey of not only my PhD but also my undergraduate and 
honours degrees. Your friendship, support and singular understanding of what it is like to undertake 
a PhD in the V.E.L has been life-saving.  
Special thanks go to my parents and brother, without whose support I would have never made it 
through my PhD, let alone the past 9 years at UQ. To their continued understanding of the unhealthy 
inability to decide what I want to do with my life and the drive that is my passion for science, for 
instilling in me the qualities of persistence and determination so that I could accomplish something 
such as a PhD. You have supported every decision I have made and been on the science journey right 
xv 
 
beside me. My partner who deserves thanks for the countless conversations he has had to endure 
about my research, even when he has absolutely no clue what I am talking about, yet supports me in 
my decision to peruse a PhD. To all of the above, you have given me strength in believing in me when 
I didn’t always believe in myself. Thank you for your patience and understanding throughout this 
extremely rewarding journey.  
  
xvi 
 
Financial support 
This research was supported by the Australian Research Council DP190100304, by an Australian 
Postgraduate Award, by the University of Queensland Candidature Development Award (2018) and 
by the Queensland Women in STEM Award (2017) sponsored by Advanced Queensland.  
 
Keywords 
Crotalinae, Colubridae, Asian pit viper, coagulation, venom, anticoagulant, procoagulant, evolution, 
fibrinogen, antivenom, transcriptome. 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
ANZSRC code: 030406 Proteins and Peptides 30% 
ANZSRC code: 110202 Haematology 50% 
ANZSRC code: 060409 Molecular Evolution, 20% 
 
Fields of Research (FoR) Classification 
FoR code: 0603, Evolutionary Biology, 30% 
FoR code: 1102 Cardiorespiratory Medicine and Haematology, 40% 
FoR code: 0601 Biochemistry and Cell Biology, 30% 
  
xvii 
 
Table of Contents  
ABSTRACT ............................................................................................................................................................. II 
DECLARATION BY AUTHOR ............................................................................................................................. IV 
PUBLICATIONS INCLUDED IN THIS THESIS ................................................................................................... V 
SUBMITTED MANUSCRIPTS INCLUDED IN THIS THESIS ........................................................................ VIII 
OTHER PUBLICATIONS DURING CANDIDATURE ..................................................................................... VIII 
CONTRIBUTIONS BY OTHERS TO THE THESIS ........................................................................................... XII 
ACKNOWLEDGEMENTS ................................................................................................................................. XIV 
INDEX OF FIGURES (BY CHAPTER): ........................................................................................................... XXII 
INDEX OF TABLES (BY CHAPTER): ........................................................................................................... XXIII 
ABBREVIATIONS ............................................................................................................................................ XXIV 
NOTE ON STYLE TO THE READER ............................................................................................................. XXVI 
CHAPTER 1: INTRODUCTION – A BRIEF OVERVIEW OF COAGULATION AND SNAKE VENOM .......... 1 
1.1 THE HUMAN COAGULATION CASCADE: A BRIEF OVERVIEW ............................................................................... 1 
1.2 SNAKE VENOMS AND COAGULATION ............................................................................................................... 3 
1.3 AIMS AND DIRECTIONS ................................................................................................................................... 6 
CHAPTER 2: COAGULATING COLUBRIDS: EVOLUTIONARY, PATHOPHYSIOLOGICAL AND 
BIODISCOVERY IMPLICATIONS OF VENOM VARIATIONS BETWEEN BOOMSLANG (DISPHOLIDUS 
TYPUS) AND TWIG SNAKE (THELOTORNIS MOSSAMBICANUS) ................................................................... 7 
2.1 ABSTRACT ..................................................................................................................................................... 7 
2.2 INTRODUCTION .............................................................................................................................................. 7 
2.3 RESULTS .......................................................................................................................................................11 
2.3.1 Skull and Venom Gland Anatomical Comparisons .........................................................................................11 
2.3.2 Proteomics ...................................................................................................................................................11 
2.3.3 Enzymatic Assays .........................................................................................................................................13 
2.3.4 Fluorescent Determination of sPLA2 Activity .................................................................................................15 
2.3.5 Procoagulation Analysis ...............................................................................................................................16 
2.4 DISCUSSION ..................................................................................................................................................20 
2.5 MATERIALS AND METHODS ...........................................................................................................................22 
2.5.1 Venom Supplies ............................................................................................................................................22 
2.5.2 Micro-Computed Tomography (CT) ..............................................................................................................22 
2.5.3 Magnetic Resonance Imaging .......................................................................................................................22 
2.5.4 Proteomics ...................................................................................................................................................23 
2.5.5 Nano HPLC-ESI-Triple Time of Flight (TOF) Mass Spectral Analysis ...........................................................23 
2.5.6 Protein Identification ....................................................................................................................................24 
2.5.7 Orbitap Elite Mass Spectrometer for SHOTGUNS .........................................................................................24 
xviii 
 
2.5.8 Enzymatic Activity Assays .............................................................................................................................25 
2.5.8.1 Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity ............................................. 25 
2.5.8.2 Fluorescent Determination of PLA2 Activity ............................................................................................... 25 
2.5.8.3 Enzymatic Statistical Analysis ................................................................................................................... 25 
2.5.9 Procoagulation Analysis ...............................................................................................................................26 
2.5.9.1 Whole Plasma Clotting .............................................................................................................................. 26 
2.5.9.2 Antivenom Studies .................................................................................................................................... 27 
2.5.10 Statistical Analysis ...................................................................................................................................27 
2.5.10.1 Whole Plasma Clotting EC50 Concentration and Asymptotic Time .............................................................. 27 
2.5.10.2 Antivenom EC50 Concentration .................................................................................................................. 28 
CHAPTER 3: THE SWEET SIDE OF VENOM: GLYCOSYLATED PROTHROMBIN ACTIVATING 
METALLOPROTEASES FROM DISPHOLIDUS TYPUS (BOOMSLANG) AND THELOTORNIS 
MOSSAMBICANUS (TWIG SNAKE) .....................................................................................................................29 
3.1 ABSTRACT ....................................................................................................................................................29 
3.2 INTRODUCTION .............................................................................................................................................29 
3.3 RESULTS .......................................................................................................................................................31 
3.3.1 Transcriptomics ............................................................................................................................................31 
3.3.2 SVMP phylogeny ..........................................................................................................................................32 
3.3.3 Proteomics ...................................................................................................................................................34 
3.3.4 FX and Prothrombin activation .....................................................................................................................35 
3.4 DISCUSSION ..................................................................................................................................................36 
3.5 MATERIALS AND METHODS ...........................................................................................................................38 
3.5.1 Venom Supplies ............................................................................................................................................38 
3.5.2 Venom gland RNA extraction and mRNA purification: reconstruction of SVMP phylogeny ............................38 
3.5.2.1 Sequencing ............................................................................................................................................... 38 
3.5.2.2 Assembly .................................................................................................................................................. 39 
3.5.2.3 Annotation ................................................................................................................................................ 39 
3.5.2.4 Phylogenetic reconstruction ....................................................................................................................... 40 
3.5.3 De-glycosylation of venom proteins: .............................................................................................................40 
3.5.4 Factor X activation and prothrombin activation ............................................................................................41 
CHAPTER 4: BASAL BUT DIVERGENT: CLINICAL IMPLICATIONS OF DIFFERENTIAL 
COAGULOTOXICITY IN A CLADE OF ASIAN VIPERS...................................................................................42 
4.1 ABSTRACT ....................................................................................................................................................42 
4.2 INTRODUCTION .............................................................................................................................................42 
4.3 RESULTS .......................................................................................................................................................44 
4.3.1 Enzymatic assays ..........................................................................................................................................44 
4.3.2 Coagulation analysis: human plasma and fibrinogen ....................................................................................46 
4.3.3 Thromboelastography: plasma and fibrinogen ..............................................................................................48 
4.3.4 FX activation and prothrombin activation .....................................................................................................50 
4.3.5 Fibrinolysis ± tPA ........................................................................................................................................50 
4.3.6 Fibrinogen gels ............................................................................................................................................51 
4.4 DISCUSSION ..................................................................................................................................................54 
xix 
 
4.5 MATERIALS AND METHODS ...........................................................................................................................56 
4.5.1 Venoms ........................................................................................................................................................56 
4.5.2 Enzyme assays ..............................................................................................................................................56 
4.5.2.1 Fluorescent substrate activation ................................................................................................................. 57 
4.5.2.2 Plasminogen activation .............................................................................................................................. 57 
4.5.2.3 Prothrombin activation .............................................................................................................................. 58 
4.5.2.4 Factor X activation .................................................................................................................................... 58 
4.5.3 Phylogenetic comparative analyses ...............................................................................................................58 
4.5.4 Coagulation assays .......................................................................................................................................59 
4.5.4.1 Action upon plasma and fibrinogen: Clot formation or inhibition assays...................................................... 59 
4.5.4.2 Thromboelastography ................................................................................................................................ 60 
4.5.4.3 Fibrinogen SDS PAGE electrophoresis and gel image analysis ................................................................... 60 
4.5.4.4 Factor X activation and prothrombin activation .......................................................................................... 61 
4.5.4.5 Fibrinolysis ± tPA ..................................................................................................................................... 62 
CHAPTER 5: HABU COAGULOTOXICITY: CLINICAL IMPLICATIONS OF THE FUNCTIONAL 
DIVERSIFICATION OF PROTOBOTHROPS SNAKE VENOMS ........................................................................63 
5.1 ABSTRACT ....................................................................................................................................................63 
5.2 INTRODUCTION .............................................................................................................................................63 
5.3 RESULTS .......................................................................................................................................................65 
5.3.1 Enzymatic assays on the Fluoroskan Ascent ..................................................................................................65 
5.3.2 Coagulation analyses....................................................................................................................................67 
5.3.2.1 Action upon plasma ................................................................................................................................... 67 
5.3.2.2 Action upon fibrinogen .............................................................................................................................. 69 
5.3.2.3 Platelet agglutination and inhibition ........................................................................................................... 75 
5.4 DISCUSSION ..................................................................................................................................................76 
5.5 MATERIALS AND METHODS ...........................................................................................................................78 
5.5.1 Enzyme assays ..............................................................................................................................................79 
5.5.1.1 Fluorescent substrate activation ................................................................................................................. 79 
5.5.1.2 Plasminogen activation .............................................................................................................................. 80 
5.5.1.3 Prothrombin activation .............................................................................................................................. 80 
5.5.1.4 Factor X activation .................................................................................................................................... 80 
5.5.1.5 Protein C activation ................................................................................................................................... 81 
5.5.2 Phylogenetic comparative analyses ...............................................................................................................81 
5.5.3 Coagulation analysis ....................................................................................................................................81 
5.5.3.1 Action upon plasma ................................................................................................................................... 81 
5.5.3.2 Action upon fibrinogen .............................................................................................................................. 83 
5.5.3.3 Platelet agglutination and inhibition ........................................................................................................... 85 
CHAPTER 6: CLINICAL IMPLICATIONS OF COAGULOTOXIC VARIATIONS IN MAMUSHI 
(VIPERIDAE: GLOYDIUS) SNAKE VENOMS .....................................................................................................87 
6.1 ABSTRACT ....................................................................................................................................................87 
6.2 INTRODUCTION .............................................................................................................................................87 
6.3 RESULTS .......................................................................................................................................................89 
6.3.1 Procoagulation and anticoagulation studies ..................................................................................................89 
xx 
 
6.3.2 Fibrinolytic activity ......................................................................................................................................93 
6.3.3 Thromboelastography ...................................................................................................................................96 
6.3.4 Fibrinolysis assessment ................................................................................................................................99 
6.3.5 Snake venom serine protease contribution ................................................................................................... 100 
6.4 DISCUSSION ................................................................................................................................................ 100 
6.5 MATERIAL AND METHODS ........................................................................................................................... 102 
6.5.1 Venoms ...................................................................................................................................................... 102 
6.5.2 Coagulation analysis .................................................................................................................................. 102 
6.5.3 Fibrinolytic activity .................................................................................................................................... 104 
6.5.4 Thromboelastography (fibrinogen and plasma) ........................................................................................... 104 
6.5.5 Fibrinolysis ................................................................................................................................................ 105 
CHAPTER 7: CLINICAL IMPLICATIONS OF DIFFERENTIAL ANTIVENOM EFFICACY IN 
NEUTRALISING COAGULOTOXICITY PRODUCED BY VENOMS FROM SPECIES WITHIN THE 
ARBOREAL VIPERID SNAKE GENUS TRIMERESURUS ............................................................................... 106 
7.1 ABSTRACT .................................................................................................................................................. 106 
7.2 INTRODUCTION ........................................................................................................................................... 107 
7.3 RESULTS ..................................................................................................................................................... 108 
7.3.1 Coagulation analyses on plasma ................................................................................................................. 108 
7.3.2 Coagulation analyses on fibrinogen ............................................................................................................ 110 
7.3.3 Thromboelastography (plasma) .................................................................................................................. 114 
7.3.4 Thromboelastography (fibrinogen).............................................................................................................. 116 
7.3.5 Fibrinogen chain degradation ..................................................................................................................... 118 
7.3.6 Fibrinolysis ................................................................................................................................................ 121 
7.3.7 FXa, thrombin and FIXa enzyme inhibition studies...................................................................................... 121 
7.4 DISCUSSION ................................................................................................................................................ 124 
7.5 MATERIALS AND METHODS ......................................................................................................................... 126 
7.5.1 Venoms ...................................................................................................................................................... 126 
7.5.2 Coagulation analyses on plasma and fibrinogen.......................................................................................... 126 
7.5.3 Inhibition of FIXa, FX or thrombin ............................................................................................................. 127 
7.5.4 Thromboelastography analyses on plasma and fibrinogen ........................................................................... 128 
7.5.5 Fibrinogenolysis analysis ........................................................................................................................... 129 
7.5.6 Fibrinolysis ................................................................................................................................................ 129 
7.5.7 Antivenom efficacy assessment .................................................................................................................... 130 
7.5.8 Phylogenetic comparative analyses ............................................................................................................. 130 
CHAPTER 8: VIPER VENOM BOTOX: THE MOLECULAR ORIGIN AND EVOLUTION OF THE 
WAGLERIN PEPTIDES USED IN ANTI-WRINKLE SKIN CREAM ............................................................... 131 
8.1 ABSTRACT .................................................................................................................................................. 131 
8.2 INTRODUCTION ........................................................................................................................................... 131 
8.3 RESULTS AND DISCUSSION .......................................................................................................................... 131 
8.4 METHODS ................................................................................................................................................... 132 
xxi 
 
CHAPTER 9: CONCLUSIONS AND FUTURE DIRECTIONS .......................................................................... 135 
9.1 RESEARCH OVERVIEW ................................................................................................................................. 135 
9.2 KEY FINDINGS ............................................................................................................................................. 135 
9.2.1 Procoagulation ........................................................................................................................................... 135 
9.2.2 Anticoagulation .......................................................................................................................................... 136 
9.2.3 Other toxins ................................................................................................................................................ 137 
9.2.4 Therapeutic applications ............................................................................................................................ 137 
9.3 FUTURE DIRECTIONS ................................................................................................................................... 138 
9.4 CONCLUSION .............................................................................................................................................. 138 
REFERENCES ....................................................................................................................................................... 140 
APPENDIX............................................................................................................................................................. 157 
  
xxii 
 
Index of Figures (by chapter): 
FIGURE 1.1 COAGULATION CASCADE ............................................................................................................................ 2 
FIGURE 2.1 CT AND MRI SCAN....................................................................................................................................11 
FIGURE 2.2 1D SDS PAGE ...........................................................................................................................................12 
FIGURE 2.3 2D SDS PAGE ...........................................................................................................................................13 
FIGURE 2.4 SNAKE VENOM METALLOPROTEASE ACTIVITY OF VENOM ..........................................................................14 
FIGURE 2.5 KALLIKREIN ACTIVITY OF VENOM ..............................................................................................................15 
FIGURE 2.6 PHOSPHOLIPASE A2 ACTIVITY ....................................................................................................................16 
FIGURE 2.7 ASYMPTOTIC PLOT ....................................................................................................................................18 
FIGURE 2.8 COAGULATION AND ANTIVENOM CLOTTING CURVES ...................................................................................18 
FIGURE 2.9 NORMALISATION OF TRANSFORMED DATA..................................................................................................20 
FIGURE 3.1 TPM PLOTS ...............................................................................................................................................32 
FIGURE 3.2 SVMP PHYLOGENY ...................................................................................................................................33 
FIGURE 3.3 1D SDS PAGE .........................................................................................................................................34 
FIGURE 3.4 DE-GLYCOSYLATION .................................................................................................................................35 
FIGURE 3.5 PROTHROMBIN ACTIVATION.......................................................................................................................36 
FIGURE 4.1 ENZYMATIC SUBSTRATE ACTIVITY .............................................................................................................45 
FIGURE 4.2 COAGULATION ANALYSIS ..........................................................................................................................47 
FIGURE 4.3 FIBRINOGEN CLOTTING ACTIVITY ...............................................................................................................48 
FIGURE 4.4 THROMBOELASTOGRAPHY PLASMA TRACES ...............................................................................................49 
FIGURE 4.5 THROMBOELASTOGRAPHY FIBRINOGEN TRACES .........................................................................................49 
FIGURE 4.6 FACTOR X ACTIVATION .............................................................................................................................50 
FIGURE 4.7 FIBRINOLYSIS............................................................................................................................................51 
FIGURE 4.8 FIBRINOGEN CHAIN CLEAVAGE - GEL ..........................................................................................................52 
FIGURE 4.9 FIBRINOGEN CHAIN CLEAVAGE - % INTACT ................................................................................................53 
FIGURE 5.1 ENZYME SUBSTRATE ACTIVITY ..................................................................................................................66 
FIGURE 5.2 PROCOAGULANT CO-FACTOR DEPENDENCY ................................................................................................67 
FIGURE 5.3 THROMBOELASTOGRAPHY PLASMA TRACES ...............................................................................................68 
FIGURE 5.4 FACTOR XA INHIBITION .............................................................................................................................69 
FIGURE 5.5 PROCOAGULANT CO-FACTOR DEPENDENCY – FIBRINOGEN ..........................................................................70 
FIGURE 5.6 THROMBOELASTOGRAPHY FIBRINOGEN TRACES .........................................................................................71 
FIGURE 5.7 FIBRINOGEN CHAIN CLEAVAGE - GEL ..........................................................................................................72 
FIGURE 5.8 FIBRINOGEN CHAIN CLEAVAGE - % INTACT ................................................................................................73 
FIGURE 5.9 ANCESTRAL STATE RECONSTRUCTION OF COAGULATION CLOTTING TIMES ...................................................74 
FIGURE 5.10 FIBRINOLYSIS ..........................................................................................................................................75 
FIGURE 5.11 PLATELET AGGLUTINATION INHIBITION ....................................................................................................76 
FIGURE 6.1 COFACTOR DEPENDENCY – PLASMA ...........................................................................................................90 
FIGURE 6.2 COFACTOR DEPENDENCY – FIBRINOGEN .....................................................................................................91 
FIGURE 6.3 CLOTTING FACTOR INHIBITION ...................................................................................................................92 
FIGURE 6.4 FIBRINOGEN CHAIN CLEAVAGE - GEL ..........................................................................................................94 
FIGURE 6.5 FIBRINOGEN CHAIN CLEAVAGE - % INTACT ................................................................................................95 
FIGURE 6.6 THROMBOELASTOGRAPHY PLASMA TRACES ...............................................................................................97 
xxiii 
 
FIGURE 6.7 THROMBOELASTOGRAPHY FIBRINOGEN TRACES .........................................................................................98 
FIGURE 6.8 FIBRINOLYSIS............................................................................................................................................99 
FIGURE 6.9 SVSP INHIBITION .................................................................................................................................... 100 
FIGURE 7.1 COFACTOR DEPENDENCY – PLASMA ......................................................................................................... 109 
FIGURE 7.2 COFACTOR DEPENDENCY – FIBRINOGEN ................................................................................................... 111 
FIGURE 7.3 ANTIVENOM NEUTRALIZATION ................................................................................................................ 112 
FIGURE 7.4 ANTIVENOM NEUTRALIZATION EFFICACY HEAT MAP ................................................................................. 113 
FIGURE 7.5 SVSP INHIBITION .................................................................................................................................... 114 
FIGURE 7.6 THROMBOELASTOGRAPHY PLASMA TRACES ............................................................................................. 115 
FIGURE 7.7 THROMBOELASTOGRAPHY FIBRINOGEN TRACES ....................................................................................... 117 
FIGURE 7.8 HEAT MAP OVERLAY PHYLOGENY FIBRINOGEN THROMBOELASTOGRAPHY ................................................. 118 
FIGURE 7.9 FIBRINOGEN CHAIN CLEAVAGE - GEL ........................................................................................................ 119 
FIGURE 7.10 FIBRINOGEN CHAIN CLEAVAGE - % INTACT............................................................................................. 120 
FIGURE 7.11 FIBRINOLYSIS ........................................................................................................................................ 121 
FIGURE 7.12 CLOTTING FACTOR INHIBITION ............................................................................................................... 123 
FIGURE 8.1 WAGLERIN’S NATRIURETIC PEPTIDE ......................................................................................................... 133 
FIGURE 8.2 BAYESIAN RECONSTRUCTION OF C-TYPE NP ............................................................................................ 134 
 
Index of Tables (by chapter):  
TABLE 2.1 AVERAGE CLOTTING TIMES .........................................................................................................................17 
TABLE 2.2 ASYMPTOTIC REGRESSION MODEL COEFFICIENT ESTIMATES .........................................................................17 
TABLE 6.1 SPECIES LIST ..............................................................................................................................................89 
TABLE 6.2 ANTICOAGULATION ASSAY DETAILS .......................................................................................................... 104 
TABLE 7.1 ANTICOAGULATION ASSAY DETAILS .......................................................................................................... 128 
xxiv 
 
Abbreviations 
1D SDS PAGE 
(R/NR) 
one-dimensional (1D) sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) - reduced/ non-reduced 
2D SDS PAGE (R) two-dimensional (2D) sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) - reduced 
3D Three dimensional  
3FTx Three finger toxin  
ABC ammonium bicarbonate 
ACN acetonitrile  
AEBSF 4-benzenesulfonyl fluoride hydrochloride 
ANOVA Analysis of Variance 
APC activated Human Protein C 
APS ammonium sulphate 
aPTT activated Partial Thromboplastin Time 
BLAST basic local alignment search tool 
CaCl2 Calcium Chloride  
CRiSP cysteine rich secretory protein 
DTT dithiothreitol 
fX, fVIII eg Factor 10, Factor 13 
fXa, fVIIIa active form of eg. factor 10, factor 13 
FA formic acid 
HMWK high molecular weight kininogen 
HPLC High Pressure Liquid Chromatography  
IAA iodoacetamide 
IEF  isoelectric focusing machine 
IPG strip immobilized pH gradient strip 
kDA kilodaltons  
LC-MS/MS liquid chromatography mass spectrometry/mass spectrometry  
MALDI matrix assisted laser desorption ionization mass spectrometry  
MMP matrix metalloprotease 
MRI Magnetic Resonance Imaging  
mRNA messenger ribonucleic acid 
PBS phosphate buffered saline  
PCR polymerase chain reaction 
xxv 
 
pI value isoelectric point  
PLA2 Phospholipase A2 
PLB Phospholipase B 
RM Repeated measures  
RNA Ribonucleic acid 
HPLC reversed phase high performance liquid chromatography  
SEC size exclusion chromatography  
snaclec snake venom C-type lectin 
SVMP snake venom metalloprotease P-I, P-II, P-III 
SVSP snake venom serine protease  
TEG Thromboelastography  
TEMED tetramethylethylenediamine 
TPM Transcripts Per Million  
TOF Time Of Flight 
TFA trifluoroacetic acid 
tPA tissue plasminogen activator 
tRNA total RNA  
µg microgram  
μL microliter  
µM micromolar  
 
  
xxvi 
 
Note on style to the reader 
This thesis is presented as a series of manuscripts that have been published and recently accepted for 
publication. As a result, there may be repetition across the introductions of each chapter and may be 
certain inconsistencies between chapters. 
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Chapter 1: Introduction – a brief overview of coagulation and snake venom 
 
1.1 The human coagulation cascade: a brief overview   
The human coagulation cascade is an extremely complex intricate highway of factor cascades which 
catalyse together in order to form a stable fibrin clot. The cascade is made up of three main pathways: 
extrinsic, intrinsic and common pathway. The extrinsic pathway begins by triggering FVII through 
trauma or external tissue damage. This event releases tissue factor (FIII), which combined with Ca2+ 
activates FVII into FVIIa (Jin and Gopinath, 2016; Mackman, 2009). The intrinsic pathway begins 
via negatively charged surface contact, such as that triggered by a disruption to the endothelium 
lining, by a response to the presence of pathophysiological materials and invasion pathogens such as 
bacteria in septic shock or prolonged severe inflammation (Vogler and Siedlecki, 2009; Wu, 2015). 
This surface contact activates FXII along with free platelets signalled to the area. Both the intrinsic 
and extrinsic pathways cross over at a mid-point, governed by Factor X (FX) (cleavage of FX into 
FXa is the beginning of the common pathway). The end goal is to form a stable fibrin clot to prevent 
further bleeding. FXa directly activates prothrombin (FII) into its active form, thrombin (FIIa). 
Thrombin is used to activate FVIII into FVIIIa and FV into FVa. These factors lead directly to a 
stable fibrin clot and help facilitate further clot formation. Fibrinogen is converted by thrombin into 
a fibrin monomer, adhering to fibrin polymers A and B, which aggregates with platelets to also form 
a stable fibrin clot, and at the same time FXIII is cleaved into FXIIIa. FXIIIa is essential for the 
formation of covalent bridges between fibrin units, resulting in cross-linked fibrin which is insoluble 
and resistant to lysis (Al-Horani et al., 2016; Heil et al., 2013; Shi and Wang, 2017). All of these 
catalytic reactions require the presence of Ca2+ (Figure 1.1).  
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Figure 1.1 Coagulation cascade  
Simplified clotting cascade outlining extrinsic, intrinsic and common pathways along with activation 
steps of factors to form a fibrin clot.  
 
While the common pathway is complex on its own, it is also the place where majority of inhibition 
of factors takes place, regulating coagulation to prevent thrombotic diseases. Activated Protein C 
(APC) is a circulating zymogen which selectively inactivates FVa and FVIIIa, both essential co 
factors for FX activation (Esmon et al., 1987). If Protein C is inhibited, then FX will continuously 
activate and uncontrollable catalysing of the common pathway will continue, resulting in 
unmodulated fibrin being produced. Another major inhibition step taken to prevent thrombosis is 
plasminogen activation into plasmin which, in turn, destroys fibrin clots. This occurs once a clot has 
served its purpose in preventing blood loss, modulating clot formations and is known as fibrinolysis 
(Cesarman‐Maus and Hajjar, 2005; Collet et al., 2000). Tissue plasminogen activator (tPA) is present 
in endothelial cells and is released in the presence of fibrin which makes up the clot. tPA is responsible 
for catalysing plasminogen into plasmin which degrades the fibrin network into soluble products 
(Cesarman‐Maus and Hajjar, 2005; Rijken and Lijnen, 2009).  
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1.2 Snake venoms and coagulation  
Venom is defined as a secretion produced in specialised cells that is delivered to a target animal 
through a wound which consequently disrupts normal physiological or biochemical processes (Fry et 
al., 2009a; Fry et al., 2009b; Nelsen et al., 2014). Venoms are complex mixtures of enzymes, toxins, 
peptides, organic molecules and salts (Fry et al., 2009a; Fry et al., 2009b) which are used to facilitate 
feeding (Fry et al., 2008; Fry et al., 2013; Fry et al., 2009b; Jackson et al., 2013), defence such as that 
found in spitting cobras (Cascardi et al., 1999; Hayes et al., 2008) or competition (Deufel and Cundall, 
2003) for the producing organism (Fry and Wüster, 2004; Sunagar et al., 2013). Numerous studies 
have demonstrated that venom genes evolve at a much faster rate than housekeeping genes, 
facilitating a drive towards a highly specialised and complex venom composition (Casewell et al., 
2013; Jackson et al., 2013; Sunagar et al., 2013; Vonk et al., 2013). This facilitated diversification 
allows toxins within venom to evolve rapidly, and at different rates, through a variety of different 
selective mechanisms. These mechanisms include but are not limited to: ecological niche occupation, 
which is in-turn directly related to prey ecology, and in some cases taxon-specific toxins (Jackson et 
al., 2013; Koludarov et al., 2014; Li et al., 2005; Pawlak et al., 2006; Pawlak et al., 2009); 
geographical location; and morphology (Daltry et al., 1996b; Fry et al., 2013; Sunagar et al., 2013; 
Sunagar et al., 2014). The toxic ‘cocktail’ that is venom is a mixture of proteins secreted by 
specialized cells, such as venom glands (Casewell et al., 2013; Fry et al., 2009a; Fry et al., 2012). 
These proteins have evolved from those normally expressed within the body to being recruited for 
secretion via the oral (venom) glands (Fry et al., 2015c; Fry et al., 2005). General characteristics of 
recruited proteins (despite diversification) include recruitment from secretory protein families, pre-
existing biochemical roles and recruitment more frequently from body proteins which are more stable 
in their tertiary structures with an increase in cysteine cross-linking (Fry et al., 2015c). All proteins 
present within secreted venom exhibit characteristics of both plesiotypic (basal) and apotypic 
(derived) structural and functional forms (for further detail see (Fry, 2005; Fry et al., 2009a; Fry et 
al., 2012; Fry et al., 2008; Fry et al., 2013; Fry and Wüster, 2004). 
Particular focus has been taken within this project to investigate the activity of two enzymes 
responsible for the majority of coagulant activity: snake venom metalloproteases (SVMPs) and serine 
proteases (SVSPs). These enzymes play an important role in coagulation activity by venoms, acting 
directly on platelet activity or cascade factors. Procoagulation and the varying effects of 
anticoagulation are the major focal points of this thesis. Procoagulant toxins can be simplified into 
four groups: prothrombin activators (Bos and Camire, 2010; Joseph and Kini, 2002; Kini, 2005a; 
Kornalik and Blombäck, 1975; Pirkle et al., 1972; Rogalski et al., 2017; Rosing and Tans, 1992; 
Yamada et al., 1996), Factor X activators (Chen et al., 2008; Joseph and Kini, 2002; Oulion et al., 
2018; Tans and Rosing, 2002; Yamada et al., 1997), Factor V activators (Bos and Camire, 2010; Bos 
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et al., 2016; Rosing et al., 2001; Williams et al., 1994; Zdenek et al., 2019), and thrombin-like 
enzymes (Cho et al., 2001; Esnouf and Tunnah, 1967; Huang et al., 2011; Lin et al., 2009; Nielsen, 
2016b; Ouyang and Teng, 1976, 1978; Pradniwat and Rojnuckarin, 2015; Tan, 2010; Tan et al., 2012; 
Zhang et al., 2007), while anticoagulants can affect any number of factors singularly or 
synergistically, such as blocking clotting enzymes while activating Protein C (Bakker et al., 1993; 
Esmon et al., 1987; Jin and Gopinath, 2016; Kisiel et al., 1987; Kogan et al., 1993; Nakagaki et al., 
1990). These types of activators or inhibitors have been found and isolated from a number of varying 
families and species of venomous snakes.  
This PhD focuses on members from two of these families: Colubridae and Viperidae. The Colubridae 
has a global distribution, and are often referred to as ‘non-front-fanged snakes’. The Viperidae is a 
family of snakes known as the vipers (or viperid snakes), with a geographical distribution on every 
continent excluding Australia and Antarctica. The Viperidae is divided in to two main subfamilies; 
Viperinae (true or pit-less vipers) and Crotalinae (Pit Vipers). Chapters included in this thesis focus 
specifically on two infamous procoagulant species from the Colubridae subfamily Colubrinae, and 
the entire Asian Pit viper clade from the Viperidae subfamily, Crotalinae. By screening such a large 
group of predatory venoms (those subjected to evolutionary selection pressures for prey 
immobilisation (Jackson and Fry, 2016; Yang et al., 2016)) for novel coagulant properties from these 
snakes, this will hopefully lead to new biodiscoveries of toxins used for possible medications in blood 
clotting disorders.  
Evolutionary selection pressures acting upon predatory venoms select for actions that facilitate prey 
capture via target sites reachable by the blood. Toxins that target the blood coagulation cascade do so 
via one of two mutually exclusive functional mechanisms: anticoagulation or procoagulation. 
Procoagulation, unlike anticoagulation, is a novel characteristic of snake venoms, while anticoagulant 
properties are more widespread across venomous lineages. Anticoagulant venoms, such as those 
found in most pit vipers, participate in the induction of haemorrhagic shock through a combined 
chemical assault on targets. These anticoagulant targets range from cleavage of fibrinogen (whether 
outright destruction or the production of weak clots which are readily broken down by the abundant 
plasmin produced by synergistic toxins which activate plasminogen) (Kini, 2006), through to platelets 
(aggregation inhibition or unnatural clumping effects which disrupt the normal role platelets serve in 
clotting) (Andrews et al., 2001; Gan et al., 1988; Kini and Koh, 2016; Navdaev et al., 2011; Peng et 
al., 1991; Shin and Morita, 1998; Tai et al., 2004; Wang et al., 1999); these toxic effects accompanied 
by other toxins that increase the permeability of the vascular bed (Assafim et al., 2016; Calvete et al., 
1991; Fry et al., 2009a; Fry et al., 2015c; Gan et al., 1988; Gould et al., 1990; Samel et al., 2006). 
These venoms are often employed by ambush feeding vipers, which specialise upon warm-blooded 
prey items, and are able to efficiently track post-bite using chemoreception and heat detection sensory 
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arrays (Gracheva et al., 2010; Panzano et al., 2010). Procoagulant venoms however, are selected for 
in lineages which feed upon prey with fast-moving blood circulation rates. Such prey lineages are 
vulnerable to toxins which produce blood clots that rapidly subjugate through stroke induction, such 
as taipans (Oxyuranus species) feeding upon rodents (Herrera et al., 2012; Zdenek et al., 2019).  
 
The boomslang and twig snakes: The Colubrinae 
The boomslang (Dispholidus typus) and the twig snakes (Thelotornis spp.) are iconic African snakes 
belonging to the subfamily Colubrinae (Colubridae). Both genera produce strikingly similar lethal 
procoagulant pathologies (Debono et al., 2017a). Both genera cause mortality to humans and are of 
medical importance (Grasset and Schaafsma, 1940; Hiestand and Hiestand, 1979). Prior to the first 
documented deaths, they were thought to be of little harm and were commonly kept in many private 
collections around the world. This was until each killed two eminent herpetologists (Chapman, 1968; 
FitzSimons, 1909b, 1919; FitzSimons, 1962; Pla et al., 2017; Pope, 1958; Weinstein et al., 2011; 
Weinstein et al., 2013). Both genera are now known to cause massive haemorrhaging within 12-24 
hours’ post-bite (Isbister, 2010; Weinstein et al., 2011), causing a slow death. Despite these 
similarities, antivenom is only produced for treating bites by D. typus and the mechanism of action 
of both venoms have been understudied. For further details please see Chapters 2 and 3.  
 
The Asian Pit viper clade: The Crotalinae 
In the course of over 40 million years of evolution, Asian pit vipers have undergone a rapid radiation 
accompanied by extensive venom diversification. There are 10 main genera (Alencar et al., 2016) 
which inhabit every niche across the Asian continent, both arboreal and terrestrial, including tropical 
rainforests, swamp lands, mangroves, coastal hinterland, rocky offshore islands and rocky outcrops 
at high mountainous altitudes. They are subject to high evolutionary pressures, reflective of their prey 
ecology in their diverse venom compositions. Pit vipers are known for their anticoagulant effects on 
prey. Examples of toxins isolated for their anticoagulant properties include Ancrod, a Toxicofera 
Venom (TV)-Kallirkein isolated from Calloselasma rhodostoma (Samsa et al., 2002; Vaiyapuri et 
al., 2015), and Jararhagin from Bothrops species which affects haemostasis through fibrinogen 
degradation and inhibition of platelets (Kamiguti et al., 1994; Kamiguti et al., 1996; Paine et al., 
1992). In contrast, there have also been procoagulant components isolated from individual pit vipers, 
including Alborhagin, a snaclec (snake venom C-type like-lectin proteins) isolated from Trimeresurus 
albolabris which aggregates platelets by binding to the GbIP receptor (Andrews et al., 2001; 
Arlinghaus et al., 2015; Peng et al., 1991) and Ecarin isolated from Echis carinatus which activates 
prothrombin directly (Casewell et al., 2015; Kornalik and Blombäck, 1975; Nishida et al., 1995). 
Through my research it is evident there is no one defining characteristic among the Asian pit vipers 
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(for further details please see Chapters 4, 5, 6, 7 and 8). There is a large diversification of haemotoxins 
and neurotoxins within such venoms which have been recruited on multiple occasions. This is 
reflective of the sporadic and random nature of evolution (Fry et al., 2009b).  
1.3 Aims and directions  
The main aim of this thesis was to investigate and understand the coagulant properties of members 
from the Colubrinae and Crotalinae families. Snake bite across the world still remains a neglected 
tropical disease, and with increased urbanisation and human population expanse, this number will 
only increase in future years to come (Fry, 2018; Gutiérrez et al., 2017; Gutiérrez et al., 2006; 
Kasturiratne et al., 2008; Williams et al., 2010; Williams et al., 2011). The combination of findings 
from the following chapters will increase our understanding of not only the biodiscovery potential of 
these medically important species but also increase our knowledge of the pathological relationship 
between venom and the human coagulation cascade. By applying this information, we can improve 
treatments, methodologies and diagnostics for clinical patients, especially for species which may not 
have antivenom currently available for treatment or in the case where medical help is not easily 
accessible. In doing so we can increase our overall understanding of coagulant venom which in turn 
can lead onto novel drug design surrounding this field.  
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Chapter 2: Coagulating Colubrids: Evolutionary, Pathophysiological and 
Biodiscovery Implications of Venom Variations between Boomslang (Dispholidus 
typus) and Twig Snake (Thelotornis mossambicanus) 
 
2.1 Abstract  
Venoms can deleteriously affect any physiological system reachable by the bloodstream, including 
directly interfering with the coagulation cascade. Such coagulopathic toxins may be anticoagulants 
or procoagulants. Snake venoms are unique in their use of procoagulant toxins for predatory purposes. 
The boomslang (Dispholidus typus) and the twig snakes (Thelotornis species) are iconic African 
snakes belonging to the family Colubridae. Both species produce strikingly similar lethal 
procoagulant pathologies. Despite these similarities, antivenom is only produced for treating bites by 
D. typus, and the mechanisms of action of both venoms have been understudied. In this study, we 
investigated the venom of D. typus and T. mossambicanus utilising a range of proteomic and 
bioactivity approaches, including determining the procoagulant properties of both venoms in relation 
to the human coagulation pathways. In doing so, we developed a novel procoagulant assay, utilising 
a Stago STA-R Max analyser, to accurately detect real time clotting in plasma at varying 
concentrations of venom. This approach was used to assess the clotting capabilities of the two venoms 
both with and without calcium and phospholipid co-factors. We found that T. mossambicanus 
produced a significantly stronger coagulation response compared to D. typus. Functional enzyme 
assays showed that T. mossambicanus also exhibited a higher metalloprotease and phospholipase 
activity but had a much lower serine protease activity relative to D. typus venom. The neutralising 
capability of the available boomslang antivenom was also investigated on both species, with it being 
11.3 times more effective upon D. typus venom than T. mossambicanus. In addition to being a faster 
clotting venom, T. mossambicanus was revealed to be a much more complex venom composition 
than D. typus. This is consistent with patterns seen for other snakes with venom complexity linked to 
dietary complexity. Consistent with the external morphological differences in head shape between 
the two species, CT and MRI analyses revealed significant internal structural differences in skull 
architecture and venom gland anatomy. This study increases our understanding of not only the 
biodiscovery potential of these medically important species but also increases our knowledge of the 
pathological relationship between venom and the human coagulation cascade. 
2.2 Introduction 
Venoms are used for competitor deterrence, defence, and prey capture. These chemical cocktails use 
a myriad of protein types as starting substrates for the evolution of their toxic arsenals. Many of these 
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protein families have been convergently recruited into the secretions of various venomous animal 
classes (Fry et al., 2009a). Novel expression of a normal body protein in the venom gland is followed 
by fixation and diversification of the proteins, with duplication and diversification leading to 
neofunctionalisation. In reptiles, such compounds have been recruited for use at different times in the 
diverse history of venom in this lineage with relative expression levels rising and falling for a 
particular toxin type along the evolutionary continuum (Fry et al., 2015c). As venoms evolve through 
the birth-and-death model of protein evolution (Fry et al., 2003b), there are many instances of toxins 
also being lost from within a lineage (Dowell et al., 2016).  
Rather than prey death, prey immobilization is the driving selection pressure upon the venom, as there 
is no functional difference between a prey item that is physically unable to flee or defend itself and 
one that is dead (Jackson et al., 2013; Yang et al., 2016). Prey capture involving chemicals will 
produce a different form of injury than one involving mechanical subjugation techniques such as 
claws or cutting teeth. Interactions among toxins are selected for a combined function, which 
facilitates prey subjugation in a time dependent manner. Evolutionary pressures from other variables 
such as post-envenomation prey detectability and prey escape potential also shape venoms. The 
evolutionary pressures acting upon predatory venoms select specific actions that facilitate prey 
capture via target sites reachable by the blood. Actions upon nerve action potentials and the blood 
clotting cascade are two particularly important areas. Venoms that act on the nerves are typically used 
by species that include reptiles as the major prey items in their diet. The specific function selected for 
the case of elapid snakes, which feed on sleeping lizards, is caused by alpha-neurotoxins, which 
antagonistically bind to the post-synaptic nicotinic acetylcholine receptor to produce flaccid paralysis 
(Jackson et al., 2016). Conversely, the long-glanded blue coral snake (Calliophis bivirgatus) and 
mambas (Dendroaspis spp.), which feed on active prey items with a high escape potential, have 
presynaptic-acting venoms that produce excitatory neurotoxicity, resulting in uncontrollable, 
uncoordinated spastic paralysis (Yang et al., 2016). In the case of C. bivirgatus, there is an additional 
selection pressure for rapid acting venom due to specialisation upon other venomous snakes, which 
in turn have a high chance of prey retaliation. 
Toxins that target the blood coagulation cascade do so in one of two mutually exclusive functional 
mechanisms; overall net anticoagulation or procoagulation. Anticoagulant venoms, such as those 
found in most pit-vipers, participate in the formation of haemorrhagic shock through a combined 
chemical assault, which may include the use of procoagulant pathways as part of the net anticoagulant 
function. Targets ranging from the cleavage of fibrinogen (whether outright destruction or the use of 
procoagulant pathways to produce weak, unnatural clots that are readily broken down by the abundant 
plasmin produced by synergistic toxins, which activate plasminogen) through to platelets 
(aggregation inhibition or unnatural clumping effects, which disrupt the normal role platelets serve 
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in clotting), with these toxic effects accompanied by other toxins that increase the permeability of the 
vascular bed (Assafim et al., 2016; Calvete et al., 1991; Fry, 2015; Fry et al., 2009a; Gan et al., 1988; 
Gould et al., 1990; Samel et al., 2006). These venoms are often employed by ambush feeding vipers, 
which specialise upon warm-blooded prey items, and are able to be efficiently tracked post-bite using 
chemoreception and heat detection sensory arrays (Gracheva et al., 2010; Panzano et al., 2010). In 
contrast, strong clot forming procoagulant venoms are selected for lineages that feed upon prey with 
fast moving blood circulation rates. Such prey lineages are vulnerable to toxins that produce blood 
clots that rapidly subjugate through stroke induction, such as taipans (Oxyuranus species) feeding 
upon rodents (Herrera et al., 2012).  
The African boomslang (Dispholidus typus) and the twig snakes (Thelotornis species) are closely 
related iconic African snakes belonging to the family Colubridae, and both inhabit arboreal, predatory 
niches that include prey items with a high potential for escape (Visser and Chapman, 1978; Weinstein 
et al., 2011). The limited work that has been undertaken upon them has revealed that both have clot-
forming, procoagulant venoms (Chapman, 1968; Grasset and Schaafsma, 1940; Kamiguti et al., 2000; 
Smith and FitzSimons, 1958; Weinstein et al., 2011; Weinstein et al., 2013). While the venoms appear 
to be functionally similar in their potent action upon blood chemistry, the relative complexity of the 
venoms is unknown. While Dispholidus has been shown to have a venom dominated by P-III snake 
venom metalloprotease (SVMP) (Fry et al., 2008; Kamiguti et al., 2000; Pla et al., 2017), other toxin 
types are present in the venom in lower amounts (Fry et al., 2008; Fry et al., 2003b). In vipers, certain 
procoagulant P-III SVMPs have been shown to activate prothrombin (Bernardoni et al., 2014; 
Isbister, 2009; Joseph and Kini, 2002; Rosing and Tans, 1992) or Factor X (Bernardoni et al., 2014; 
Isbister, 2009; Tans and Rosing, 2002). Strong clot forming procoagulant function has been 
convergently evolved in the venom of D. typus. Similar activities are suggested for T. capensis 
(Atkinson et al., 1980). The venom composition for any Thelotornis species is unknown so the toxin 
type responsible for procoagulation can only be inferred as likely being a P-III SVMP like its related 
genera Dispholidus. From a functional perspective, these two related but very divergent snakes share 
a coagulotoxic action with their last common ancestor (Fry et al., 2008; Fry et al., 2003b). These 
snakes have evolved procoagulant venoms convergently in relation to vipers in the Daboia genus 
(Mukherjee, 2008, 2014) or elapids in the Oxyuranus or Pseudonaja genera (Isbister et al., 2010a; 
Marshall and Herrmann, 1983). Daboia use serine proteases to activate factor X, while Oxyuranus 
and Pseudonaja use a mutated factor Xa:factor Va complex to escape hemostatic control (Bos and 
Camire, 2010).  
Dispholidus is genetically close to the genus Thrasops. Dispholidus and Thrasops are in turn sister to 
Thelotornis. The two genera differ in their occupied niches and morphology. Dispholidus is a 
monotypic genus consisting of the boomslang (D. typus), which is an active foraging snake with very 
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large eyes with circular pupils and acute vision, large round heads, and variable colour, ranging from 
uniform brown to green with darkened scale edges (Chapman, 1968; Weinstein et al., 2011). The 
large head is quite similar to the tree cobras (e.g. Naja goldii), including enlarged eyes. In contrast, 
Thelotornis is a genus of ambush feeding, highly cryptically and intricately patterned snakes with 
large eyes, horizontal pupils, and near binocular vision (Chapman, 1968; Shine et al., 1996; Weinstein 
et al., 2011). The elongate heads are convergently similar to other Colubridae, particularly the 
Ahaetulla genus from Asia and the Oxybelis genus of the southern U.S. and Central America.  
Birds account for the majority of Dispholidus prey items as it hunts in the canopy. The fast-moving, 
endothermic blood circulatory system of avians is similar to mammals in being vulnerable to rapid 
prey subjugation by stroke formation, thus neutralising the high escape potential posed by prey items 
with flight ability. While lizards such as chameleons form a percentage of the Dispholidus diet (Visser 
and Chapman, 1978; Weinstein et al., 2011), they are non-dangerous and slow moving and are also 
taken during their diurnal activity period when blood circulation is at its maximum. Thelotornis may 
have a more complex diet than D. typus as it occupies a niche located near or on the forest floor and 
snakes of this genus are perhaps also more likely to be sensitive to prey escape potentials due to their 
slower movements relative to the fast moving Dispholidus (Shine et al., 1996; Visser and Chapman, 
1978; Weinstein et al., 2011).  
Neither genus of snakes was thought to be of significant medical consequence until each killed an 
eminent herpetologist (Robert Mertens and Karl Patterson Schmidt, respectively) (Pla et al., 2017). 
However, the ability for D. typus to cause serious harm to humans, and even death, had previously 
been reported by F.W. Fitzsimons as early as 1909 (Chapman, 1968; FitzSimons, 1909a, 1919; 
FitzSimons, 1962; Pope, 1958; Weinstein et al., 2011; Weinstein et al., 2013). Strikingly, T. capensis 
has been shown to produce nearly identical human clinical symptoms as reported for D. typus, with 
death the result of internal bleeding such as cerebral haemorrhage (Atkinson et al., 1980; Smith and 
FitzSimons, 1958; White, 2005). However, the existing antivenom manufactured to treat bites caused 
by D. typus is said to be ineffective in cases of T. capensis envenomation (Atkinson et al., 1980; 
Weinstein et al., 2011; Weinstein et al., 2013). While prey injected with significant concentrations of 
procoagulant venoms succumb to stroke (Martin, 1893), human deaths from these venoms are due to 
internal haemorrhage, due to the dilution of the procoagulant venom into a volume of blood much 
larger than the concentrated effects in prey animals, resulting in defibrinogenation due to venom 
induced consumptive coagulopathy (Fry, 2015; Herrera et al., 2012; Isbister, 2009; Isbister et al., 
2010b; White, 2005). 
Despite a monovalent antivenom existing and routinely administered to bite victims (Kamiguti et al., 
2000; Weinstein et al., 2011), limited research has been conducted on the function of D. typus venom, 
with the literature being dominated by bite case reports or proteomics in the absence of bioactivity 
11 
 
testing. Even less is known about Thelotornis venoms, with limited previous publications having 
mainly dealt only with T. capensis, while the rest of the genus is unknown in its venom composition. 
We aimed to investigate the key similarities and differences between the two genera utilising a range 
of proteomic and bioactivity approaches to reconstruct their functional evolution in response to prey 
preference and ecological niche occupied. It is hypothesised that T. mossambicanus has a greater 
diversity of venom toxin components, reflective of its diverse diet and their associated heighted 
potential for prey escape, than the more specialised feeder D. typus. 
 
2.3 Results 
 
2.3.1 Skull and Venom Gland Anatomical Comparisons 
Both species displayed enlarged rear-fangs, consistent with their demonstrated efficient venom 
delivery in predation and also defensive bites. Reflective of their difference in head shape, the T. 
mossambicanus venom gland was more elongate than that of D. typus (Figure 2.1). 
 
 
Figure 2.1 CT and MRI scan  
Contrast tomography (left column) and magnetic resonance imaging (right column) comparison of 
D. typus (top row) and T. mossambicanus (bottom row). 
 
2.3.2 Proteomics  
Shotgun mass spectrometry analysis recovered the same five toxin types from each venom; CRiSP, 
PLA2 Type IIE, 3FTx, and SVMP. However, 1D and 2D gels showed significantly different relative 
expression and complexity levels. While both 1D and 2D SDS gels indicate that both species are 
dominated by P-III SVMP (Figure 2.2 and Figure 2.3), T. mossambicanus also contained 
phospholipase A2 (PLA2 Type IIE) in high amounts. The presence of PLA2 Type IIE is a significant 
discovery as it is the third type of PLA2 to be characterised in snake venoms (Fry et al., 2012). The 
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molecular weights of identified P-III SVMP correspond to previous transcriptome and proteome data 
for D. typus (Pla et al., 2017). 
 
 
 
Figure 2.2 1D SDS Page 
1D SDS page with identified groups of proteins. D.t = Dispholidus typus, T.m = Thelotornis 
mossambicanus. Reduced conditions on the left, Non-reduced conditions on the right. Molecular 
weight marker indicated by centered numbers (kDa). Annotations (right) refer to bands identified 
(white numbers) within the reduced column.  
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Figure 2.3 2D SDS Page  
(A) 2D SDS page of Dispholidus typus under reducing conditions; (B) 2D SDS page of Thelotornis 
mossambicanus under reducing conditions. Molecular weight markers (kDa) are as for Figure 2. pI 
range is 3–10 (left to right) in red.  
 
2.3.3 Enzymatic Assays 
Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity 
Despite T. mossambicanus having a more complex venom profile than D. typus, and thus lower 
relative amounts of P-III SVMP, it actually displayed a higher rate of cleavage of a matrix 
metalloprotease specific substrate (Figure 2.4). A two-way (RM) ANOVA (α = 0.05) indicates that 
there is a significant difference in Column Factor (species and concentration), accounting for 78.6% 
of the total variance (after adjusting for matching); F(3, 8) = 45.2, p < 0.001. Tukey’s post-hoc test 
indicated that there is a significant difference in activity between D. typus and T. mossambicanus at 
a concentration of 0.5 µg/100 μL (p ≤ 0.04). The levels of T. mossambicanus were of a high level, 
similar to that of the viperid snake Gloydius saxitilis included for comparison.  
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Figure 2.4 Snake Venom Metalloprotease Activity of venom 
Snake Venom Metalloprotease Activity of venom (10 ng/μL and 50 ng/μL) was measured based on 
its ability to cleave a fluorogenic peptide substrate (Mca-PLGL-Dpa-AR-NH2 Fluorogenic MMP 
Substrate, Cat#ES001). Column graph of Matrix Metalloprotease activity assay of D. typus and T. 
mossambicanus obtained from normalisation of slope values. X axis: species name and concentration; 
Y axis: absorbance percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and 
error bars indicate standard deviation. 
 
Contrastingly, D. typus venom demonstrated a much higher kallikrein activity compared to that of T. 
mossambicanus. D. typus had an active concentration of 0.1 µg/100 μL and 0.5 µg/100 μL, compared 
to T. mossambicanus, which was only slightly active at 0.5 µg/100 μL (Figure 2.5). A two-way (RM) 
ANOVA (α = 0.05) indicates that there is a significant difference within the test, with Column Factor 
(species and concentration) accounting for 80.1% of the total variance (after adjusting for matching); 
F(3, 7) = 136.6, p ≤ 0.001. Tukey’s post-hoc test indicated that there is a highly significant difference 
in activity between D. typus and T. mossambicanus at both concentrations (p ≤ 0.001). This is 
indicated by the increased presence of kallikrein-like serine proteases in D. typus’ venom profile 
(Figure 2.2). However, even the proportionally higher D. typus activity levels were insignificant in 
relation to the representative viperid Trimeresurus vogeli included for comparison, thus indicating 
that this function is a trivial aspect of the venom, consistent with the non-detection in our proteomics 
and low-levels in the published D. typus transcriptome (Pla et al., 2017). 
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Figure 2.5 Kallikrein activity of venom 
The kallikrein activity of venom (10 ng/μL and 50 ng/μL) was measured based on its ability to cleave 
a fluorogenic peptide substrate (Boc-VPR-AMC Fluorogenic Peptide Substrate, Cat#ES011). 
Column graph of Kallikerin activity assay of D. typus and T. mossambicanus obtained from 
normalisation of slope values. There is a highly significant difference in activity between D. typus 
and T. mossambicanus at both concentrations (p ≤ 0.001). X axis: species name and concentration; Y 
axis: absorbance as a percentage. Analysis of triplicates was conducted on GraphPad PRISM 7.0 and 
error bars indicate standard deviation.  
 
2.3.4 Fluorescent Determination of sPLA2 Activity  
We tested for continuous secretory phospholipase A2 (sPLA2) enzymatic activity over 100 
measurement cycles using and following the EnzChek® Phospholipase A2 Assay Kit  
(Cat#E10217). T. mossambicanus showed increased levels of sPLA2 activity compared to  
D. typus at a concentration of 50 ng/μL (Figure 2.6). This increase in activity by T. mossambicanus 
is also mimicked in the venom profiling of both venoms via 1D SDS PAGE (Figure 2.2). A two-way 
RM ANOVA (α = 0.05) indicates that there is a significant difference within the assay, with Column 
Factor (species and concentration) accounting for 63.41% of total variance (after adjusting for 
matching); F(2, 6) = 78.75, p ≤ 0.001. Tukey’s post-hoc test indicated there is a highly significant 
difference in activity between D. typus from the positive control and between D. typus and T. 
mossambicanus (p ≤ 0.001). Tukey’s post-hoc test also indicates a significant difference of T. 
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mossambicanus from the positive control (p ≤ 0.01). The T. mossambicanus levels were similar to 
that of the representative viperid snake Azemiops feae included for comparison. 
 
Figure 2.6 Phospholipase A2 activity  
Secretory Phospholipase A2 was measured by its ability to cleave a fluorogenic peptide substrate 
EnzChek® (Cat# E10217). Column graph of sPLA2 activity assay of D. typus and T. mossambicanus 
obtained from normalisation of slope values. There is a highly significant difference in activity 
between D. typus from the positive control and between D. typus and T. mossambicanus (p ≤ 0.001). 
There is also a significant difference of T. mossambicanus from the positive control (p ≤ 0.01). X 
axis: species name and concentration; Y axis: slope as a relative percentage. Analysis of triplicates 
was conducted on GraphPad PRISM 7.0 and error bars indicate standard deviation. 
 
2.3.5 Procoagulation Analysis  
While both venoms were potently procoagulant, we find that the venom of T. mossambicanus is much 
faster compared to that of D. typus (Figure 2.7 and Figure 2.8). At a 20 µg/mL concentration, T. 
mossambicanus venom clots the plasma on average in 7.5 sec (SD 0.15 sec), compared to D. typus, 
which clots the plasma on average in 11.2 sec (SD 0.06 sec) (Table 2.1). The T. mossambicanus 
venom is amongst the most potently coagulotoxic of any we have tested, being on par with Oxyuranus 
and Pseudonaja venoms tested under identical conditions (unpublished results). At a 0.05 µg/mL 
concentration, T. mossambicanus venom clots the plasma on average in 80.4 sec (SD 0.52 sec), 
compared to D. typus, which clots the plasma on average in 146.6 sec (SD 5.23 sec) (Table 2.1). 
Figure 2.6 demonstrates the relative potency of T. mossambicanus venom against human plasma, 
compared to D. typus, in the reduced variation in clotting times between dilutions. The distance 
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between the first vertical line and the second vertical line is longer in T. mossambicanus than in D. 
typus, illustrating that there is a longer rise in clotting times, depicting that T. mossambicanus venom 
holds its potency between dilutions more so than D. typus (Figure 2.7, Table 2.2). This is also 
demonstrated by the point where the curve crosses the X axis, which is higher in D. typus than in T. 
mossambicanus (R0 ϕ2 = 37.83 and 23.17 sec respectively) (Table 2.2). The additional investigation 
with and without cofactors CaCl2 and phospholipid had no impact on the clotting times of either 
species, with clotting times remaining the same at all dilutions (data not shown). This is indicative of 
both venoms being calcium and phospholipid independent in exerting their procoagulant 
coagulotoxic actions.  
 
Table 2.1 Average clotting times 
Average clotting times with standard deviations (SD) (in seconds) of D. typus and T. mossambicanus 
at varying dilutions with and without the addition of boomslang antivenom. 
  
Concentration Without Antivenom With Antivenom 
D. typus T. 
mossambicanus 
D. typus T. 
mossambicanus 
 Mean SD Mean SD Mean SD Mean SD 
20 µg/mL 11.27 0.06 7.57 0.15 20.73 1.07 9.6 0.17 
10 µg/mL 15.95 1.88 9.55 0.17 155 5.2 16 0.17 
6.66 µg/mL 19.34 0.21 11.20 0.34 214.56 21.28 21.16 0.23 
5 µg/mL 21.22 0.22 12.43 0.08 255 10.56 35.13 1.32 
3.33 µg/mL 24.72 0.22 14.95 0.65 343.2 8.97 43.33 1.86 
2.5 µg/mL 27.63 0.14 16.45 0.18 432.3 35.32 53.43 0.11 
2 µg/mL 30.91 0.47 18.27 0.13 444.93 23.43 58.46 1.29 
1.33 µg/mL 36.32 1.61 20.50 0.58 525.86 51.19 75.43 2.15 
1 µg/mL 39.60 0.54 24.30 0.74 594.86 61.15 83.33 3.86 
0.66 µg/mL 43.91 0.56 27.44 1.03 735.3 6.94 100.8 1.97 
0.4 µg/mL 53.77 6.21 31.67 0.19 790.36 9.41 128.4 0.52 
0.25 µg/mL 61.95 7.95 35.91 0.64 966.76 35.88 163.23 2.6 
0.125 µg/mL 83.31 6.51 54.89 0.14 999 0 226.33 2.6 
0.05 µg/mL 146.65 5.23 80.44 0.52 999 0 381.23 4.71 
 
 
Table 2.2 Asymptotic regression model coefficient estimates 
Asymptotic regression model coefficient estimates for D. typus and T. mossambicanus normal plasma 
clotting times. In this example, ϕ1 is the asymptote as x (concentration) approaches ∞, ϕ2 is the 
response at x = 0, and t0.5 is the half-life. Parameter ϕ3 is the logarithm of the rate constant which is 
used to enforce positivity so that an asymptote is reached in the model. The corresponding half-life 
is written t0.5 = log2/exp(ϕ3). Analysis and output performed in R Studio (refer to methodology 3.4.3 
Coagulation Statistical analysis). 
 
Species Coefficient Estimates 
Aym ϕ1 R0 ϕ2 lrc ϕ3 
D. typus 9.095161 (s) 37.83835 (s) −0.6711807 
T. mossambicanus 2.068652 (s) 23.17609 (s) −0.8289048 
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Figure 2.7 Asymptotic plot 
Asymptotic plots of D. typus and T. mossambicanus procoagulation clotting against human plasma. 
Asymptotic time depicted by horizontal line, D. typus asymptote 9.09 (sec), T. mossambicanus 
asymptote 2.06 (sec). X axis: log concentration (µg/mL). Y axis: Time in seconds. Analysis and plots 
created in R Studio.  
 
 
 
 
Figure 2.8 Coagulation and antivenom clotting curves 
Comparison of procoagulation clotting curves of D. typus and T. mossambicanus, with and without 
the addition of antivenom. D. typus clotting curve given in blue circles, AV D. typus = antivenom 
response curve given in purple circles, T. mossambicanus clotting curve given in red squares, AV T. 
mossambicanus = antivenom response curve given in green squares. X axis: final venom 
concentration (µg/mL), Y axis: clotting time in seconds. Values are averages of triplicates (single 
dilution measured three times) and standard deviation error bars are shown for each, although for 
most the error range is smaller than the line icon. 
 
With the addition of diluted boomslang monovalent antivenom to the dilution series, it is evident that 
the antivenom neutralises D. typus remarkably well, in contrast to having little neutralising effect on 
T. mossambicanus (Figure 2.8). At 20 µg/mL venom concentration with the antivenom at a final 
concentration in the 250 μL cuvette volume of 1% of that of the original vial concentration, T. 
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mossambicanus clotted the plasma in 9.6 sec (SD 0.17 sec) instead of the 7.5 sec without antivenom, 
compared to D. typus, which clotted the plasma at 20.7 sec (SD 1.07 sec) instead of the 11.2 sec 
without antivenom (Table 2.1). At a 0.05 µg/mL venom concentration, the added antivenom had some 
effect on T. mossambicanus, which clotted in 381.2 sec (SD 4.71 sec) instead of 80.4 sec without 
antivenom (Table 2.1). D. typus however reached maximum clotting time of 999.9 sec (Table 2.1) at 
a venom concentration of 0.05 µg/mL with the addition of antivenom, demonstrating a significantly 
greater effective neutralising ability against this species.  
Comparing EC50 outputs, it is evident that, despite the variation in clotting times between the species 
(Figure 2.8), half-maximal concentration is reached at a similar point by both species. This is due to 
the dilution series following the same trajectory regardless of time (Figure 2.8). When transformed, 
this trajectory becomes more evident, as there is little x-axis difference between T. mossambicanus 
with and without antivenom (0.24 µg/mL: 95% CI 0.22–0.26 µg/mL, and 0.23 µg/mL: 95% CI 0.20–
0.26 µg/mL respectively) and T. mossambicanus and D. typus without antivenom (0.24 µg/mL and 
0.20 µg/mL: 95% CI 0.18–0.23 µg/mL respectively) (Figure 2.9). However, when antivenom is 
introduced with D. typus, the EC50 x-axis shifts significantly to the right (1.62 µg/mL: 95% CI 1.49–
1.76 µg/mL) (Figure 2.9). Due to each sub data set being transformed, first by log concentration and 
then the normalisation of clotting time, each final data point reaches 100% (Figure 2.9). Taking into 
account the y-axis shift in addition to the x-axis shift (Figure 2.8), the T. mossambicanus venom has 
an antivenom induced relative shift in the clotting curve of 4.69, while the D. typus venom has an 
antivenom induced relative shift in the clotting curve of 53.12. Thus, the antivenom is 11.3 times 
more effective at neutralizing D. typus venom than T. mossambicanus venom. Thus, if the antivenom 
had no significant effect upon T. mossambicanus under such ideal circumstances as conducted in this 
study, then there is little chance of it having a therapeutic effect in a clinical scenario without the use 
of extreme amounts of antivenom.  
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Figure 2.9 Normalisation of transformed data 
Normalisation of transformed data; antivenom and procoagulant effects of D. typus and T. 
mossambicanus. D. typus clotting curve given in blue circles, AV D. typus = antivenom response 
curve given in purple circles, T. mossambicanus clotting curve given in red squares, AV T. 
mossambicanus = antivenom response curve given in green squares. X axis: log concentration, Y 
axis: Normalised time (%) (for sub data sets). Analysis performed in GraphPad PRISM 7.0. Values 
are averages of triplicates (single dilution measured three times), and standard deviation error bars 
are shown for each, although for most the error range is smaller than the line icon. 
 
2.4 Discussion 
Both venoms tested here were found to be highly procoagulant without requiring calcium or 
phospholipid as co-factors. However, T. mossambicanus is notably more potent than D. typus, as well 
as being extremely poorly neutralised by SAIMR boomslang antivenom (Table 2.1 and Table 2.2, 
Figure 2.7, Figure 2.8 and Figure 2.9). The decoupling from co-factors is a notable discovery as this 
lack of shift between tests with or without co-factors had only been well-documented for Echis 
carinatus. This is the first extensive antivenom comparison of both species marking the relative 
effectiveness of the available boomslang monovalent antivenom. 
Previous reports have described these two species as exhibiting strikingly similar lethal 
envenomations (Atkinson et al., 1980; Chapman, 1968; FitzSimons, 1909a, 1919; FitzSimons, 1962; 
Pope, 1958; Smith and FitzSimons, 1958; Weinstein et al., 2011; Weinstein et al., 2013) that can be 
attributed to their venoms being dominated by P-III SVMPs (Figure 2.2 and Figure 2.3). It is notable 
that, despite T. mossambicanus having a lower concentration of SVMP due to its greater venom 
complexity, it displayed a higher relative rate of metalloprotease activity in addition to being more 
potently coagulotoxic (Figure 2.4, Figure 2.7 and Figure 2.8). Further, T. mossambicanus possesses 
two distinct molecular weight classes of SVMP as opposed to the single band present in D. typus 
venom (Figure 2.2). Thus, the differential proteomics profile is mirrored by differential coagulotoxic 
activity. This key difference between the species’ venom profiles may also shed light as to why the 
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available antivenom for D. typus has only a small neutralising effect on T. mossambicanus venom 
(Figure 2.8 and Figure 2.9, Table 2.1).  
Calcium-independent prothrombin activation is a rare feature in snake venoms, with most venoms 
typically requiring calcium for such a coagulotoxic activity. A previously documented notable 
exception is the ecarin-type P-III SVMP from Echis carinatus, which does not have a marked shift 
between tests with or without co-factors (Kornalik and Blombäck, 1975; Rosing and Tans, 1992). 
Thus, the presence of such an activity in the venoms of these two colubrid snakes’ points towards a 
remarkable case of functional convergence within the same toxin class.  
Procoagulation accompanied by plasmin inhibition is an effective way to potentiate the coagulotoxic 
effects as the blood clots formed would have a longer half-life since the role of plasmin is to break 
blood clots down. This synergistic activity has been documented in viper venoms (e.g. Daboia) and 
elapid venoms (e.g. Pseudonaja), where the procoagulation is accomplished by very different toxin 
types (SVMP and fXa:fVa, respectively), but the plasmin inhibition is exerted by the same toxin type 
(kunitz peptide) (Cheng and Tsai, 2014; Masci et al., 2000). However, neither D. typus or T. 
mossambicanus venoms displayed this synergistic action.  
Despite having the same procoagulant mechanism, it appears evident that additional external 
evolutionary pressures are driving the variation between these two species. In addition to differential 
complexity, the venoms were functionally variable relative to each other in non-procoagulant 
activities, with D. typus having serine protease activity (Figure 2.5), while conversely T. 
mossambicanus had strong PLA2 activity (Figure 2.6). It is known that evolution among arboreal 
specialists further influences venom composition of toxins’ families (Debono et al., 2016). This is 
usually in the form of prey ecology, dependent on niche occupation. Even though both species occupy 
an arboreal habitat, their differential morphology and behaviour allow for varying prey interactions, 
thus potentially further contributing to venom variation and punctuated evolution. As D. typus is an 
agile and fast-moving snake, it is able to pursue prey, thus minimising escape potential. T. 
mossambicanus however is a slower moving cryptic snake that ambush feeds, and thus the prey 
escape potential may be significantly higher. Thus, there may be a stronger selection pressure 
operating upon T. mossambicanus for a venom which rapidly immobilises prey. This is consistent 
with what has been observed in other lineages of venomous animals in which prey escape potential 
is a significant shaping factor and thus the venom is under extreme selection pressure for rapid 
immobilising action (Aman et al., 2015; Dutertre et al., 2014; Eng et al., 2015; Fry, 2015; Fry et al., 
2015a; Fry et al., 2015c; Harvey and Anderson, 1985; Harvey and Karlsson, 1980; Herrera et al., 
2012; Jackson et al., 2013; Jin et al., 2015; Karlsson et al., 1983; Osman et al., 1973; Utkin et al., 
2015; Yang et al., 2016).  
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Thus, this investigation not only has revealed the differential evolution of D. typus and T. 
mossambicanus venoms and the poor performance of boomslang antivenom against T. 
mossambicanus venom, but it has also reinforced that there are commonalities to venom evolution 
such that there may be levels of predictability in regards to niche occupation and prey escape potential 
shaping venom relative rates of action. The differences in ecological niches occupied was also 
reflected in differential skull morphology (Figure 2.1). This reinforces that, in addition to the applied 
application of venom research in regards to biodiscovery and clinical effects, research such as this 
contributes to the growing body of venom evolutionary theory. 
 
2.5 Materials and Methods  
2.5.1 Venom Supplies 
Pooled venoms from Dispholidus typus (South African origin) and Thelotornis mossambicanus 
(Mozambique) were supplied by Latoxan (Portes-lès-Valence, France). 
 
2.5.2 Micro-Computed Tomography (CT) 
We scanned representative boomslang (Dispholidus typus) and the twig snakes (Thelotornis 
mossambicanus) with a Siemens Inveon micro-CT scanner. The scanner was operated at 80 KV 
energy, 250 µA intensity with 360 projections per 360°, and 2300 ms exposure time. The samples 
were scanned at a nominal isotropic resolution of 27.8 µm. The data were reconstructed using a 
Feldkamp conebeam back-projection algorithm provided by an Inveon Acquisition Workstation from 
Siemens. The images in 3D were visualized and processed with ImageJ v1.51f (Schneider et al., 
2012), Materialise Mimics v19.0 (Materialise, Leuven, Belgium), and MeshLab v1.3.3 (Institute of 
the National Research Council of Italy, Pisa, Italy). 
 
2.5.3 Magnetic Resonance Imaging 
MRI was used to obtain a three-dimensional (3D) shape of the venom glands without intrusive 
dissection or sectioning techniques. For fixation, neutral buffered formalin (NBF) preserved 
specimens had the formalin removed by four individual hours of washing steps in phosphate buffered 
saline (PBS) and incubated overnight in 0.1% Magnevist® (Bayer, Leverkusen, Germany) in PBS. 
After the removal of NBF, the sample was submersed in perfluoro-ether Fomblin (Solvay Solexis, 
Alessandria, Italy) and placed under vacuum to prevent air artifacts. Imaging was performed on a 
16.4 T (700 MHz) vertical 89-mm-bore system (Bruker BioSpin, Rheinstetten, Germany) using a 
Bruker Micro 2.5 gradient system (2.5 G/cm A), transmit/receive radiofrequency coils with diameters 
of 10 mm, and a quadrature birdcage resonator (M2M Imaging, Brisbane, Australia). Bruker 
ParaVision 6.0.1 software was used for image acquisition and anatomical images were acquired using 
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a 3D FLASH (Fast Low Angle Shot) gradient echo sequence. The imaging parameters were: TR/TE 
= 50/8 ms, flip angle 30 °C, two excitations. The field-of-view and matrix sized to fit the sample with 
the resulting voxels having 50–62.5 μm isotropic resolution. Total scan time was approximately 1 h 
per sample. MRI data was processed using Medical Imaging Processing, Analysis, and Visualization 
v6.0.0 (MIPAV, Centre for Information Technology, National Institutes of Health, Bethesda, MD, 
USA), and 3D image segmentation, surface rendering, and volumetric measurements of the glands 
were performed manually using ITK-SNAP (Yushkevich et al., 2006). 
 
2.5.4 Proteomics  
Our proteomic investigations including using 1D and 2D SDS-PAGE, protein band purification and 
crude venom Shotgun analysis. They were performed as previously described by us (Debono et al., 
2016) with the exception of additional LC-MS/MS analysis, following protein extraction from 
isolated 1D gel bands. Shotgun samples were analyzed using the methods described below. 
 
2.5.5 Nano HPLC-ESI-Triple Time of Flight (TOF) Mass Spectral Analysis 
Protein extracts from gel bands were analysed by LC-MS/MS using a Q Exactive™ Hybrid 
Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher Scientific, Waltham, MA, USA) equipped 
with a nano electrospray ion source. An aliquot (8 μL) of each extract was injected onto a C18 trap 
column (75 μm × 2 cm, Thermo Scientific, Waltham, MA, USA) at 6 μL/min. Samples were de-salted 
on the trap column for 5 min using 0.1% formic acid at 6 μL/min. The trap column was then placed 
in-line with the analytical nano HPLC column (15 cm × 75 μm C18, 3.5 μm, Thermo Fisher Scientific, 
Waltham, MA, USA) for mass spectrometry analysis. Solvent A consisted of 2% ACN/0.1% formic 
acid, and solvent B contained 100%ACN, 2% LC-MS water, and 0.1% formic acid. Peptide elution 
was made possible via linear gradients of 1 to 40% solvent B over 32 min at 300 nl/min flow rate, 
followed by a steeper gradient from 40% to 95% solvent B over 3 min. Solvent B was held at 95% 
for 2.5 min to allow for washing of the column and returned to 1% solvent B for equilibration prior 
to the next sample injection. The ion spray voltage was set to 1.8 kV, and the temperature of capillary 
was 300 °C. The mass spectrometer acquired 3 × 106 ion count with the max injection time of 20 ms 
for a full scan TOF-MS data followed by 106 ions count with the max injection time of 110ms for a 
full scan product ion data in an Information Dependant Acquisition (IDA) mode. Full scan TOF-MS 
data was acquired over the mass range of 300–1800 m/z, while the product ion ms/ms was 100–1800 
m/z. Ions observed in the TOF-MS scan exceeding a threshold of 1.8 x 105 for the precursor selection 
with a charge state of +1 to +8 were set to trigger the acquisition of the product ion, with ms/ms spectra 
of the resultant 20 most intense ions. The data was acquired and processed using Xcalibur™ software 
(Thermo Fisher Scientific, Waltham, MA, USA). 
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2.5.6 Protein Identification 
Protein database searches were conducted against Uniprot for broad protein identification. A 
composite target decoy database was built with the forward and reverse sequences for calculating the 
FDR. Proteins were identified by database searching using PEAKS v7.5 (Bioinformatics Solutions 
Inc., Waterloo, ON, Canada) against the protein database. The search parameters were as follows: 
precursor ion mass tolerance, 10 ppm; fragment ion mass tolerance, 0.05 Da; fully tryptic enzyme 
specificity; one missed cleavage; monoisotopic precursor mass a fixed modification of cysteine 
carbamidomethylation; and variable modifications, including methionine oxidation, conversion of 
glutamine and glutamic acid to pyroglutamic acid, deamidation of asparagine, phosphorylation, 
acetylation, and sulfation. For PEAKS, de novo sequencing, database search, and characterising 
unspecific post-translational modifications (PTMs) were used to maximise the identifications; false 
discovery rate (FDR) was set to ≤1%; and the individual peptide ion score [−10·Log(p)] was 
calculated accordingly, where p is the probability that the observed match is a random event. 
 
2.5.7 Orbitap Elite Mass Spectrometer for SHOTGUNS 
For LC-MS/MS analysis, the parameters are as follows; the samples were separated using RP-
chromatography on a Dionex Ultimate 3000 RSLC nano-system (Lifetech, Carlsbad, CA, USA). The 
samples were desalted on a Thermo PepMap 100 C18 trap (Lifetech, Carlsbad, CA, USA) (0.3 × 5 
mm, 5 µm) for 5 min with a flow rate of 30 μL/min. This was followed by separation on an Acclaim 
PepMap RSLC C18 (Lifetech, Carlsbad, CA, USA) (150 mm × 75 µm) column at a flow rate of 300 
nL/min. A gradient of 10%–70% was applied buffer B over 7 min, where buffer A (1% ACN/0.1% 
FA) and buffer B (80% ACN/0.1% FA) were used to separate peptides. The eluted peptides were 
directly analysed on an Orbitap Elite mass spectrometer (Thermo Scientific, Carlsbad, CA, USA) 
using an NSI electrospray interface. The source parameters included a capillary temperature of 
275°C; S-Lens RF level at 60%, source voltage of 2 kV, and maximum injection times of 200 ms for 
MS and 150 ms for MS2. The instrument parameters included an FTMS scan across m/z range 350–
1800 at 60,000 resolution followed by information dependent acquisition of the top 10 peptides across 
m/z 40–1800. Dynamic ion exclusion was employed using a 15 sec interval. Charge state screening 
was enabled with the rejection of +1 charged ions, and monoisotopic was precursor selection enabled. 
Data was converted to mascot generic format (mgf) using the msConvert software (ProteoWizard 
v3.0.9576, SCIEX, Concord, ON, Canada) and searched using Protein Pilot™ v5.0 (SCIEX, Concord, 
ON, Canada,) via the Uniprot database ‘metazoa’.  
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2.5.8 Enzymatic Activity Assays 
2.5.8.1 Fluorescent Determination of Matrix Metalloprotease and Kallikrein Activity 
A working stock solution of freeze dried venom was reconstituted in a buffer containing 50% 
MilliQ/50% glycerol (>99.9%, Sigma, St Louis, MO, USA) at a 1:1 ratio to preserve enzymatic 
activity and reduce enzyme degradation. Varying concentrations of crude venom (10 ng/μL and 50 
ng/μL) were plated out in triplicates on a 384-well plate (black, Lot#1171125, nunc™ Thermo 
Scientific, Rochester, NY, USA) and measured by adding 90 μL quenched fluorescent substrate per 
well (total volume 100 μL/well, 10 μL/ 5mL enzyme buffer, 150 mM NaCl, and 50 mM Tri-HCl (pH 
7.3), Fluorogenic Peptide Substrate, R & D systems, Cat#ES001 & ES011, Minneapolis, Minnesota). 
Fluorescence was monitored by a Fluoroskan Ascent™ (Thermo Scientific, Vantaa, Finland) 
Microplate Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland) (Cat#ES001 for Matrix 
Metalloprotease at an excitation of 320 nm, emission at 405 nm; Cat#ES011 for Kallikrein at an 
excitation of 390 nm, emission at 460 nm) over 400 min or until activity had ceased. Data was 
collected using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland).  
2.5.8.2 Fluorescent Determination of PLA2 Activity  
We assessed the continuous Phospholipase A2 (PLA2) activity of the venoms using a fluorescence 
substrate assay (EnzChek® Phospholipase A2 Assay Kit, Cat#E10217, Thermo Scientific, Rochester, 
NY, USA), measured on a Fluoroskan Ascent® Microplate Fluorometer (Cat#1506450, Thermo 
Scientific, Vantaa, Finland). As above, we used a working stock solution of freeze dried venom 
reconstituted in a buffer containing 50% MilliQ / 50% glycerol (>99.9%, Sigma) at a 1:1 ratio. A 
concentration of enzyme activity in venom (50 ng/μL) was brought up in 12.5 μL 1× PLA2 reaction 
buffer (50 mM Tris-HCL, 100 mM NaCl, 1 mM CaCl2, pH 8.9) and plated out in triplicates on a 384-
well plate (black, Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, USA). The triplicates 
were measured by dispensing 12.5 μL quenched 1 mM EnzChek® (Thermo Scientific, Rochester, 
NY, USA) Phospholipase A2 Substrate per well (total volume 25 μL/well) over 100 min or until 
activity had ceased (at an excitation of 485 nm, emission 538 nm). Purified PLA2 from bee venom (1 
U/mL) was used as a positive control and data was collected using Ascent® Software v2.6 (Thermo 
Scientific, Vantaa, Finland).  
2.5.8.3 Enzymatic Statistical Analysis  
For each of the methods performed on the Fluoroskan Ascent™ (Thermo Scientific, Vantaa, Finland) 
Microplate Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland), data was collected using 
Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). All raw data were firstly blank corrected 
using the Ascent® software (v2.6, Thermo Scientific, Vantaa, Finland) package and then exported for 
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further analysis using Windows Excel 2016 and GraphPad PRISM 7.0 (GraphPad Prism Inc., La 
Jolla, CA, USA).  
Graphs: Using Excel, averages of blank corrected data triplicates were calculated. From these 
averages, maximum absorbance was calculated and absorbance value plotted in a column graph for 
relative percentages.  
Two-way (RM) ANOVA and Tukey’s Post-hoc test: the blank corrected data was transformed, setting 
the top value as 100 and lowest as 0 across sub columns within a data set. A two-way repeated 
measures (RM) ANOVA was performed, followed by a Tukey’s post-hoc multiple comparison test, 
comparing every mean with every other mean.  
 
2.5.9 Procoagulation Analysis  
2.5.9.1 Whole Plasma Clotting 
Healthy human plasma (citrate 3.2%, Lot#1690252, approval # 16-04QLD-10) was obtained from 
the Australian Red Cross (44 Musk Street, Kelvin Grove, Queensland 4059). Coagulopathic toxin 
effects were measured by a modified procoagulant protocol on a Stago STA-R Max coagulation robot 
(France) using Stago Analyser software v0.00.04 (Stago, Asniéres sur Seine, France). Plasma clotting 
baseline parameters were determined by performing the standardised activated Partial 
Thromboplastin Time (aPTT) test (Stago Cat# T1203 TriniCLOT APTT HS). This was used as a 
control to determine the health of normal clotting plasma according to the universal standard range 
of between 27–35 sec. Plasma aliquots of 2 mL, which had been flash frozen in liquid nitrogen and 
stored in a −80 °C freezer, were defrosted in an Arctic refrigerated circulator SC150-A40 at 37°C. In 
order to determine clotting times effected by the addition of varying venom concentrations, a 
modified aPTT test was developed. A starting volume of 50 μL of crude venom (5 µg/50 μL) was 
diluted with STA Owren Koller Buffer (Stago Cat# 00360). A 14-dilution series of 1 (20 µg/mL), 1/2 
(10 µg/mL), 1/3 (6.66 µg/mL), 1/4 (5 µg/mL), 1/6 (3.33 µg/mL), 1/8 (2.5 µg/mL), 1/10 (2 
µg/mL),1/15 (1.33 µg/mL), 1/20 (1 µg/mL), 1/30 (0.66 µg/mL), 1/50 (0.4 µg/mL), 1/80 (0.25 µg/mL), 
1/160 (0.125 µg/mL), and 1/400 (0.05 µg/mL) was performed in triplicate. CaCl2 (50 μL; 25 mM 
stock solution Stago Cat# 00367 STA CaCl2 0.025M) was added with 50 μL phospholipid 
(solubilized in Owren Koller Buffer adapted from STA C.K Prest standard kit, Stago Cat# 00597). 
An additional 25 μL of Owren Koller Buffer was added to the cuvette and incubated for 30 sec at 
37°C before adding 75 μL of human plasma. Relative clotting was then monitored for 999 sec or until 
plasma clotted (whichever was sooner). Additional tests were run, both with and without CaCl2 and 
phospholipid, respectively, to test for CaCl2 or phospholipid dependency. STA Owren Koller Buffer 
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was used as a substitute, using the same volumes to allow for consistency in the final volumes (250 
μL). 
2.5.9.2 Antivenom Studies 
The monovalent antivenom effects on both D. typus and T. mossambicanus crude venoms was 
investigated. Previously established whole plasma clotting times against both venoms were measured 
and used as a guide for antivenom effects. The South African Institute for Medical Research 
Boomslang Antivenom (refined equine immunoglobulins, Lot M03852) was purchased from South 
African Vaccine Producers Pty Ltd (1 Modderfontein Rd Edenvale, Gauteng). One vial of antivenom 
(10 mL) was centrifuged at 12000 rpm on an Allegra™ X-22R Centrifuge (Lot#982501, Beckman 
Coulter, Brea, CA, USA) for 10 min at 4 °C, supernatant extracted, filtered (0.45 µm Econofltr PES, 
Lot#131127028, Agilent Technologies, Beijing, China) and stored at 4 °C. A final stock solution of 
10% antivenom and 90% Owren Koller Buffer was produced. Modifying the section 3.4.1 protocol, 
25 μL of antivenom stock was used in place of 25 μL of OK buffer, with the venom, Ca2+, 
phospholipid, and antivenom mixture being incubated for 120 sec at 37°C before adding 75 μL of 
human plasma and monitoring clotting for 999 sec or until plasma clotted (whichever was sooner). 
Experiments were conducted in triplicate. Note that antivenom does not clot plasma and that a control 
was performed to rule out any additional effects antivenom has on the plasma. Antivenom was 
substituted into the above outlined protocol in replacement of a venom sample. 
 
2.5.10 Statistical Analysis 
2.5.10.1 Whole Plasma Clotting EC50 Concentration and Asymptotic Time 
Venom dilutions in triplicates were mapped over time using GraphPad PRISM 7.0 to produce 
concentration curves. The statistical program R (Team, 2016) was used to calculate asymptotic 
clotting times using the Asymptotic Regression Model. This can be written as y(x) = ϕ1 + (ϕ2 − ϕ1) 
exp[−exp(ϕ3)x], using the nlme package (J. Pinheiro, 2016). This asymptotic regression model was 
used to model the response of y (time) when approaching a horizontal asymptote, when x 
(concentration) approaches ∞ (Pinheiro and Bates, 2000). In this example, ϕ1 is the asymptote as x 
(concentration) approaches ∞, ϕ2 is the response at x = 0, and t0.5 is the half-life. Parameter ϕ3 is the 
logarithm of the rate constant that is used to enforce positivity so that an asymptote is reached in the 
model. The corresponding half-life is written as t0.5 = log2/exp(ϕ3). The EC50 can be explained as the 
half-maximal Effective Concentration, or the concentration at which 50% of the maximal effect is 
observed. To calculate this, the EC50 function in GraphPad PRISM 7.0 was used for each data set. 
Each data set was transformed by the log of the concentration, and the values were normalised by 
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individual sub data sets. A non-linear regression curve fit was then modelled, and a log-reversed EC50 
value was produced. 
2.5.10.2 Antivenom EC50 Concentration 
Venom dilutions in triplicates were mapped over time using GraphPad PRISM 7.0 to produce 
concentration curves. The EC50 function in GraphPad PRISM 7.0 was used to calculate the EC50 for 
each data set. Each data set was transformed by the log of the concentration, and the values were 
normalised by individual sub data sets. A non-linear regression curve fit was then modelled, and a 
log-reversed EC50 value was produced.
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Chapter 3: The sweet side of venom: glycosylated prothrombin activating 
metalloproteases from Dispholidus typus (boomslang) and Thelotornis 
mossambicanus (twig snake) 
 
3.1 Abstract 
Dispholidus typus and Thelotornis mossambicanus are closely related rear-fanged colubrid snakes 
that both possess strongly procoagulant venoms. However, despite similarities in overall venom 
biochemistry and resulting clinical manifestations, the underlying venom composition differs 
significantly between the two species. As a result, the only available antivenom—which is a 
monovalent antivenom for D. typus—has minimal cross reactivity with T. mossambicanus and is not 
a clinically viable option. It was hypothesised that this lack of cross reactivity is due to the additional 
large metalloprotease protein within T. mossambicanus venom, which may also be responsible for 
faster coagulation times. In this study, we found that T. mossambicanus venom is a more powerful 
activator of prothrombin than that of D. typus and that the SVMP transcripts from T. mossambicanus 
form a clade with those from D. typus. The sequences from D. typus and T. mossambicanus were 
highly similar in length, with the calculated molecular weights of the T. mossambicanus transcripts 
being significantly less than the molecular weights of some isoforms on the 1D SDS-PAGE gels. 
Analyses utilising degylcosylating enzymes revealed that T. mossambicanus SVMPs are glycosylated 
during post-translational modification, but that this does not lead to the different molecular weight 
bands observed in 1D SDS-PAGE gels. However, differences in glycosylation patterns may still 
explain some of the difference between the enzymatic activities and neutralization by antivenom that 
have been observed in these venoms. The results of this study provide new information regarding the 
treatment options for patients envenomated by T. mossambicanus as well as the evolution of these 
dangerous snakes.  
3.2 Introduction   
Procoagulant species of venomous snakes are responsible for devastating effects upon the coagulation 
systems of envenomed patients. These venoms activate clotting factor zymogens (Factor X or 
prothrombin) to generate endogenous thrombin, resulting in the production of stable fibrin clots 
(Lister et al., 2017; Oulion et al., 2018; Rogalski et al., 2017; Sousa et al., 2018; Zdenek et al., 2019). 
Venoms which activate prothrombin are divided into functional groups (A, B, C, or D) based upon 
their requirement for the cofactors FVa and calcium  (Joseph and Kini, 2002; Kini, 2005a; Kini and 
Koh, 2016; McCleary and Kini, 2013; Rosing and Tans, 1991; Rosing and Tans, 1992). Group A and 
B are metalloproteases while C and D are serine proteases. Group A prothrombin activators do not 
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require the aid of any cofactors and are found in several viper venoms, most notably Echis carinatus 
‘ecarin’, while B requires the aid of calcium, such as ‘carinactivase-1’, also found in Echis carinatus 
(Joseph and Kini, 2002; Kini, 2005a; Kini and Koh, 2016; McCleary and Kini, 2013; Rosing and 
Tans, 1991; Rosing and Tans, 1992; Yamada et al., 1996, 1997).   It must be noted, however, that 
these convenient functional divisions are artificial distinctions based upon studies of purified toxins. 
However, the total venom composition is such that the venoms may be quite variable in their cofactor 
requirements. Thus relative calcium dependence is best viewed a sliding scale, rather than discrete 
divisions, as has been shown for venoms including vipers such as Bothrops and Echis and elapids 
including Hoplocephalus, Notechis, Oxyuranus, Paroplocephalus, Pseudonaja, and Tropidechis 
(Lister et al., 2017; Oulion et al., 2018; Rogalski et al., 2017; Sousa et al., 2018; Zdenek et al., 2019). 
For example, Echis carinatus varies from populations activity for which activity is decreased by only 
40% in the absence of calcium but with activity decreased over 400% for other populations (Rogalski 
et al., 2017). Thus the simplistic division into Type A and Type B venoms does not reflect the more 
complex biological reality. This is a critically important when making conclusions based upon 
coagulation patterns, for if calcium is not included in the assay conditions there may be a radical shift 
in the venom patterns and thus evolutionary or clinical interpretations.  
In addition to being central to the clinical picture of front-fanged snakes, procoagulation has also been 
shown to be responsible for the lethal effects of rear-fanged genera such as the closely related rear-
fanged colubrid genera Dispholidus and Thelotornis, with this action being calcium and phospholipid 
independent in these species (Bradlow et al., 1980; Debono et al., 2017a; Grasset and Schaafsma, 
1940; Guillin et al., 1978; Hiestand and Hiestand, 1979; Kamiguti et al., 2000). While D. typus has 
been shown to be a true procoagulant species through prothrombin activation, closely related 
members of the Thelotornis genus have had far less investigation performed, despite their equal 
medical importance (Atkinson et al., 1980; Chapman, 1968; Debono et al., 2017a; Du Toit, 1980; 
FitzSimons, 1909a, 1919; FitzSimons, 1962; Weinstein et al., 2011; Weinstein et al., 2013). 
In a previous study we investigated the variation in venom composition, activity, and antivenom 
neutralization between D. typus and T. mossambicanus. Despite both genera presenting virtually 
identical clinical symptoms, we found that T. mossambicanus venom was far more complex in 
composition and activity than that of D. typus. This was particularly noteworthy among the SVMP 
toxin family which is largely responsible for the potentially lethal procoagulant action of these 
venoms. As a result of these differences, Dispholidus antivenom had little to no effect on T. 
mossambicanus venom (Debono et al., 2017a). Because of this, replacement therapy is the only 
treatment available for bite victims (Atkinson et al., 1980; Du Toit, 1980; Grasset and Schaafsma, 
1940; Visser and Chapman, 1978; Weinstein et al., 2011). Here we investigated the molecular 
variation between both Dispholidus typus and Thelotornis mossambicanus by exploring their venom 
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gland transcriptomes. We focused on variation within the SVMP toxin family, which could lead to a 
variation in prothrombin activating capabilities. In addition, we investigated variations in 
glycosylation within both venoms as this may also contribute to a lack of antivenom neutralisation. 
This is the first time that factor X or prothrombin activation and transcriptomics have been 
investigated for Thelotornis mossambicanus. This research reinforces the high rates of venom 
diversification even between closely related snake species and how this can have direct implications 
for the treatment of envenomed patients.  
3.3 Results 
3.3.1 Transcriptomics  
Transcriptomics recovered a diversity of toxin types including 3FTx, C-type lectin, CRiSP (cysteine 
rich secretory protein), PLA2 (phospholipase A2), PLB (phospholipase B), SVMP (snake venom 
metalloprotease). PLA2 toxins were the most diverse toxin family and accounted for the greatest share 
of Transcripts Per Million (TPM) (72.4%, from 12 transcripts) while SVMPs contributed 11.0% of 
TPM from 4 transcripts (Figure 3.1Figure 3.1 TPM plots). We recovered 6 unique C-type lectins, yet 
these were expressed at relatively low levels (4% of total TPM). CRiSP and 3FTx were both 
responsible for greater shares of TPM despite lower numbers of total transcripts recovered (7.8% 
from 1 transcript and 4.7% from 2 transcripts, respectively). These results are consistent with our 
proteomics that showed abundant PLA2s, but also significant quantities of SVMPs.  
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Figure 3.1 TPM plots 
A) Transcripts Per Million (Y axis = TPM) for each toxin family from Thelotornis mossambicanus 
venom gland transcriptome, B) Percentage of TPM from toxin families recovered from T. 
mossambicanus transcriptome, C) Total number of transcripts from toxin families recovered from T. 
mossambicanus transcriptome. Other = Kallikrein, Waprin, Kunitz, VEGF, hyaluronidase, SVSPs, 
PLB. 
 
 
3.3.2 SVMP phylogeny  
Four complete SVMP transcripts were recovered from the T. mossambicanus venom gland 
transcriptome. These transcripts were nested within complete, publicly available D. typus SVMPs 
transcripts (GHOQ01000060, GHOQ01000051, GHOQ01000015), distinct from neighbouring 
genera Boiga and Ahaetulla (Figure 3.2). The SVMPs from D. typus and T. mossambicanus formed 
a tight, distinct clade within a larger rear-fanged and elapid clade separate from viper SVMPs, thus 
supporting D. typus and T. mossambicanus SVMP originating from a common molecular ancestor 
despite the poor cross-neutralisation of D. typus antivenom (Debono et al., 2017a).  
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Figure 3.2 SVMP phylogeny 
Phylogeny of publicly available SVMPs amino acid sequences, with all recovered Thelotornis 
mossambicanus SVMP venom gland transcriptome sequences. Scale bar represents 0.5 substitutions 
per site. 
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3.3.3 Proteomics  
As transcriptomes were not available at the time, previous proteomic work focused on protein ID 
(Debono et al., 2017a) and did not investigate in-depth the structural differences of SVMP between 
D. typus and T. mossambicanus that result in the two distinct SVMP bands in T. mossambicanus when 
investigated on 1D SDS-PAGE (bands 5 and 6 in Figure 3.3). Therefore, digestion with a 
deglycosylation enzyme was undertaken, with both D. typus and T. mossambicanus SVMP showing 
evidence of extensive glycosylation, as demonstrated by molecular weight changes between 
homologous bands in gel lanes with and without the deglycosylation enzyme (Figure 3.4). 
 
 
 
Figure 3.3 1D SDS PAGE 
1D SDS page with identified groups of proteins (as previously published by us (Debono et al., 
2017a)). D.t = Dispholidus typus, T.m = Thelotornis mossambicanus. Reduced conditions on the left, 
Non-reduced conditions on the right. Molecular weight marker indicated by centered numbers (kDa). 
Annotations (right) refer to bands identified (white numbers) within the reduced column. 
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Figure 3.4 De-glycosylation  
 Differential glycosylation of Dispholidus typus and Thelotornis mossambicanus venoms. e = ± 
deglycosylation enzyme, l = ladder. Lane 1 = control enzyme, Lanes 2 and 3 = D. typus ± 
deglycosylation enzyme, Lane 4 = ladder, Lanes 5 and 6 = T. mossambicanus ± deglycosylation 
enzyme.  
 
3.3.4 FX and Prothrombin activation  
To evaluate the comparative ability of D. typus and T. mossambicanus venoms to activate FX and 
prothrombin, assessment was carried out using a Stago STA R Max coagulation analyser robot 
following the previously validated colorimetric assay (Debono et al., 2019a). Zymogen testing 
revealed that neither species was able to activate FX (data not shown). While FX activation has also 
been shown from Dispholidus typus (Bradlow et al., 1980), this activity was recovered from ground 
up venom gland as opposed to venom milking which may have contributed to it being an artefact in 
activity due to the presence of non-venom proteins or activated blood factors. However, when testing 
for prothrombin activation, a starting concentration of 20 µg/mL exceeded the maximum reading 
capacity for both species indicating extremely high activation of prothrombin, so a lower level of 
venom concentration was tested. At a half dilution concentration of venom (10 µg/mL), Thelotornis 
mossambicanus produced a stronger prothrombin activation effect compared to the positive control 
of pure thrombin (Liquid Fib, Stago, LOT 253337) which was not diluted (p <0.0001)  (Figure 3.5). 
Dispholidus typus also had a strong prothrombin activating response but weaker than that of T. 
mossambicanus, being just slightly less than that of the thrombin control (p <0.0001).  This variation 
was consistent with previously published differential clotting times for both species, indicating their 
extreme but divergent procoagulant effects (Debono et al., 2017a).  
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Figure 3.5 Prothrombin activation 
Prothrombin activation of Dispholidus typus and Thelotornis mossambicanus at 10 µg/mL over 300 
seconds. Blue line = T. mossambicanus activity, Red line = D. typus activity, Black line = positive 
control thrombin. Y axis = OD, optical density. X axis = time (sec). N = 3, data points = average with 
standard deviation.  
 
3.4 Discussion  
Our Thelotornis mossambicanus transcriptome revealed major differences in overall venom 
composition compared to that of D. typus (published by (Pla et al., 2017)). While D. typus venom is 
dominated by P-III SVMP (Figure 3.3), T. mossambicanus has a higher percentage of smaller toxins 
such as PLA2 and CRiSP than D. typus (Figure 3.1). The SVMP of both venoms were shown for the 
first time to be heavily glycosylated (Figure 3.4), as has been previously shown for pit viper venoms 
such as Bothrops species (Andrade-Silva et al., 2016; Oliveira et al., 2010; Zelanis et al., 2012; 
Zelanis et al., 2010). Despite the fact that T. mossambicanus venom contains proportionally less 
procoagulant SVMPs than D. typus, T. mossambicanus is much more powerfully procoagulant 
(Debono et al., 2017a), due to stronger prothrombin activation compared to Dispholidus typus (Figure 
3.5). 
While D. typus and T. mossambicanus are lethally potent procoagulant colubrids, the currently 
available antivenom is effective for only one of the species – D. typus (Debono et al., 2017a). 
Therefore, the only currently available treatment for Thelotornis bites is replacement therapy, strictly 
on a case-by-case basis (Weinstein et al., 2013). The potent procoagulant activity of T. 
mossambicanus venom is entirely independent of cofactors, meaning that neither calcium nor 
phospholipid is required for such fast clotting of plasma (Debono et al., 2017a). This had previously 
been shown and reported for D. typus (Bradlow et al., 1980; Guillin et al., 1978; Hiestand and 
Hiestand, 1979; Weinstein et al., 2011; Weinstein et al., 2013; Yamada et al., 1997), however not for 
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T. mossambicanus. SVMPs are the likely source of both species’  procoagulant nature as these toxins 
are known prothrombin activators and both venoms express them at relatively high levels (Joseph 
and Kini, 2002; Kini, 2005a; Kini and Koh, 2016; Rogalski et al., 2017; Rosing and Tans, 1991; 
Rosing and Tans, 1992; Rosing and Tans, 2010; Sousa et al., 2018). Furthermore, due to neither 
species requiring cofactors to cause such potent procoagulation, their potent prothrombin activating 
SVMPs can be categorised into Group A prothrombin activators (Joseph and Kini, 2002; Kini, 2005a; 
Kini and Koh, 2016; Rosing and Tans, 1991; Rosing and Tans, 1992; Rosing and Tans, 2010) and 
are resistant to natural endogenous coagulation inhibitors such as serpins and antithrombin III (Kini, 
2005a; Kini and Koh, 2016; Yamada et al., 1996). To date, the best characterised Group A 
prothrombin activator is ecarin, isolated from Echis carinatus (Kini, 2005a; Kini and Koh, 2016; 
Kornalik and Blombäck, 1975; Rogalski et al., 2017; Rosing and Tans, 1991; Rosing and Tans, 1992). 
SVMPs from vipers are well documented with many representatives displayed in Figure 3.2. 
Interestingly, the SVMPs isolated from T. mossambicanus and D. typus form their own prothrombin 
activating clade, distinct from other Group A prothrombin activators such as from species within the 
Echis genus of vipers. This is evidence for the first time that the prothrombin activating SVMPs do 
not cluster with any of the other prothrombin activating SVMPs from other species. This also suggests 
that prothrombin activation as a neofunctionalisation of SVMP convergently evolved multiple 
independent occasions, spanning the full advanced snake taxonomical range from rear-fanged 
colubrids to viperid front-fanged snakes (Figure 3.2).  
Despite large similarities in P-III SVMPs from both species, four distinct transcripts were recovered 
from the venom gland transcriptome of T. mossambicanus. The amino acid sequence is identical for 
73.9% of the total length of the mature peptide for each of the SVMPs. Because of this, the predicted 
molecular weights of these transcripts cannot fully explain the different SVMP band pattern between 
D. typus and T. mossambicanus. Post-translational modifications such as glycosylation can have 
significant effects on the weight of mature proteins and variation in glycosylation is a feature that has 
been shown in pit vipers to be linked to variations in activity and antivenom recognition (Andrade-
Silva et al., 2016; Chen et al., 2008; Lin et al., 2010; Oliveira et al., 2010; Zelanis et al., 2012).  
However, our results revealed similar levels of N-glycosylation in D. typus SVMPs as well as both 
SVMP bands from T. mossambicanus. It is possible that each of these possesses different patterns of 
glycosylation along the length of the actual protein, but determining if that is the case and, if so, what 
effect that might have on the enzymatic activity of these toxins, is a subject for future studies. The 
cause of the weight difference between the two bands of T. mossambicanus SVMPs remains unclear, 
but it is likely the result of some other process of post-translational modification. 
Irrespective of antivenom efficacy, these two species have been the centre of controversial discussion, 
with both genera causing infamous deaths to two imminent herpetologists as both species were 
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deemed non-venomous (Atkinson et al., 1980; Bradlow et al., 1980; Chapman, 1968; Du Toit, 1980; 
FitzSimons, 1962; Grasset and Schaafsma, 1940). However, decades later, there is plenty of evidence 
to state otherwise, as both species are extremely procoagulant, with strong prothrombin activation 
capabilities (Bradlow et al., 1980; Debono et al., 2017a; Du Toit, 1980; FitzSimons, 1909a; Grasset 
and Schaafsma, 1940; Guillin et al., 1978; Hiestand and Hiestand, 1979; Visser and Chapman, 1978; 
Weinstein et al., 2011). Differences in venom composition, despite producing identical clinical 
symptoms, can be best attributed to recent evolutionary pressures from diet and prey escape potential 
linked to variations in ecology between the two lineages, leading to subtle structural and surfaces 
changes to key toxin families such as post translational modifications in the form of glycosylation, 
which should be the focus of future work. Research such as this can lead to improving alternative 
therapeutic designs and pave the way for further P-III SVMP research and Group A prothrombin 
activators. 
3.5 Materials and Methods  
 
3.5.1 Venom Supplies 
Pooled venoms from Dispholidus typus (South African origin) and Thelotornis mossambicanus 
(Mozambique) were supplied by Latoxan (Portes-lès-Valence, France). 
 
3.5.2 Venom gland RNA extraction and mRNA purification: reconstruction of SVMP phylogeny 
Venom gland tissue (20 mg) was homogenized using a rotor homogenizer and total ribonucleic acid 
(RNA) extracted using the standard TRIzol Plus methodology (Invitrogen). RNA quality was 
assessed using a Nanodrop (Nanodrop 2000, Spectrophotometer, Thermo Scientific). mRNA was 
extracted and isolated using standard Dynabeads mRNA DIRECT Kit (Life Technologies Ambion, 
1443431). Dynabeads work by hybridising poly-thymine (polyT) sequences, covalently bound to the 
Dynabead surface, to the mRNA poly-adenine (polyA) tail. This ensured that mRNA was selected 
for and not lost in centrifuge and washing stages, while other RNA forms (which do not have a polyA 
tail) are removed. This therefore facilitates a higher concentration of mRNA yield for sequencing 
purposes. 
3.5.2.1 Sequencing 
Venom gland transcriptomics were conducted by the IMB Sequencing Facility (Institute for 
Molecular Bioscience, The University of Queensland, St Lucia, Qld, Australia). Libraries were 
prepared with the TruSeq Stranded mRNA kit (Illumina, San Diego, CA, USA), and were sequenced 
on the Illumina NextSeq (Illumina) 500 using 2 × 150 bp reads and V2 chemistry. 
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The transcriptome described in this paper was one of several species that were part of a multiplexed 
run. Throughout our workflow GNU parallel 20170822 was used to run similar tasks in 
simultaneously, CD-HIT 4.8.1 was used to remove duplicate sequences, and Seqtk 1.2 was used to 
obtain subsets of sequence files (Fu et al., 2012; Li, 2012; Li and Godzik, 2006; Tange, 2011). Also, 
as a result of multiplexing, we experienced the common problem of low, but meaningful amounts of 
cross contamination between our multiplexed samples (Kircher et al., 2011). We attempted to 
mitigate this issue at several points in our methodology. 
3.5.2.2 Assembly 
Illumina reads that were likely to be cross contamination between multiplexed samples were removed 
from our read files by identifying 57 nucleotide k-mers in our focal read set that were present in 
another read set from the same lane at a 1000-fold or higher level. Reads with 25% or more of their 
sequence represented by such k-mers were filtered from the data set. This was accomplished using 
Jellyfish 2.2.6 (Marçais and Kingsford, 2011) and K-mer Analysis Toolkit (KAT) 2.3.4 (Mapleson et 
al., 2016). We then removed adaptors and low-quality bases from the reads and removed any reads 
shorter than 75 base pairs using Trim Galore version 0.4.3 (Krueger, 2015). We then used PEAR 
0.9.10 (Zhang et al., 2013) to combine pairs of reads whose ends overlapped into one, longer, merged 
read. We then carried out several independent de novo assemblies of these reads using the programs 
Extender version 1.04 (Rokyta et al., 2012), Trinity version 2.4.0 (Grabherr et al., 2011), and 
SOAPdenovo version 2.04 (Xie et al., 2014). SOAPdenovo was run repeatedly with k-mer sizes of 
31, 75, 97, and 127.  
3.5.2.3 Annotation 
The de novo assemblies were concatenated and TransDecoder 5.2.0 was used to predict open reading 
frames within the contigs (Haas et al., 2013). We removed any ORFs that did not include both a start 
and stop codon. The remaining ORFs were then compared against reference toxin sequences obtained 
from UniProt using ProteinOrtho 6.01 (Lechner et al., 2011; The UniProt Consortium, 2016). The 
resulting ORFs with similarity to known toxins were further quality controlled by manual inspection 
and BLAST searches against the Reptilia subsection of the NCBI Nucleotide database (Altschul et 
al., 1990; Altschul et al., 1997; Madden et al., 1996). The Burrows–Wheeler Aligner (BWA) 0.7.16a 
and SAMtools 1.5 were used to align the original reads from each species to the total list of annotated 
ORFs from every assembly (Li and Durbin, 2009; Li et al., 2009). These results were visualized using 
Tablet 1.15 to screen for signs of chimerical assembly (Milne et al., 2012). Those that showed sharp 
discontinuities in coverage maps across all species were removed from further analysis. A 
combination of read coverage, assembly quality, and BLAST search results were used to confirm the 
species of origin for each remain ORF. Given the evolutionary distance between the species we 
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sequenced and the rate at which toxin genes mutate, it is extremely unlikely that any two of these 
species would express identical toxins. Because of this, we interpret reads from multiple species 
aligning to a single contig as instances of contamination and tentatively assign the contig to the 
species with significantly higher expression levels. This assignation can be further reinforced if our 
BLAST results indicate that the sequence in question is more similar to the high-expression taxon 
than the lower one. The distribution of reads mapped to the sequence can also be informative if the 
pattern matches the norm for that toxin family in one species but not the others. For most sequences, 
all three indicators were unambiguous and in agreement while in a small minority of cases two other 
indicators could be used to decide between somewhat equivocal results of a third. No sequences that 
had made it to this point of the quality control process could not be confidently assigned using these 
methods. 
Information regarding the transcriptome, the short reads, and the final toxin sequences that were 
determined to originate from the transcriptome of Thelotornis mossambicanus have been deposited 
in GenBank under the BioProject accession code PRJNA561062. 
3.5.2.4 Phylogenetic reconstruction 
Protein sequences for SVMP sequences from representative taxa were downloaded from the UniProt 
database (The UniProt Consortium, 2016). These were then combined with the translated SVMP 
sequences from our T. mossambicanus transcriptome and all available full-length high quality 
Dispholidus typus SVMP sequences (Pla et al., 2017). The sequences were aligned using the MUltiple 
Sequence Comparison by Log-Expectation (MUSCLE) algorithm implemented in AliView 1.18 
(Edgar, 2004; Larsson, 2014). We reconstructed the phylogeny of these sequences using MrBayes 
3.2 for 15,000,000 generations and 1,000,000 generations of burnin with lset rates=invgamma 
(allows rate to vary with some sites invariant and other drawn from a γ distribution) and prset 
aamodelpr=mixed (allows MrBayes to generate an appropriate amino acid substitution model by 
sampling from 10 predefined models) (Ronquist et al., 2012). The runs were stopped when 
convergence values reached 0.01.  
 
3.5.3 De-glycosylation of venom proteins: 
For protein de-glycosylation under denaturing conditions, 20 µg of crude venom samples from 
Dispholidus typus and Thelotornis mossambicanus were subjected to analysis following the 
manufacturer’s instructions from New England Bio Labs ‘De-glycosylation’ (Lot #10034949, USA). 
Total reaction volumes of 10 μL were incubated with 1 μL Glycoprotein denaturing buffer (10x) (Bio 
Labs, Lot #10017111) for 10 min at 100°C. Following denaturing, 2 μL 10x Glycoprotein 2 (Lot 
#10029303), 2 μL 10% NP-40 (Lot# 10021820) and 1 μL (454 U) PNGase F (Lot #10018057) was 
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added to the mixture and incubated for 1 hr at 37°C. Post incubation, samples were submitted to 1D 
SDS PAGE under reducing and non-reducing conditions (by addition of DTT or not) following 
methods previously described (Debono et al., 2017a).  
 
3.5.4 Factor X activation and prothrombin activation 
To determine the relative rate of Factor X activation or prothrombin activation by venom samples, a 
colorimetric assay was performed previously validated by us (Debono et al., 2019a). A working stock 
solution (at 1 mg/mL in 50% deionized H2O+ 50% glycerol) was manually diluted with OK buffer 
(STA Owren Koller Buﬀer) (50 μL at 20 µg/mL) to a cuvette. A total of 50 μL of CaCl2 (25 mM), 50 
μL phospholipid (cephalin prepared from rabbit cerebral tissue from STA C.K Prest standard kit, 
solubilized in OK buﬀer) and 25 μL of OK buffer was added to cuvette and incubated for 120 sec at 
37°C before adding 75 μL of a solution containing the colorimetric substrate (Liquid Anti-Xa 
substrate, Stago Lot #253047) and either 0.01 μg/μL FX (Human Factor X, Lot #HH0315, HTI) or 
0.1 μg/μL prothrombin (Human Prothrombin, Lot #GG1026, HTI) (total volume 250 μL/cuvette). A 
change in the optical density (OD) was measured each second for 300 sec using a STA-R Max® 
automated analyzer (Stago, Asnières sur Seine, France). All tests were performed in triplicate. The 
rate of FX activation or prothrombin activation, by the samples, was calculated in comparison to the 
variation in the optical density – corresponding to the cleavage of the substrate by FXa or thrombin, 
after the activation of the zymogen by the samples, in relation to direct cleavage of substrate by the 
samples in the absence of the zymogen. Human FXa (Liquid Anti-Xa FXa Lot #253047) or thrombin 
(Liquid Fib, Stago, Lot #253337) was used as positive control to ensure quality of the substrate. The 
samples analyzed, in same conditions, without the presence of the zymogen were used as a negative 
control to establish and venom-induced baseline substrate cleavage in the absence of the zymogen. A 
solution containing deionized H2O/glycerol at a 1:1 ratio was used as a second negative control. 
Multiple linear regression and ANOVA on the AUC values were used to test for differences between 
the three treatments and yielded similar results.  
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Chapter 4: Basal but divergent: Clinical implications of differential 
coagulotoxicity in a clade of Asian vipers     
 
4.1 Abstract  
Envenomations by Asian pit vipers can induce multiple clinical complications resulting from 
coagulopathic and neuropathic effects. While intense research has been undertaken for some species, 
functional coagulopathic effects have been neglected. As these species’ venoms affect the blood 
coagulation cascade, we investigated their effects upon the human clotting cascade using venoms of 
species from the Azemiops, Calloselasma, Deinagkistrodon and Hypnale genera. Calloselasma 
rhodostoma, Deinagkistrodon acutus, and Hypnale hypnale produced net anticoagulant effects 
through pseudo-procoagulant clotting of fibrinogen, resulting in weak, unstable, transient fibrin clots. 
Tropidolaemus wagleri was only weakly pseudo-procoagulant, clotting fibrinogen with only a 
negligible net anticoagulant effect.  Azemiops feae and Tropidolaemus subannulatus did not affect 
clotting. This is the first study to examine in a phylogenetic context the coagulotoxic effects of related 
genera of basal Asiatic pit-vipers. The results reveal substantial variation between sister genera, 
providing crucial information about clinical effects and implications for antivenom cross-reactivity. 
4.2 Introduction  
Snakebite is one of the most neglected tropical diseases worldwide (Fry, 2018; Gutiérrez et al., 2006; 
Williams et al., 2010; Williams et al., 2011). Human-snake conflicts are increasing due to a myriad 
of factors including human population expansion and increase in snake activity periods due to climate 
change (Fry, 2018). Consequently a need for a better understanding into the effects of envenomations 
in humans is required. Snakebite is considered a current global health crisis, however it has been 
neglected, ignored, underestimated and misunderstood despite its ever-increasing significance (Fry, 
2018). Additionally, there is lack of appropriate medical treatment and assistance to those who are 
affected by snakebite due to several contributing factors including education, financial aid and 
proximity to health care facilities. Many people who are envenomated and survive are left with 
permanent disabilities and crippling medical bills, even if medical treatment is sought out. Although 
antivenoms do exist for some species, many species of venomous snakes do not have an appropriate 
antivenom available or it is far too expensive for patients to purchase. Snakebite however is not 
restricted to the poorer regions of the world and many exotic venomous snake species kept in private 
collections can inflict potentially fatal envenomations, which is only potentiated by unsupported 
questionable alternative first aid treatments that are being supplied (Fry, 2018).   
Snake venom is made up of a myriad of toxins which can deleteriously affect any part of haemostasis, 
resulting in an array of variable outcomes. In humans this can range from localised tissue swelling 
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and damage, to necrosis, respiratory failure, renal failure, kidney failure and haemorrhagic shock 
(Alirol et al., 2010; Ariaratnam et al., 2008; Dharmaratne and Gunawardena, 1988; Fry, 2018; Oulion 
et al., 2018; Sutherland, 1983; Tan and Tan, 1989; Tang et al., 2016; White, 2005). Venoms that 
affect coagulation do so via various coagulotoxic mechanisms ranging from procoagulant through to 
strong anticoagulant activities, through the disruption of clotting enzymes (Fry et al., 2009a). 
Procoagulant snake venoms produce endogenous thrombin through the activation of Factor X or 
prothrombin, resulting in strong, stable fibrin clots while anticoagulant venoms effect upon fibrinogen 
is either through destructive cleavage of fibrinogen or the pseudo-procoagulant mechanism of 
cleaving fibrinogen to form abnormal, short-lived fibrin clots (thus having a net anticoagulant effect) 
(Dambisya et al., 1994; Debono et al., 2019c; Fry et al., 2009a; Isbister, 2009).  
The Viperidae snake family mainly affect the blood coagulation system and are responsible for a 
large proportion of global snake bites. Vipers inhabit Africa, the Americas, Asia, and Europe. 
Viperidae is split into three sub families; Crotalinae (pit vipers), Viperinae (true vipers) and 
Azemiopinae (Alencar et al., 2018; Alencar et al., 2016). This split occurred approximately 50 million 
years ago (MYA) and Crotaline has been under immense diversification and expansion for the past 
41 MYA (Alencar et al., 2018; Alencar et al., 2016). Crotalinae occupy a large geographical range, 
from most of Asia throughout all of the Americas, and includes genera such as, Bothrops, Crotalus, 
and Trimeresurus. In Asia, a basal clade consists of the morphologically similar terrestrial genera, 
Calloselasma, Deinagkistrodon and Hypnale along with the highly derived arboreal genus 
Tropidolaemus (Alencar et al., 2018). This clade is a mixture of terrestrial and arboreal species and 
therefore provides an excellent opportunity to investigate venom adaptive evolution. The highly 
derived semi-fossorial genus Azemiops provides a further point of comparison. 
Asian viper venoms are well known for effects on bite victims including haemorrhagic shock, 
necrosis and thrombocytopenia, spontaneous haemorrhage and acute kidney injury (Ariaratnam et al., 
2008; de Silva et al., 1994; Herath et al., 2012; Joseph et al., 2007; Maduwage et al., 2013a; 
Maduwage et al., 2013b; Tang et al., 2016; Weerakkody et al., 2016; Withana et al., 2014). 
Haemorrhagic effects are potentiated by fibrinogenolytic enzymes which may act upon fibrinogen to 
either directly produce anticoagulation, by destructively cleaving fibrinogen, or to indirectly produce 
anticoagulation by cleaving fibrinogen to form short-lived, weak clots in a pseudo-procoagulant 
manner (Coimbra et al., 2018; Debono et al., 2019c; Dobson et al., 2018; Esnouf and Tunnah, 1967; 
Huang et al., 1992; Levy and Del Zoppo, 2006; Nielsen, 2016a; Premawardena et al., 1998; Trookman 
et al., 2009; Zulys et al., 1989).  
There are significant variations in the venoms of this clade which have accumulated during long 
periods of evolutionary divergence contributing to variable antivenom efficacy (Ali et al., 2013a; 
Daltry et al., 1996a; Mebs et al., 1994; Tan et al., 2017b; Tang et al., 2016). Previous studies have 
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shown that some species affect various sites along the cascade such as platelet activity (Kong and 
Chung, 2001; Navdaev et al., 2011; Shin and Morita, 1998; Wang et al., 1999), FX activation and 
prothrombin activation (Ainsworth et al., 2018; Leong et al., 2014; Yamada et al., 1997).  
The inter-genus venom variation between Asian pit vipers is unknown and some lineages have been 
left completely unstudied. As a result, there is limited knowledge about their effects on coagulation 
of the human body. Here we investigate the relationship and mechanisms behind their coagulotoxicity 
and illustrate the variations within the basal Asian pit vipers genera Azemiops, Calloselasma, 
Deinagkistrodon, Hypnale and Tropidolaemus. By contributing to the broader understanding of 
venom functional variation, improvement in clinical management strategies may be developed, as 
well as the potential for discovery of novel compounds useful in the advancement of blood clotting 
disorder therapeutics and diagnostics surrounding thrombosis and haemostasis.   
4.3 Results  
4.3.1 Enzymatic assays 
Significant variation was evident upon artificial substrates which are in general cleaved by 
metalloproteases (ES001, ES003, ES005, ES010), serine proteases (ES002, ES011), or phospholipase 
A2 (Figure 4.1).  For all six venoms, none of the substrates displayed a strong taxonomical signal or 
a pattern regarding ecological niche occupied (arboreal versus terrestrial). None of the venoms 
cleaved ES005, and therefore this data is not shown.  
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Figure 4.1 Enzymatic substrate activity  
Ancestral state reconstruction of enzymatic substrate activity of the Basal clade species based on their 
ability to cleave the following substrates; A: fluorogenic peptide substrate (Mca-PLGL-Dpa-AR-NH2 
Fluorogenic Matrix Metalloprotease  Substrate, Cat#ES001), B: fluorogenic peptide substrate (Mca-
RPKPVE-Nval-WRK(Dnp)-NH2 Fluorogenic MMP Substrate, Cat#ES002) which detects additional 
metalloprotease activity and Factor X, C: fluorogenic peptide substrate (Mca-PLAQAV-Dpa-
RSSSR-NH2 Fluorogenic Peptide Substrate, Cat#ES003) which detects additional metalloprotease 
activity, D: fluorogenic peptide substrate (Mca-KPLGL-Dpa-AR-NH2 Fluorogenic Peptide 
Substrate, Cat#ES010) which detects additional metalloprotease activity, E: fluorogenic peptide 
substrate (Boc-VPR-AMC Fluorogenic Peptide Substrate, Cat#ES011) which detects serine protease 
activity, F: Phospholipase A2 substrate activity, EnzChek® (Cat# E10217). Warmer colours represent 
more potent substrate cleavage. Bars indicate 95% confidence intervals for the estimate at each node. 
Phylogeny follows (Alencar et al., 2016). 
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4.3.2 Coagulation analysis: human plasma and fibrinogen 
At the initial 20 µg/mL venom concentration, only C. rhodostoma (20.5 ± 2.6 sec), D. acutus (41.9 ± 
0.5) and H. hypnale displayed the ability to clot plasma quicker than the negative control (spontaneous 
clotting of recalcified plasma) time of 300 ± 50 sec (Figure 4.2). All other species were equal or above 
the negative control. 8-point dilution series were undertaken with the two most potent venoms (C. 
rhodostoma and D. acutus) under three experimental conditions: with both cofactors (calcium and 
phospholipid), with just calcium, and with just phospholipid. While the phospholipid cofactor was 
not a significant variable for either venom, for calcium there was an area under the curve shift of 79.3 
± 4 % for D. acutus and a shift of 49.1 ± 1 % for C. rhodostoma (if there was no shift in the area 
under the curve, the value would have been zero) (Figure 4.2). An 8-point dilution series were also 
undertaken for C. rhodostoma and D. acutus with fibrinogen under three experimental conditions: 
with both cofactors (calcium and phospholipid), with just calcium, and with just phospholipid (Figure 
4.3). While phospholipid was again not a significant variable for either venom, there was a strong 
dependency evident for calcium, with the area of the curve shifting 123.1 ± 15.2 % for C. rhodostoma 
and 345.1 ± 5.4 % D. acutus (if there was no shift in the area under the curve, the value would have 
been zero) (Figure 4.3).  
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Figure 4.2 Coagulation analysis  
A) Effect of 20 µg/mL venom concentration upon plasma clotting relative to the negative control 
(spontaneous clotting of recalcified plasma, shown with dashed line) time of 300 ± 50 sec.  Also 
shown are 8-point dose-response curves with both calcium and phospholipid (red line), with just 
calcium (blue line), and with just phospholipid (purple line) for B) C. rhodostoma and C) D. acutus. 
Data points are N = 3 with standard deviations. Note that for the line graphs in (B) and (C) the error 
bars are in some cases smaller than the line icons. 
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Figure 4.3 Fibrinogen clotting activity  
8-point dose-response curves of fibrinogen clotting activity with both calcium and phospholipid (red 
line), with just calcium (blue line), and with just phospholipid (purple line) for A) C. rhodostoma and 
B) D. acutus. Data points are N = 3 with standard deviations.  
 
4.3.3 Thromboelastography: plasma and fibrinogen 
Thromboelastography studies on plasma (Figure 4.4) revealed that while C. rhodostoma and D. 
acutus both rapidly clotted plasma, consistent with the coagulation analyser results above, only C. 
rhodostoma formed strong, stable clots and therefore was truly procoagulant. Similarly, H. hypnale 
also formed strong stable clots despite being much slower to clot plasma in the above analyses. In 
contrast, D. acutus rapidly formed weak, unstable clots and therefore was pseudo-procoagulant. None 
of the other venoms differed significantly from the spontaneous clotting negative control. 
Thromboelastography studies on fibrinogen (Figure 4.5) revealed C. rhodostoma to also have the 
ability directly clot fibrinogen in a pseudo-procoagulant manner, in contrast to the procoagulant 
manner on endogenous thrombin. Consistent with the plasma results, D. acutus displayed the ability 
to clot fibrinogen in a pseudo-procoagulant manner while H. hypnale showed only a weak ability. T. 
wagleri also showed a weak ability to clot fibrinogen in a pseudo-procoagulant manner while its sister 
species T. subannulatus displayed a weak ability to cleave fibrinogen in a non-clotting, destructive 
manner. A. feae neither clotted nor destroyed fibrinogen. 
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Figure 4.4 Thromboelastography plasma traces 
Overlaid thromboelastography traces showing effects of venoms ability to clot plasma relative to 
spontaneous clot control where species cleave plasma in a clotting manner to form weak clots.  Blue 
traces = spontaneous clot controls, green traces = thrombin induced clot or Factor Xa induced clot, 
red traces = samples. SP = split point, time taken until clot begins to form (min). R = time to initial 
clot formation where formation is 2mm+ (min). A = amplitude of detectable clot (mm). MRTGG = 
maximum rate of thrombus generation (dsc, dynes/cm2/sec). TMRTG = time to maximum rate of 
thrombus generation (min). TGG= total thrombus generation (dynes/cm2). Overlaid traces are N = 3 
for each set of control or experimental conditions. Values are N = 3 means and standard deviation. 
 
 
Figure 4.5 Thromboelastography fibrinogen traces 
Overlaid thromboelastography traces showing tests for A) ability to clot fibrinogen relative to 
thrombin control; or B) test for the ability to degrade fibrinogen for species which did not clot in (A) 
whereby thrombin was added at the end of the 30 min runs to test for intact fibrinogen. Green traces 
= thrombin controls, red traces = samples. SP = split point, time taken until clot begins to form (min). 
R = time to initial clot formation where formation is 2mm+ (min). A = amplitude of detectable clot 
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(mm). MRTGG = maximum rate of thrombus generation (dynes/cm2/sec). TMRTG = time to 
maximum rate of thrombus generation (min). TGG= total thrombus generation (dynes/cm2). Overlaid 
traces are N = 3 for each set of control or experimental conditions. Values are N = 3 means and 
standard deviation. 
 
4.3.4 FX activation and prothrombin activation   
As C. rhodostoma, H. hypnale and D. acutus displayed clotting ability, they were investigated for 
their ability activate FX and prothrombin, to establish if they generated endogenous thrombin and 
therefore were true procoagulant venoms. C. rhodostoma activated FX yet only minimal activity was 
recorded for H. hypnale from the sister genus Hypnale, and no activity was recorded for D. acutus 
(Figure 4.6). There was no activity recorded for prothrombin activation by any species (data not 
shown). 
 
Figure 4.6 Factor X activation  
Factor X activation via colourimetric analysis over time performed on a Stage STA R Max. Y axis = 
OD, optical density, X axis = time (sec). Red line = control FXa, blue line = Calloselasma 
rhodostoma, green line = Hypnale hypnale, purple line = Deinagkistrodon acutus. Data points are n 
= 3, means and SD.  
 
4.3.5 Fibrinolysis ± tPA  
The ability for species’ venoms within the basal clade to actively lyse tissue factor-induced plasma 
clots was tested at varying venom concentrations. None of the species tested returned a positive result 
of lysing a clot. However compared to a normal clot lysis time (CLT), this was decreased in the 
presence of C. rhodostoma and D. acutus venoms and tPA (Figure 4.7).   
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Figure 4.7 Fibrinolysis  
Clot Lysis Time (CLT) for each species within the basal clade in the presence of tPA at 0.1 µg, 0.5 
µg and 1 µg venom concentrations. Control is indicated in black. Columns are averages of triplicates 
and error bars given for each. Bars which are lower than the control lysed the plasma clot quicker 
than under normal tPA conditions.  
 
4.3.6 Fibrinogen gels  
Time-dependent cleavage of fibrinogen chains was also investigated using electrophoresis. Venom 
from Azemiops feae failed to cleave any of the fibrinogen, while Tropidolaemus wagleri and Hypnale 
hypnale cleaved all 3 chains within 30 minutes (Figure 4.8 and Figure 4.9). Venom from 
Calloselasma rhodostoma, Tropidolaemus subannulatus and Deinagkistrodon acutus all cleaved the 
alpha chain rapidly, while slowly cleaving the beta chain but with no effect on the gamma chain 
(Figure 4.8 and Figure 4.9).  
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Figure 4.8 Fibrinogen chain cleavage - gel 
1D SDS PAGE time dependent fibrinogen chain degradation (α, β or γ) by venom at 0.1 µg/μL 
concentration at 37ºC over 60 min. F = fibrinogen at 0 min or 60 min incubation controls, V = venom 
at 1, 5… 60 min incubation. 
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Figure 4.9 Fibrinogen chain cleavage - % intact  
Relative cleavage of alpha (blue), beta (green) or gamma (pink) chains of fibrinogen. X-axis is time 
(min), y-axis is percentage of intact chain remaining. Error bars indicate standard deviation and N = 
3 means. 
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4.4 Discussion  
The venoms within the clade studied here, formed by the genera Azemiops, Calloselasma, Hypnale, 
Deinagkistrodon and Tropidolaemus, were as functionally diverse as the snakes are themselves in 
morphology and ecological niche occupied, with the snakes ranging from semi-fossorial species, to 
ambush feeding, heavily camouflaged terrestrial, to arboreal species. There were no phylogenetic or 
ecological patterns in their actions upon enzymatic substrates (Figure 4.1) or in the functional tests. 
The camouflaged, sit and wait ambush specialists (C. rhodostoma, H. hypnale and D. acutus) were 
similar in that they clotted plasma and fibrinogen (Figure 4.2, Figure 4.3, Figure 4.4 and Figure 4.5), 
but the underlying mechanics were starkly different.  
Consistent with previous reports of this venom (Ainsworth et al., 2018; Nielsen and Bazzell, 2017; 
Yamada et al., 1997) C. rhodostoma was a true procoagulant venom. In this study it was shown to 
activate Factor X generating endogenous thrombin, forming a strong, stable fibrin clot. In contrast, 
H. hypnale venom produced a strong stable clot upon plasma but did not activate Factor X or 
Prothrombin and formed a very weak, unstable clot when tested on fibrinogen (Figure 4.4, Figure 4.5 
and Figure 4.6). Deinagkistrodon acutus venom, however, was shown to be pseudo-procoagulant in 
that it acted directly upon fibrinogen to produce transient, weak fibrin clots (Figure 4.4 and Figure 
4.5).  
Calloselasma rhodostoma retained the ability to directly clot fibrinogen in a pseudo-procoagulant 
manner, however this action was significantly slower than the true-procoagulant action of Factor X 
activation, resulting in the generation of endogenous thrombin (Figure 4.5). Therefore, prey 
subjugation would be facilitated through the induction of stroke, as has been seen convergently for 
other venoms, not only other vipers such as Echis (Rogalski et al., 2017) and Bothrops (Sousa et al., 
2018) but also diverse snakes from other families such as Dispholidus and Thelotornis with the 
Colubridae (Debono et al., 2017a), Hoplocephalus, Notechis, Paroplocephalus and Tropidechis 
within the Elapidae (Lister et al., 2017) and Atractaspis within the Lamprophiidae (Oulion et al., 
2018). However, in human bite victims the larger blood volume would dilute the venom and lessen 
the likelihood of large blood clots forming. Instead there would be a depletion of fibrinogen and 
clotting factors, as a consequence of endogenous thrombin generation which would result in a venom 
induced consumptive coagulopathy (VICC), creating a net anticoagulant state (Isbister, 2010). 
Therefore, while prey items which rapidly succumb due to venom-inducted stroke, the longer survival 
of envenomed humans would allow sufficient time for potentiation of the net anticoagulation effects 
due to the secondary action upon the remaining fibrinogen - the pseudo-procoagulant cleavage to 
form weak, transient clots with remaining fibrinogen (Ho et al., 1986; Tang et al., 2016; Warrell et 
al., 1986).  
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In contrast, the transient, weak fibrin clots shown in this study for D. acutus venom, consistent with 
previous reports (Nielsen and Frank, 2018) would have a short half-life due to their inherent 
instability. Thus the effects upon both prey and humans envenomated by D. acutus venoms would 
therefore be similar: a rapid decrease in fibrinogen levels leading to an anticoagulant state (Cheng et 
al., 2017; Ouyang and Teng, 1976, 1978), with death resulting from haemorrhagic shock, like has 
been shown for the Protobothrops genus (Debono et al., 2019c). Both D. acutus and H. hypnale 
venoms displayed similar biochemistry for their pseudo-procoagulant action, which required calcium 
for full action (Nielsen, 2016b; Nielsen and Bazzell, 2017). The activity that H. hypanle displays 
upon plasma still remains a mystery, as the venom does not activate Factor X or Prothrombin (Figure 
4.6). Additional investigation into the mechanisms behind this activity would be the focus of future 
research, such as activation of other clotting factors (ie IX or XI).  
Of the other species within this study, in the thromboelastography studies, only T. wagleri displayed 
evidence of action upon fibrinogen, showing only a moderate level of pseudo-procoagulant activity, 
yet its sister species T. subannulatus did not display such activity. Azemiops feae also did not display 
any coagulotoxic action. The low to non-existent coagulotoxic activity is consistent with Azemiops 
and Tropidolaemus both known to have contain novel neurotoxic peptides rather than the larger 
enzymes typical of viperid venoms (Schmidt and Weinstein, 1995; Shelukhina et al., 2018; Tan et al., 
2017b). In both cases, it has been shown that the neurotoxic peptides emerged in the venoms from de 
novo evolution of novel bioactive peptides in the propeptide-region of the venom forms of C-type 
natriuretic peptides (Brust et al., 2013; Debono et al., 2017b). However, as these genera are not sister 
to each other and occupy very different ecological niches (semi-fossorial for Azemiopis and arboreal 
for Tropidolaemus) the selection pressure for the molecular evolution of the peptides was differential. 
The functional variation extended to the patterns of fibrinogen chain cleavage as revealed in the SDS 
PAGE gels (Figure 4.8 and Figure 4.9). Calloselasma rhodostoma and D. acutus were similar in 
rapidly cleaving the A-alpha and B-beta chains but not the gamma, which is consistent with both 
venoms having the ability for pseudo-procoagulant direct action upon fibrinogen (Figure 4.5). T. 
wagleri was the only other venom to display significant action in the fibrinogen thromboelastography 
studies, having a moderate pseudo-procoagulant activity (Figure 4.5), and this venom cleaved all 
three fibrinogen chains (Figure 4.8 and Figure 4.9). The sister species T. subannulatus displayed a 
similar, but weaker, activity on the fibrinogen gels (Figure 4.8 and Figure 4.9) despite not having a 
significant functional activity in the venom concentration tested in the thromboelastography studies 
(Figure 4.5). Consistent with the functional studies (Figure 4.5), A. feae did not have any activity on 
the fibrinogen gels (Figure 4.8 and Figure 4.9). 
Just as the neurotoxicity exhibited by some species in this clade of snakes are unique, so too is the 
thrombin generating activity of C. rhodostoma. In contrast, D. acutus was more like the typical Asian 
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pit-viper, which are broadly known for their haemorrhagic-shock inducing venoms (Cheng et al., 
2017; Debono et al., 2019c; Hutton et al., 1990; Joseph et al., 2007; Maduwage et al., 2013a; 
Rojnuckarin et al., 1998; Warrell et al., 1986; Withana et al., 2014). Haemorrhagic effects are a result 
of anticoagulation mechanisms, or a net anticoagulant outcome. As previously mentioned, 
haemorrhagic effects were demonstrated within this group as irregular degradation of fibrinogen 
chains, which creates weak clots such as was evident for the D. acutus venom in the 
thromboelastography studies (Figure 4.4 and Figure 4.5). Such degradation of fibrinogen has 
previously been shown with the isolation and purification of a ‘thrombin-like enzyme’ (TLE) 
‘Ancrod’ from C. rhodostoma, a serine protease which is able to cleave α from Aα chain (Markland, 
1998; Nolan et al., 1976; Vaiyapuri et al., 2015).  
An in-depth investigation into these mechanisms controlling coagulation has somewhat been 
neglected from the literature, and a thorough analysis into the actions upon the blood system is 
required. The addition of co-factor analysis and dependency is extremely important when 
investigating these lineages, and the true representation of either a procoagulant or anticoagulant 
action can be demonstrated.  Applying this knowledge and gaining a more complete understanding 
of venom diversification and evolution is important for predictions of potential clinical effects and 
evidence-based management strategies, in addition to biodiscovery research.  
4.5 Materials and Methods  
4.5.1 Venoms 
Six species of Asian Viperidae (Alencar et al., 2016) were investigated for venom composition and 
coagulation effects via a multidisciplinary approach of venomics, functionality and bioactivity. 
Pooled, lyophilized venom samples from species Azemiops feae, Calloselasma rhodostoma, 
Deinagkistrodon acutus, Hypnale hypnale, Tropidolaemus subannulatus and Tropidolaemus wagleri 
were procured from captive collections (unknown localities of founding stocks). Venoms were 
resuspended in deionized H2O and protein concentrations (mg/mL) determined using a ThermoFisher 
Scientific Nanodrop™ 2000c Spectrophotometer. Working stocks of 50% deionized water/50% 
glycerol (> 99%, Sigma-Aldrich) for all venoms were prepared at 1 mg/mL and stored at -20°C to 
preserve enzymatic activity and reduce enzyme degradation. Venoms included in the following assays 
were subject to availability at the time of analysis. 
 
4.5.2 Enzyme assays  
Various enzymatic assays were performed to investigate activity on specific artificial substrates, as 
well as PLA2, plasminogen activation, prothrombin activation and FX activation. Investigation 
followed that described by (Debono et al., 2019c). Phytools heat mapping followed that of (Lister et 
al., 2017).  Details are as follows. 
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4.5.2.1 Fluorescent substrate activation 
In order to investigate Fluorescent Determination of matrix metalloprotease (ES001, ES003, ES005, 
ES010), serine protease activity (ES002, ES011) and phospholipase A2 (PLA2) enzymatic assays 
were undertaken as previously described by us (Debono et al., 2017a). For matrix metalloprotease 
and serine protease assays a working stock solution of freeze dried venom was reconstituted in a 
buffer containing 50% MilliQ/50% glycerol (>99.9%, Sigma, St Louis, MO, USA) at a 1:1 ratio to 
preserve enzymatic activity and reduce enzyme degradation. Varying concentrations of crude venom 
(10 ng/μL and 50 ng/μL) were plated out in triplicates on a 384-well plate (black, Lot#1171125, 
nunc™ Thermo Scientific, Rochester, NY, USA) and measured by adding 90 μL quenched 
fluorescent substrate per well (total volume 100 μL/well, 10 μL/ 5mL enzyme buffer, 150 mM NaCl, 
and 50 mM Tri-HCl (pH 7.3), Fluorogenic Peptide Substrate, R & D systems, Cat#ES001, ES003, 
ES005, ES010,  ES011, Minneapolis, Minnesota). Fluorescence was monitored by a Fluoroskan 
Ascent™ (Thermo Scientific, Vantaa, Finland) Microplate Fluorometer (Cat#1506450, Thermo 
Scientific, Vantaa, Finland) (Cat#ES001, ES003, ES005, ES010 for Matrix Metalloprotease at an 
excitation of 320 nm, emission at 405 nm; Cat#ES011 for Kallikrein at an excitation of 390 nm, 
emission at 460 nm) over 400 min or until activity had ceased. Data was collected using Ascent® 
Software v2.6 (Thermo Scientific, Vantaa, Finland).  
For PLA2 analysis we assessed the continuous Phospholipase A2 (PLA2) activity of the venoms using 
a fluorescence substrate assay (EnzChek® Phospholipase A2 Assay Kit, Cat#E10217, Thermo 
Scientific, Rochester, NY, USA), measured on a Fluoroskan Ascent® Microplate Fluorometer 
(Cat#1506450, Thermo Scientific, Vantaa, Finland). As above, we used a working stock solution of 
freeze dried venom reconstituted in a buffer containing 50% MilliQ / 50% glycerol (>99.9%, Sigma) 
at a 1:1 ratio. A concentration of enzyme activity in venom (50 ng/μL) was brought up in 12.5 μL 1× 
PLA2 reaction buffer (50 mM Tris-HCL, 100 mM NaCl, 1 mM CaCl2, pH 8.9) and plated out in 
triplicates on a 384-well plate (black, Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, 
USA). The triplicates were measured by dispensing 12.5 μL quenched 1 mM EnzChek® (Thermo 
Scientific, Rochester, NY, USA) Phospholipase A2 Substrate per well (total volume 25 μL/well) over 
100 min or until activity had ceased (at an excitation of 485 nm, emission 538 nm). Purified PLA2 
from bee venom (1 U/mL) was used as a positive control and data was collected using Ascent® 
Software v2.6 (Thermo Scientific, Vantaa, Finland).  
4.5.2.2 Plasminogen activation 
The same working stock solution of 1 mg/mL (outlined above and in (Debono et al., 2017a) of freeze 
dried venom was used to make the following dilutions: 10 ng/μL, 50 ng/μL and 100 ng/μL. These 
varying concentrations of enzyme activity in venom were plated out on a 384-well plate (black, 
58 
 
Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, USA) in triplicates, with and without 10 
ng/μL plasminogen per well (Lot#FF0125 HCPG-0130, Haematologic Technologies Inc., Essex 
Junction, VT, USA). Plasminogen, a serine protease, can be activated by a serine protease specific 
substrate (Fluorogenic Peptide Substrate, R & D systems, Cat# ES011, Minneapolis, Minnesota). 
Plasmin was used as a positive control (10 ng/μL per positive control well, Lot#EE1120, HCPM-
0140, Haematologic Technologies Inc., Essex Junction, VT, USA). Activation from venoms was 
measured by adding 90 μL quenched fluorescent substrate per well (total volume 100 μL/well; 20 
μL/5mL enzyme buffer - 150 mM NaCl and 50 mM Tri-HCl (pH 7.3), Fluorogenic Peptide Substrate, 
R & D systems, Cat#ES011, Minneapolis, Minnesota). Fluorescence was monitored by a Fluoroskan 
Ascent™ Microplate Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland) at excitation 
390 nm and emission at 460 nm over 150min or until activity had ceased. Data was collected using 
Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). Experiments were conducted in 
triplicate. 
4.5.2.3 Prothrombin activation 
The ability for the above crude venom to directly activate prothrombin was investigated and measured 
by modifying the above protocol used for plasminogen activation. Plasminogen was replaced with 
prothrombin (Lot#EE0930, HCP-0010, Haematologic Technologies Inc., Essex Junction, VT, USA) 
and plasmin was replaced with thrombin (Lot#FF0315, HCT-0020, Haematologic Technologies Inc., 
Essex Junction, VT, USA) as a positive control (10 ng/μL per positive control well). Data was 
collected using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). Experiments were 
conducted in triplicate. 
4.5.2.4 Factor X activation 
The ability for the above crude venom to directly activate blood coagulation Factor X (FX) was 
investigated and measured by modifying the above protocol used for plasminogen activation using 
FX (Lot#FF0407, HCX-0050, Haematologic Technologies Inc., Essex Junction, VT, USA) as the 
experimental target and FXa (Lot#EE1102, HCXA-0060, Haematologic Technologies Inc., Essex 
Junction, VT, USA) as the positive control (10 ng/μL per positive control well). Data was collected 
using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). Experiments were conducted in 
triplicate. 
 
4.5.3 Phylogenetic comparative analyses  
Observed venom activities of the different snake species were investigated in an evolutionary 
framework by mapping them on a taxon tree using Mestique and analyses  were performed via the R 
package Phytools  as per that of (Lister et al., 2017; Rogalski et al., 2017) using phylogenetic 
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Generalized Least Squares (PGLS). The phylogeny was adapted from (Alencar et al., 2016)  Analyses 
were implemented in R v3.2.5 (Team, 2016) using the APE package for basic data manipulation 
(Paradis et al., 2004).  Ancestral states of each substrate functional trait (ES001, ES002, ES003, 
ES005, ES010, ES011, PLA2, coagulation) were estimated via maximum likelihood with the contMap 
function in phytools (Revell, 2012).   
 
4.5.4 Coagulation assays  
4.5.4.1 Action upon plasma and fibrinogen: Clot formation or inhibition assays  
Ability to affect clotting of plasma and fibrinogen, including relative co-factor dependency, was 
investigated using a Stago STA-R Max coagulation analyser using protocols previously described by 
us (Debono et al., 2019c; Debono et al., 2017a). In order to investigate whole plasma and fibrinogen 
clotting and co-factor dependency clotting, we prepared healthy human plasma (citrate 3.2%, 
Lot#1690252, approval #16-04QLD-10), obtained from the Australian Red Cross (44 Musk Street, 
Kelvin Grove, Queensland 4059) and human fibrinogen (4 mg/mL, Lot#F3879, Sigma Aldrich, St. 
Louis, Missouri, United States). Coagulopathic toxin effects were measured by a modified 
procoagulant protocol on a Stago STA-R Max coagulation robot (France) using Stago Analyser 
software v0.00.04 (Stago, Asniéres sur Seine, France). Plasma clotting baseline parameters were 
determined by performing the standardised activated Partial Thromboplastin Time (aPTT) test (Stago 
Cat# T1203 TriniCLOT APTT HS). This was used as a control to determine the health of normal 
clotting plasma according to the universal standard range of between 27–35 s. Plasma aliquots of 2 
mL, which had been flash frozen in liquid nitrogen and stored in a −80 °C freezer, were defrosted in 
an Arctic refrigerated circulator SC150-A40 at 37°C. In order to determine clotting times effected by 
the addition of varying venom concentrations, a modified aPTT test was developed. A starting volume 
of 50 μL of crude venom (5 µg/50 μL) was diluted with STA Owren Koller Buffer (Stago Cat# 
00360). An 8-dilution series of 1 (20 µg/mL), 1/2 (10 µg/mL), 1/5 (4 µg/mL), 1/12 (1.6 µg/mL), 1/30 
(0.66 µg/mL), 1/80 (0.25 µg/mL), 1/160 (0.125 µg/mL), and 1/400 (0.05 µg/mL) was performed in 
triplicate. CaCl2 (50 μL; 25 mM stock solution Stago Cat# 00367 STA CaCl2 0.025M) was added 
with 50 μL phospholipid (solubilized in Owren Koller Buffer adapted from STA C.K Prest standard 
kit, Stago Cat# 00597). An additional 25 μL of Owren Koller Buffer was added to the cuvette and 
incubated for 120 sec at 37°C before adding 75 μL of human plasma. Relative clotting was then 
monitored for 999 sec or until plasma clotted (whichever was sooner). Additional tests were run, both 
with and without CaCl2 and phospholipid, respectively, to test for CaCl2 or phospholipid dependency. 
STA Owren Koller Buffer was used as a substitute, using the same volumes to allow for consistency 
in the final volumes (250 μL). 
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4.5.4.2 Thromboelastography  
Venoms were investigated for their ability to affect clot strength ability of plasma and fibrinogen 
using a Thromboelastography® 5000 using protocols previously described by us (Debono et al., 
2019c) and (Coimbra et al., 2018; Oulion et al., 2018). Using human fibrinogen (4 mg/mL) and human 
plasma venoms were investigated using a Thrombelastogram® 5000 Haemostasis analyser 
(Haemonetics®, Haemonetics Australia Pty Ltd, North Rdye, Sydney 2113, Australia) for their ability 
in clot strength. Human fibrinogen (4 mg/mL, Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United 
States) was reconstituted in enzyme buffer (150 mM NaCl and 50 mM Tri-HCl (pH 7.3)). Natural 
pins and cups (Lot# HMO3163, Haemonetics Australia Pty Ltd, North Rdye, Sydney 2113, Australia) 
were used with the following solution; 7 μL venom working stock (1 mg/mL outlined in (Debono et 
al., 2017a)) or 7 μL thrombin as a positive control (stable thrombin from Stago Liquid Fib kit, 
unknown concentration from supplier (Stago Cat#115081 Liquid Fib)), 72 μL CaCl2 (25mM stock 
solution Stago Cat# 00367 STA), 72 μL phospholipid (solubilized in Owren Koller Buffer adapted 
from STA C.K Prest standard kit, Stago Cat# 00597), and 20 μL Owren Koller Buffer (Stago Cat# 
00360) was combined with 189 μL fibrinogen or human plasma and run immediately for 30 min to 
allow for ample time for clotting formation. An additional positive control of 7 μL Factor Xa 
(unknown concentration from supplier, Liquid Anti-Xa FXa Cat#253047, Stago) was also 
incorporated for plasma only. When no clot was formed from the effects of anticoagulant venoms, an 
additional 7 μL thrombin was added to the pin and cup to generate a clot and to determine the effects 
of fibrinogen degradation. 
4.5.4.3 Fibrinogen SDS PAGE electrophoresis and gel image analysis  
Venoms from Azemiops feae, Calloselasma rhodostoma, Deinagkistrodon acutus, Hypnale hypnale, 
Tropidolaemus subannulatus and Tropidolaemus wagleri were investigated for ability to cleave 
fibrinogen using protocols previously described by us (Debono et al., 2019c; Dobson et al., 2018). 
Human fibrinogen (Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States) was reconstituted 
to a concentration of 1 mg/mL in isotonic saline solution, flash frozen in liquid nitrogen and stored at 
-80ºC until use. Freeze-dried venom was reconstituted in deionised H2O and concentrations were 
measured using a Thermo Fisher Scientific™ NanoDrop 2000 (Waltham, MA, USA). Assay 
concentrations were a 1:10 ratio of venom:fibrinogen. Human fibrinogen (Lot#F3879, Sigma Aldrich, 
St. Louis, Missouri, United States) stock of 1 mg/mL was dispensed into ten 120 μL aliquots. 
Fibrinogen from each aliquot (10 μL) was added to 10 μL buffer dye (5 μL of 4× Laemmli sample 
buffer (Bio-Rad, Hercules, CA, USA), 5 μL deionised H2O, 100 mM DTT (Sigma-Aldrich, St. Louis, 
MO, USA)) as an untreated control lane. An additional fibrinogen aliquot (10 μL) was firstly 
incubated for 60 min at 37ºC before immediately adding 10 μL buffer dye. Venom stock (1 μL at 1 
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mg/mL) was added to the remaining 100 μL fibrinogen aliquot and incubated over 60 min at 37ºC, 
taking out 10 μL at varying time points (1, 5, 10, 15, 20, 30, 45 and 60 min). This 10 μL was 
immediately added to an additional 10 μL buffer dye. Once all 8-time points including the two 
controls (untreated, unincubated fibrinogen and untreated, incubated fibrinogen 60min at 37ºC) were 
added to the buffer dye these were incubated at 100oC for 4 minutes then immediately loaded into the 
precast 1D SDS-PAGE gel. Gels were prepared in triplicate under the described conditions per venom 
and were run in 1× gel running buffer (as described by (Debono et al., 2017a; Koludarov et al., 2017) 
at room temperature at 120 V (Mini Protean3 power-pack from Bio-Rad, Hercules, CA, USA) until 
the dye front neared the bottom of the gel. Gels were stained with colloidal coomassie brilliant blue 
G250 (34% methanol (VWR Chemicals, Tingalpa, QLD, Australia), 3% orthophosphoric acid 
(Merck, Darmstadt, Germany), 170 g/L ammonium sulfate (Bio-Rad, Hercules, CA, USA), 1 g/L 
Coomassie blue G250 (Bio-Rad, Hercules, CA, USA), and destained in deionised H2O. 
Fibrinogen gel analysis (ImageJ and PRISM) 
Using the publicly available software ImageJ (V1.51r, Java 1.6.0_24, National Institutes of Health, 
Bethesda, Maryland, USA) (Schneider et al., 2012), gels that had been scanned using a standard 
printer/scanner were loaded onto the software. Scans were changed to 32 bit to emphasise darken 
bands of fibrinogen chains so that the image could be manipulated to view individual peaks and 
troughs representing the alpha, beta and gamma chains. The intensity represents the amount of protein 
within that particular band and as the chain degrades the intensity decreases. Using the ‘wand 
function’ each peak within the graph was selected automatically producing a quantity for the area 
under the curve. AUC was graphed using GraphPad PRISM 7.0 (GraphPad Prism Inc., La Jolla, CA, 
USA). This process was repeated for all three triplicates for each venom.  
4.5.4.4 Factor X activation and prothrombin activation 
To determine the relative rate of Factor X activation or prothrombin activation by venom samples, a 
working stock solution (at 1 mg/mL in 50% deionized H2O+ 50% glycerol) was manually diluted 
with OK buffer (STA Owren Koller Buﬀer) (50 μL at 20 µg/mL) to a cuvette. A total of 50 μL of 
CaCl2 (25 mM), 50 μL phospholipid (cephalin prepared from rabbit cerebral tissue from STA C.K 
Prest standard kit, solubilized in OK buﬀer) and 25 μL of OK buﬀer was added to cuvette and 
incubated for 120 sec at 37°C before adding 75 μL of a solution containing the colorimetric substrate 
(Liquid Anti-Xa substrate, Stago LOT 253047) and either 0.01 μg/μL FX (Human Factor X, Lot 
#HH0315, HTI) or 0.1 μg/μL prothrombin (Human Prothrombin, Lot # GG1026, HTI) (total volume 
250 μL/cuvette). A change in the optical density (OD) was measured each second for 300 sec using 
a STA-R Max® automated analyzer (Stago, Asnières sur Seine, France). All tests were performed in 
triplicate. The rate of FX activation or prothrombin activation, by the samples, was calculated in 
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comparison to the variation in the optical density – corresponding to the cleavage of the substrate by 
FXa or thrombin, after the activation of the zymogen by the samples, in relation to direct cleavage of 
substrate by the samples in the absence of the zymogen. Human FXa (Liquid Anti-Xa FXa LOT 
253047) or thrombin (Liquid Fib, Stago, LOT 253337) was used as positive control to ensure quality 
of the substrate. The samples analyzed, in same conditions, without the presence of the zymogen were 
used as a negative control to establish and venom-induced baseline substrate cleavage in the absence 
of the zymogen. A solution containing deionized H2O/glycerol at a 1:1 ratio was used as a second 
negative control. 
4.5.4.5 Fibrinolysis ± tPA 
The ability of venoms from Azemiops feae, Calloselasma rhodostoma, Deinagkistrodon acutus, 
Tropidolaemus subannulatus and Tropidolaemus wagleri to activity lyse clots was investigated in the 
presence or absence of tPA following methods described previously by us (Debono et al., 2019c). To 
investigate the fibrinolysis ability of the above venoms, varying concentrations of venom (100 ng/μL, 
500 ng/μL and 1 µg/μL) were tested under varying conditions with the addition of tissue plasminogen 
activator (tPA, Sekisui Diagnostics, Lexington, MA, USA). Aliquots (100 μL) of normal pooled 
human plasma (Leiden University Medical Center (Leiden, NL)) stored at -80°C were defrosted in a 
water bath at 37°C. A 96-well plate was prepared under the following conditions: 6 pM tissue factor 
(TF) (Innovin, Siemens, USA) was added to 10 µM phospholipid vesicles (PCPS, 75% 
phosphatidylcholine and 25% phosphatidylserine, Avanti Polar Lipids, Alabama, USA) in HEPES 
buffer (25 mM HEPES, 137mM NaCl, 3.5 mM KCl, 0.1% BSA (Bovine Serum Albumin A7030, 
Sigma Aldrich, St Louis, MD, USA)) and gently incubated at 37ºC for 1 hr in a water bath. 17 mM 
CaCl and 37.5 U/mL tPA (diluted in dilution buffer (20 mM HEPES, 150 mM NaCl, 0.1% PEG-8000 
(Polyethylene glycol 8000,1546605 USP, Sigma Aldrich, St Louis, MD, USA), pH 7.5)) was then 
added to the solution. A volume of 30 μL of this solution was added to each experimental well, along 
with 10 μL of venom at varying concentrations and an additional 10 μL of HEPES buffer, prepared 
on ice (total well volume of 100 μL). Normal pooled plasma (50 μL) was immediately added to each 
well (heated to 37ºC). Absorbance measuring commenced immediately and was measured every 30 
sec over 3 hr at 405 nm on a Spectra Max M2e (Molecular Devices, Sunnyvale, CA, USA) plate 
reader, heated to 37ºC. Measurements were captured on Softmax Pro software (V 5.2, Molecular 
Devices, Sunnyvale, CA, USA) and data points analysed using GraphPad PRISM 7.0 (GraphPad 
Prism Inc., La Jolla, CA, USA). All experimental conditions were repeated in triplicates and 
averaged. 
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Chapter 5: Habu coagulotoxicity: Clinical implications of the functional 
diversification of Protobothrops snake venoms 
 
5.1 Abstract 
Venom can affect any part of the body reachable via the bloodstream. Toxins which specifically effect 
the coagulation cascade do so either by anticoagulant or procoagulant mechanisms. Here we 
investigated the coagulotoxic effects of six species within the medically important viper genus 
Protobothrops (Habu) from the Chinese mainland and Japanese islands, a genus known to produce 
hemorrhagic shock in envenomed patients. Differential coagulotoxicity was revealed: P. jerdonii and 
P. mangshanensis produced an overall net anticoagulant effect through the pseudo-procoagulant 
clotting of fibrinogen; P. flavoviridis and P. tokarensis exhibit a strong anticoagulant activity through 
the destructive cleavage of fibrinogen; and while P. elegans and P. mucrosquamatus both cleaved the 
A-alpha and B-beta chains of fibrinogen they did not exhibit strong anticoagulant activity. These 
variations in coagulant properties were congruent with phylogeny, with the closest relatives 
exhibiting similar venom. The results indicate that anticoagulation mediated by pseudo-procoagulant 
cleavage of fibrinogen is the basal state, while anticoagulation produced by destructive cleavage of 
fibrinogen is the derived state within this genus. This is the first in depth study of its kind highlighting 
extreme enzymatic variability, functional diversification and clotting diversification within one genus 
surrounding one target site, governed by variability in co-factor dependency. The documentation that 
the same net overall function, anticoagulation, is mediated by differential underlying mechanics 
suggests limited antivenom cross-reactivity, although this must be tested in future work. These results 
add to the body of knowledge necessary to inform clinical management of the envenomed patient. 
5.2 Introduction 
Venom is defined as a secretion produced in specialised cells that is delivered to a target animal 
through a wound, and consequently disrupts normal physiological or biochemical processes (Fry et 
al., 2009a; Fry et al., 2009b; Jackson and Fry, 2016; Jackson et al., 2017; Nelsen et al., 2014). Venoms 
are complex mixtures of enzymes, toxins, peptides, organic molecules and salts (Fry et al., 2009a; 
Fry et al., 2009b) which are used to facilitate feeding, (Fry et al., 2008; Fry et al., 2013; Fry et al., 
2009b; Jackson et al., 2013) defence such as that found in spitting cobras (Cascardi et al., 1999; Hayes 
et al., 2008; Panagides et al., 2017) or competition (Deufel and Cundall, 2003) for the producing 
organism (Fry and Wüster, 2004; Sunagar et al., 2013). Numerous studies have demonstrated that 
venom genes evolve at a much faster rate than housekeeping genes, facilitating a drive towards a 
highly specialised and complex venom composition (Casewell et al., 2013; Jackson et al., 2013; 
Sunagar et al., 2013; Vonk et al., 2013). This facilitated diversification allows toxins within venom 
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to evolve rapidly, and at different rates, through a variety of different selective mechanisms. These 
mechanisms include but are not limited to ecological niche occupation, which is in-turn directly 
related to prey ecology, and in some cases taxon-specific toxins including the potential for prey 
escape or prey retaliation (Daltry et al., 1996b; Fry et al., 2013; Jackson et al., 2013; Koludarov et al., 
2014; Li et al., 2005; Pawlak et al., 2006; Pawlak et al., 2009; Sunagar et al., 2013; Sunagar et al., 
2014; Yang et al., 2016).  
Snake venoms are made up of a myriad of mutated protein families, each responsible for varying 
pathophysiological effects (Fry, 2005). Coagulatoxins target the blood coagulation cascade via one 
of two mutually exclusive functional mechanisms: anticoagulation or procoagulation (Fry et al., 
2009a). Anticoagulation that is mediated via proteolytic cleavage is accomplished through two 
different mechanisms: cleavage in a non-clotting, destructive manner which results in direct 
anticoagulation; or cleavage in a pseudo-procoagulant manner, resulting in weak fibrin clots with 
very short-half lives. While kallikrein-type serine proteases  and snake venom metalloproteases 
(SVMP) both may cleave fibrinogen in a non-clotting, destructive manner (Casewell et al., 2015; 
Vaiyapuri et al., 2015), only kallikrein toxins are currently known for the pseudo-procoagulant 
activity. 
Fibrinogen is a trinodular protein, present in high concentrations in plasma (Wolberg, 2007), and is 
made up of three polypeptide chains (Aα, Bβ, γ). Under normal cleavage by thrombin, fibrinopeptides 
A and B are cleaved from the Aα and Bβ chains, thereby exposing the γ chain and producing strong, 
well-ordered lattices. These fibrin clots are further strengthened by thrombin-mediated activation of 
Factor XIII into FXIIIa, with FXIIIa in turn additionally cross linking the fibrin strands (Bagoly et 
al., 2012; Collet et al., 2000; Koh and Kini, 2012; Longstaff and Kolev, 2015; Ryan et al., 1999; 
Wolberg, 2007). When fibrinogen is cleaved by snake venom in a non-clotting manner, SVMPs 
cleave the Aα-chain while kallikreins cleave the Bβ-chain (Kini, 2005b; Kini and Koh, 2016; Sajevic 
et al., 2011; Swenson and Markland, 2005) with both cleaving at sites distinct from that of thrombin. 
In contrast, when fibrinogen is cleaved in a pseudo-procoagulant manner by kallikreins, 
fibrinopeptides A or B (or both) are cleaved from their respective chains but through aberrant 
cleavage sites, resulting in disordered lattice-works and weak, short-lived clots  (Sajevic et al., 2011; 
Swenson and Markland, 2005).  
The wide-ranging Asian pit viper genus Protobothrops occupies the islands of Japan, mainland China 
and islands off China. Protobothrops bites are known for potent haemorrhagic shock effects in prey 
and human bite victims (Chen et al., 2009; Nishimura et al., 2016). Target sites include impeding 
primary haemostasis by disruption along the cascade from the blockage of platelet aggregation 
through to inhibiting clot formation due to the unnatural cleavage of fibrinogen (Collet et al., 2000; 
Kolev and Longstaff, 2016; Longstaff and Kolev, 2015; Mosesson, 2005).  
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Despite the medical importance of these snakes, a comprehensive examination of intra-genus venom 
variation has not been undertaken. Such data will provide fundamental information which may aid 
the prediction of clinical effects and thus guide snake bite case management. This study used a myriad 
of techniques to investigate the effects of six Protobothrops venoms upon the clotting cascade, with 
a particular focus upon their actions upon fibrinogen.  
5.3 Results  
5.3.1 Enzymatic assays on the Fluoroskan Ascent 
Enzymatic assays were using substrates typically cleaved by metalloproteases (ES001, ES003, and 
ES010), serine proteases (ES002 and ES011) or PLA2. While these are artificial substrates and may 
not necessarily directly correlate with ‘real world’ bioactivity, they are useful for elucidating 
differences between the venoms. Indeed, significant variation was observed between the venoms for 
each substrate class (Figure 5.1). In addition to variation between venoms, there was also significant 
variation between substrate types, whereby the strongest for one substrate type was not the strongest 
for another substrate within the same generalised class (whether within the metalloprotease or serine 
protease class). For ES001 P. flavoviridis was twice as active as the next strongest venom (the sister 
species P. tokarensis), and three times as active as P. mucrosquamatus with the other species only 
showing low levels of activity (Figure 5.1A). A broadly similar pattern was observed for ES010, with 
P. flavoviridis being significantly more active than the other venoms, however with some venoms 
that showed only trace activity upon ES001 showing significant activity upon ES010 (P. elegans, and 
P. mangshanensis) (Figure 5.1D). In contrast, for ES003 (also a metalloprotease substrate), P. 
mucrosquamatus was much more active than all other venoms, being four times as active as the next 
potent species (P. tokarensis) (Figure 5.1C). A similar level of variation between the serine protease 
substrates was also observed, where P. elegans was the most potent, but all other venoms displaying 
at least moderate levels of activity, while for P. jerdonii and P. mangshanensis were both potent while 
all other venoms displayed only trace or undetectable levels of activity (Figure 5.1B and 1E). P. 
flavoviridis displayed the highest activity upon the PLA2 substrate, with the next nearest venom (P. 
elegans) being 66% as potent, followed by P. tokarensis (33%), and all others showing only very low 
levels of activity (Figure 5.1F). These variations are strongly suggestive of differential activity of the 
venoms under physiological conditions. The extreme variation between species was evident in the 
ancestral state reconstructions (Figure 5.1), which is consistent with rapid diversification away from 
the ancestral state.  
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Figure 5.1 Enzyme substrate activity  
Ancestral state reconstruction of enzymatic substrate activity of Protobothrops species based on their 
normalised relative ability to cleave the following substrates; A: fluorogenic peptide substrate (Mca-
PLGL-Dpa-AR-NH2 Fluorogenic Matrix Metalloprotease  Substrate, Cat#ES001), B: fluorogenic 
peptide substrate (Mca-RPKPVE-Nval-WRK(Dnp)-NH2 Fluorogenic MMP Substrate, Cat#ES002) 
which detects additional metalloprotease activity and Factor X, C: fluorogenic peptide substrate 
(Mca-PLAQAV-Dpa-RSSSR-NH2 Fluorogenic Peptide Substrate, Cat#ES003) which detects 
additional metalloprotease activity, D: fluorogenic peptide substrate (Mca-KPLGL-Dpa-AR-NH2 
Fluorogenic Peptide Substrate, Cat#ES010) which detects additional metalloprotease activity, E: 
fluorogenic peptide substrate (Boc-VPR-AMC Fluorogenic Peptide Substrate, Cat#ES011) which 
detects serine protease activity, F: Phospholipase A2 substrate activity, EnzChek® (Cat# E10217). 
Warmer colours represent more potent substrate cleavage. Bars indicate 95% confidence intervals for 
the estimate at each node. Phylogeny follows (Alencar et al., 2016).  
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5.3.2 Coagulation analyses 
5.3.2.1 Action upon plasma 
Plasma clotting and co-factor dependency of Ca2+ and phospholipid  
Only P. elegans, P. mangshanensis, and P. jerdonii and displayed the ability to clot human plasma 
(Figure 5.2). At a 20µg/mL venom concentration, P. mangshanensis was able to clot plasma in 32.0 
± 5.4 sec, compared to P. jerdonii (139.0 ± 11.9 sec) and P. elegans (98.9 ± 6.66 sec), relative to the 
spontaneous clotting time of the recalcified plasma of 325.0 ± 25.0 sec. In contrast, the P. flavoviridis 
and P. tokarensis venom demonstrated a potently anticoagulant effect, with both species reaching the 
machine maximum clotting time measurement of 999.99 sec. P. mucrosquamatus venom was also 
anticoagulant at a 20 µg/mL venom concentration but weaker than P. flavoviridis and P. tokarensis 
(Figure 5.2). The venoms displayed significant variation in the relative dependency upon calcium or 
phospholipid, with calcium being a much stronger variable (Figure 5.2).  
 
Figure 5.2 Procoagulant co-factor dependency 
Comparison of procoagulant co-factor dependency clotting curves of Protobothrops at varying 
venom concentrations on human plasma. X axis: final venom concentration (µg/mL), Y axis: clotting 
time in seconds. Data points are N = 3 and error bards indicate standard deviation. Red line = 
procoagulant dilution series with calcium and phospholipid against human plasma. Blue line = 
Phospholipid dependency, procoagulant dilution series with calcium added only against human 
plasma. Purple line = Calcium dependency, procoagulant dilution series with phospholipid added 
only against human plasma.  
 
As the clotting of plasma could be due to procoagulant functions through the generation of 
endogenous thrombin (producing strong fibrin clots), or pseudo-procoagulant functions by directly 
acting upon fibrinogen (producing weak clots), additional tests were conducted to ascertain the ability 
to activate Factor X or prothrombin, and also to determine the relative strength of fibrin clots in the 
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plasma tests. None of the venoms, even the ones which produced clots in the above analyses, were 
able to activate FX or PT. Further, the clots formed by the venoms in plasma were weak, indicated 
by reduced clot strength relative to the controls (Figure 5.3). As this was strongly suggestive of direct 
action upon fibrinogen in a pseudo-procoagulant manner (Oulion et al., 2018), additional tests were 
undertaken to characterise the cleavage and clotting effects upon fibrinogen.  
 
 
Figure 5.3 Thromboelastography plasma traces  
Overlaid thromboelastography traces showing effects of 20 µg/mL venoms ability to clot plasma 
relative to spontaneous clot control:  blue traces = re-calcified plasma spontaneous clotting control; 
green traces = Factor Xa or thrombin controls; red traces = venom samples. SP = split point, time 
taken until clot begins to form. R = time to initial clot formation where formation is 2 mm+ (min). A 
(parameter) = detectable clot strength (mm) which may be < 2 mm. As P. flavoviridis and P. 
tokarensis did not induce a clot in A), thrombin was added in B) in order to induce a clot and measure 
fibrinogen degradation. Overlaid traces are N = 3 for each set of control or experimental conditions. 
Values are N = 3 means and standard deviation.  
 
Plasma anticoagulant inhibition – FXa and thrombin  
Additional testing was conducted to investigate the anticoagulant properties of the two most potent 
anticoagulant species, P. tokarensis and P. flavoviridis based off their initial inability to clot human 
plasma (Figure 5.2). Given that both species failed to form any clot (Figure 5.2), their venom 
components may interfere with specific reactions in the coagulation cascade. FXa inhibition and 
thrombin inhibition were investigated across a range of concentrations. While both venom species 
were unable to successfully inhibit thrombin, they were able to inhibit FXa, with P. flavoviridis being 
much more potent than P. tokarensis (Figure 5.4). 
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Figure 5.4 Factor Xa inhibition 
Factor Xa inhibition tests (FXa IT) for P. flavoviridis and P. tokarensis measured over 120, 300 and 
600 sec incubation times. X axis: final venom concentration (µg/mL), Y axis: clotting time in seconds. 
Data points are N = 3 and error bars indicate standard deviation. Red line: P. tokarensis.  Blue line: 
P. flavoviridis. 
5.3.2.2 Action upon fibrinogen 
As the above tests suggested that the clotting venoms are pseudo-procoagulant in that they are 
producing weak fibrin clots, additional tests were undertaken to determine the specific effects upon 
fibrinogen.  
Fibrin clot formation 
Using the same STA-R Max coagulation analyser protocol as above for plasma, we tested the ability 
of the venoms to form fibrin clots by replacing plasma with 4 mg/mL human fibrinogen. Consistent 
with the plasma results, and demonstrative of direct effect upon fibrinogen in a pseudo-procoagulant 
manner, the P. mangshanensis and P. jerdonii venoms were the only ones able to effectively trigger 
the formation of fibrin clots (Figure 5.5). In testing for the relative influence of the physiological co-
factors calcium and phospholipid, extensive variation was noted between the cofactors and between 
the species for a particular cofactor. Removal of calcium slowed the reaction, resulting in a 65.1 ± 
0.7% increase in the area under the curve, but the removal of phospholipid had a negligible effect, 
with the area under the curve increasing by only 6.6 ± 1.8%. In contrast, P. mangshanensis showed a 
128.9 ± 0.8% increase in the area under the curve when calcium was removed and a 37.2 ± 0.7% 
increase when phospholipid was removed.  
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Figure 5.5 Procoagulant co-factor dependency – fibrinogen  
Comparison of procoagulant co-factor dependency clotting curves of two Protobothrops species at 
varying venom concentrations on human fibrinogen (4 mg/mL). X axis: final venom concentration 
(µg/mL), Y axis: clotting time in seconds. A = P. jerdonii, B = P. mangshanensis. Red line: 
procoagulant dilution series with calcium and phospholipid against human fibrinogen, Blue line: 
procoagulant dilution series with calcium only against human fibrinogen, Purple line: procoagulant 
dilution series with phospholipid only against human fibrinogen. Data points are N = 3 and error bars 
indicate standard deviation. Area under the curve: for A = calcium dependency 0.651 ± 0.068, 
phospholipid dependency 0.066 ± 0.018. For B = calcium dependency 1.289 ± 0.008, phospholipid 
dependency 0.372 ± 0.007. 
 
Thromboelastography using TEG5000s 
In order to determine the strength of the clots formed by fibrinogen cleavage, we investigated the 
ability for venom to clot fibrinogen in the presence of Ca2+ and phospholipid. The thrombin control 
rapidly (SP = 0.2 ± 0 min, R = 0.23 ± 0.06 min) produced a strong (13.37 ± 1.24 mm). While P. 
mangshanensis was the most potent of the venoms, the clot was formed slower (SP = 1.5 ± 0.4 min, 
R = 2.07 ± 0.68 min) and weaker (7.33 ± 1.08) than the thrombin control (Figure 5.6). P. jerdonii and 
P. elegans also clotted the fibrinogen but slower and weaker than P. mangshanensis (Figure 5.6).  
As P. flavoviridis, P. mucrosquamatus and P. tokarensis did not display any ability to directly clot 
fibrinogen, additional tests were undertaken in order to ascertain if the venoms were cleaving the 
fibrinogen in a destructive manner that impeded the ability of thrombin to clot fibrinogen. Thrombin 
was added to the wells after the 30 min primary run in which no clot was formed. Consistent with 
destructive cleavage of fibrinogen by P. mucrosquamatus and P. tokarensis venoms, the addition of 
thrombin failed to produce a clot (Figure 5.6). In contrast, P. flavoviridis neither clotted the fibrinogen 
and displayed a weaker level of destructive cleavage. As this venom showed a strong anticoagulation 
activity upon the plasma (Figure 5.6), the low activity upon fibrinogen indicates that the 
anticoagulation activity is due to the direct inhibition of a clotting factor, which is consistent with the 
results showing an ability to inhibit FXa (Figure 5.4).  
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Figure 5.6 Thromboelastography fibrinogen traces 
Overlaid thromboelastography traces showing effects of 20 µg/mL venoms: A) ability to clot 
fibrinogen relative to thrombin control; B) ability to clot whereby thrombin was added to samples 
which did not clot fibrinogen after 30 min in order to test for venom-induced fibrinogen degradation 
relative to blank control. Blue traces = thrombin controls, red traces = venom samples. SP = split 
point, time taken until clot begins to form. R = time to initial clot formation where formation is 2 
mm+ (min). A (parameter) = detectable clot strength (mm) which may be <2 mm. Overlaid traces are 
N = 3 for each set of control or experimental conditions. Values are N = 3 means and standard 
deviation. 
 
Fibrinogen gels 
In order to determine the specific fibrinogen chains cleaved by the venoms, additional assays were 
undertaken to determine the time-dependent effects upon each chain. A consistent pattern emerged 
with all venoms displayed the ability to cleave the α chain (with differential potency), while the β 
chain was cleaved more slowly and only fully cleaved by the most potent α chain acting venoms 
(Figure 5.7, Figure 5.8 and Figure 5.9). Similarly, the γ chain was cleaved more slowly and only 
cleaved by the most potent α and β chain cleavers. Full cleavage of α, β and γ fibrinogen chains were 
only exhibited in P. mangshanensis and P. jerdonii. P. mangshanensis however cleaved all 3 chains 
much more quickly than P. jerdonii (Figure 5.6, Figure 5.7 and Figure 5.8). Cleavage of only the α 
and β chains were exhibited in P. elegans and P. mucrosquamatus, while P. flavoviridis and P. 
tokarensis only exhibited α chain degradation (Figure 5.7, Figure 5.8 and Figure 5.9). Ancestral state 
reconstruction suggested that the ability to cleave the α, β and γ fibrinogen chains was the basal 
condition, with the other cleavage patterns thus being derivations (Figure 5.9). 
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Figure 5.7 Fibrinogen chain cleavage - gel 
1D SDS PAGE time dependent fibrinogen chain degradation (α, β or γ) by venom at 0.1 µg/μL 
concentration, with the fibrinogen at 1 µg/μL, at 37ºC over 60 min. F = fibrinogen at 0 min or 60 min 
incubation controls, V = venom incubation times (min).  
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Figure 5.8 Fibrinogen chain cleavage - % intact  
Relative cleavage of alpha (blue), beta (green) or gamma (pink) chains of fibrinogen. X-axis is time 
(min), y-axis is percentage of intact chain remaining. Data points are N = means and error bars 
indicate standard deviation. 
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Figure 5.9 Ancestral state reconstruction of coagulation clotting times 
Ancestral state reconstruction of coagulation clotting times on human plasma relative to fibrinogen 
chain cleavage specificity. Warmer colours represent more potent substrate cleavage. Bars indicate 
95% confidence intervals for the estimate at each node. Phylogeny follows (Alencar et al., 2016). 
 
Fibrinolysis ± tPA 
The ability for Protobothrops crude venom to actively lyse a plasma clot was investigated under the 
presence or absence of tPA (tissue plasminogen activator) at varying concentrations. None of the 6-
species tested at any of the concentrations successfully lysed plasma clots without the presence of 
tPA. However, in the presence of tPA, clot lysis times (CLT) were shortened relative to the control 
(tPA against plasma) (Figure 5.10). Protobothrops mangshanensis, P. jerdonii, P. mucrosquamatus 
and P. elegans venoms demonstrated a reduced CLT in the presence of tPA as compared to the 
control. Consistent with its potent anticoagulant effect, plasma in the presence of P. flavoviridis 
venom failed to form a clot due to complete degradation by venom at 1µg concentration.  
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Figure 5.10 Fibrinolysis  
Clot lysis Time (CLT) for each Protobothrops species in the presence of tPA at 0.1µg, 0.5µg and 1µg 
venom concentrations. Control is indicated in black. Data points are N = 3 and error bars indicate 
standard deviation. Bars which are lower than the control lysed the plasma clot quicker than under 
normal tPA conditions. 
5.3.2.3 Platelet agglutination and inhibition 
The ability for Protobothrops crude venom to agglutinate and inhibit platelets was investigated, with 
only P. tokarensis and P. flavoviridis potently inhibiting platelet agglutination (Figure 5.11).    
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Figure 5.11 Platelet agglutination inhibition 
Platelet agglutination inhibition at 5 µg and partial inhibition at 2 µg for P. flavoviridis and P. 
tokarensis. Black column indicates control run, red column indicates Protobothrops flavoviridis, blue 
column indicates Protobothrops mucrosquamatus run. Y axis: platelet agglutination percentage. Data 
points are N = 3 and error bars indicate standard deviation. 
 
5.4 Discussion  
Extensive functional diversification was evident between the six Protobothrops venoms tested, both 
in artificial environments (enzyme substrate testing) and physiological conditions (plasma and 
fibrinogen testing). This was evident by the ancestral state reconstructions (Figure 5.1 and Figure 5.9) 
showing rapid diversification away from the basal condition. Enzyme substrate testing patterns were 
differential between the substrate types tested, whether metalloprotease or serine protease, with no 
consistent functional or phylogenetic pattern, consistent with rapid radiation away from the ancestral 
state. While these substrates do not necessarily correlate with a particular physiological effect, the 
differential activity indicates that the venoms would have highly variable effects in a physiological 
system. This was shown to be the case with the venoms displaying a wide variation of coagulotoxic 
activity, ranging from potently pseudo-procoagulant to potently anticoagulant. A correlation, 
however, was evident between the nature and potency of the coagulotoxicity, with the strongest 
pseudo-procoagulant venoms (P. jerdonii and P. mangshanensis) displaying an ability to aberrantly 
cleave the alpha, beta and gamma chains of fibrinogen, with this putatively being the ancestral state, 
while the most potent anticoagulant venoms (P. flavoviridis and P. tokarensis) cleaving only the alpha 
chain, with this representing an extreme derivation away from the ancestral state. 
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Thromboelastography testing confirmed the pseudo-procoagulant function of P. jerdonii and P. 
mangshanensis venoms, with both being the most rapid in clotting fibrinogen but producing only 
weak clots. As these are the two most basal species (Alencar et al., 2018; Alencar et al., 2016), and 
the two most potent anticoagulant species are sister to each other, this suggests that pseudo-
procoagulant activity is the basal condition within this genus, and that anticoagulant venoms represent 
the derived state. 
Consistent with the extreme variation in their venoms, Protobothrops species are highly variable in 
morphology and ecological niche occupied, ranging from heavily built terrestrial species (eg P. 
mangshanensis) to gracile semi-arboreal species (eg P. flavoviridis). While the venom variation is 
suggestive of this feature being a driver in their adaptive radiation, it is also indicative of the potential 
to produce differential clinical effects, in that while haemorrhagic shock may be produced by all 
(Chen et al., 2009; Nishimura et al., 2016), the underlying mechanics may be different.  
In addition to net anticoagulation produced by direct action upon fibrinogen (whether pseudo-
procoagulant or anticoagulant), anticoagulation was also produced by these venoms as a by-product 
of irregular fibrinogen cleavage. This was evident in the fibrinolysis assays, whereby plasmin was 
able to lyse clots much quicker when venom from species was present (Figure 5.10). It is hypothesised 
that this is due to venoms from some species forming a weak clot via incorrect fibrinogen degradation 
and irregular fibrin strand linking. This has been demonstrated in the literature that fibrin diameter 
and the architecture of the fibrin strands can influence the clot strength and stability (Collet et al., 
2000; Longstaff and Kolev, 2015; Mosesson, 2005; Wolberg, 2007; Wolberg and Campbell, 2008). 
Albeit both species are able to cleave all three fibrinogen chains, fibrinogen is cleaved in incorrect 
places, as opposed to where thrombin cleaves fibrinogen. This would result in larger fibrin strands 
which do not form a well-constructed clot and instead form a turbid, highly permeable clot (Collet et 
al., 2000; Wolberg, 2007; Wolberg and Campbell, 2008). In addition, FXIII is not activated and 
covalent cross linking, which would also strengthen clots, does not occur. This overall activity would 
result in a net anticoagulant outcome, despite neither species being able to activate plasminogen, 
which would aid in this weak anticoagulant effect.  
In addition to their wide-ranging fibrinogen action, co-factor dependency of fibrinogen action also 
impacts on the physiological degree of fibrinogenolysis that the venom exhibits. The co-factor 
dependency of the two most potent species, P. jerdonii and P. mangshanensis, shows that not only 
does the effect on fibrinogen differ, but also the degree of co-factor dependency for either calcium or 
phospholipid and between the two species for a particular co-factor.  This is the first study to show 
such an extensive shift in co-factor dependency on fibrinogen action from any snake species, 
illustrating that not only does the co-factor dependency differ but it also differs between species of a 
single genus. This reinforces the fundamental importance of including both co-factors in order to 
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replicate physiological conditions. While some venom studies have done this (Bos et al., 2016; 
Chester and Crawford, 1982; Debono et al., 2017a; Lister et al., 2017; Oulion et al., 2018; Pirkle et 
al., 1972; Rogalski et al., 2017), the inclusion of which is necessary to replicate physiological 
conditions, while others have neglected to include phospholipid (Isbister et al., 2010b; O'Leary and 
Isbister, 2010; Still et al., 2017; Vargas et al., 2011), or both cofactors (Ainsworth et al., 2018; Nielsen 
et al., 2018; Resiere et al., 2018; Williams et al., 1994) thereby skewing the results and hampering 
the interpretation as to the effects upon coagulation and therefore limiting the clinical and 
evolutionary relevance of the results. 
In addition to this variation in net anticoagulation produced, it was shown that the two most potent 
anticoagulant species of the genus, P. flavoviridis and P. tokarensis (those that did not form a plasma 
or fibrinogen clot) also inhibited FXa (Figure 5.4). FX inhibition has been described previously by 
P. flavoviridis due to lectin toxins (Arlinghaus et al., 2015; Atoda et al., 1995) while it has not been 
described for P. tokarensis. 
This continued variation in venom activity, enzymatic activity, functional diversification and clotting 
diversification creates further problems with predictive antivenom production raised against specific 
species, or species of a specific region. At present there are only two antivenoms that are produced 
for two of the eight species of Protobothrops, registered for P. mucrosquamatus and P. flavoviridis, 
with no available antivenom for the remainder of the genus. These include the ‘Bivalent Antivenin 
Pit Viper, National Institute of Preventative Medicine, Taiwan’, produced from P. mucrosquamatus 
and Trimeresurus stejnegeri, and the ‘Habu Antivenom (Kaketsuken), The Chemo-Sero-Therapeutic 
Research Institute (Kaketsuken), Japan’, produced from P. flavoviridis. Future works should 
investigate the ability of these antivenoms to specifically neutralise coagulotoxic effects and to what 
degree the antivenoms cross-react with non-immunising venoms. This study therefore not only 
reveals evolutionary trends of interest to biologists, but also documents substantial variation in the 
nature and potency of coagulotoxic effects that would directly inform upon potential clinical effects 
and management strategies.  
5.5 Materials and Methods 
A multidisciplinary approach was used to investigate the venomics and bioactivity of a range of 
representative species from the Asian pit viper genus Protobothrops. Venom samples from six 
Protobothrops species (P. mangshanensis, P. jerdonii, P. elegans, P. muscrosquamatas, P. 
tokarensis, P. flavoviridis) were from captive snakes: P. elegans (unknown locality founding stock), 
P. flavoviridis (Okinowa, Japan founding stock), P. jerdonii (Chinese founding stock), P. 
mangshanensis (Mt Mang, Hunan, China founding stock), P. mucrosquamatus (Sa Pa, Vietnam 
founding stock) and P. tokarensis (Tokara Island, Japan founding stock). Human plasma was obtained 
from the Australian Red Cross (Research agreement #18-03QLD-09 and University of Queensland 
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Human Ethics Committee Approval #2016000256). All plasma was prepared as 3.2% citrated stock, 
aliquoted into 1 mL quantities, which were snap frozen in liquid nitrogen, and stored in a -80°C 
freezer until needed, at which time an aliquot was defrosted by placing into a 37°C water bath for 10 
minutes. All venom and plasma work was undertaken under the University of Queensland Biosafety 
Approval #IBC134BSBS2015. 
 
5.5.1 Enzyme assays 
5.5.1.1 Fluorescent substrate activation 
In order to investigate Fluorescent Determination of matrix metalloprotease (ES001, ES003, ES005, 
ES010), serine protease activity (ES002, ES011) and phospholipase A2 (PLA2) enzymatic assays 
were undertaken as previously described by us (Debono et al., 2017a). For matrix metalloprotease 
and serine protease assays a working stock solution of freeze dried venom was reconstituted in a 
buffer containing 50% MilliQ/50% glycerol (>99.9%, Sigma, St Louis, MO, USA) at a 1:1 ratio to 
preserve enzymatic activity and reduce enzyme degradation. Varying concentrations of crude venom 
(10 ng/μL and 50 ng/μL) were plated out in triplicates on a 384-well plate (black, Lot#1171125, 
nunc™ Thermo Scientific, Rochester, NY, USA) and measured by adding 90 μL quenched 
fluorescent substrate per well (total volume 100 μL/well, 10 μL/ 5mL enzyme buffer, 150 mM NaCl, 
and 50 mM Tri-HCl (pH 7.3), Fluorogenic Peptide Substrate, R & D systems, Cat#ES001, ES003, 
ES005, ES010,  ES011, Minneapolis, Minnesota). Fluorescence was monitored by a Fluoroskan 
Ascent™ (Thermo Scientific, Vantaa, Finland) Microplate Fluorometer (Cat#1506450, Thermo 
Scientific, Vantaa, Finland) (Cat#ES001, ES003, ES005, ES010 for Matrix Metalloprotease at an 
excitation of 320 nm, emission at 405 nm; Cat#ES011 for Kallikrein at an excitation of 390 nm, 
emission at 460 nm) over 400 min or until activity had ceased. Data was collected using Ascent® 
Software v2.6 (Thermo Scientific, Vantaa, Finland).  
For PLA2 analysis we assessed the continuous Phospholipase A2 (PLA2) activity of the venoms using 
a fluorescence substrate assay (EnzChek® Phospholipase A2 Assay Kit, Cat#E10217, Thermo 
Scientific, Rochester, NY, USA), measured on a Fluoroskan Ascent® Microplate Fluorometer 
(Cat#1506450, Thermo Scientific, Vantaa, Finland). As above, we used a working stock solution of 
freeze dried venom reconstituted in a buffer containing 50% MilliQ / 50% glycerol (>99.9%, Sigma) 
at a 1:1 ratio. A concentration of enzyme activity in venom (50 ng/μL) was brought up in 12.5 μL 1× 
PLA2 reaction buffer (50 mM Tris-HCL, 100 mM NaCl, 1 mM CaCl2, pH 8.9) and plated out in 
triplicates on a 384-well plate (black, Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, 
USA). The triplicates were measured by dispensing 12.5 μL quenched 1 mM EnzChek® (Thermo 
Scientific, Rochester, NY, USA) Phospholipase A2 Substrate per well (total volume 25 μL/well) over 
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100 min or until activity had ceased (at an excitation of 485 nm, emission 538 nm). Purified PLA2 
from bee venom (1 U/mL) was used as a positive control and data was collected using Ascent® 
Software v2.6 (Thermo Scientific, Vantaa, Finland).  
5.5.1.2 Plasminogen activation 
The same working stock solution of 1 mg/mL (outlined above and in (Debono et al., 2017a) of freeze 
dried venom was used to make the following dilutions: 10 ng/μL, 50 ng/μL and 100 ng/μL. These 
varying concentrations of enzyme activity in venom were plated out on a 384-well plate (black, 
Lot#1171125, nunc™ Thermo Scientific, Rochester, NY, USA) in triplicates, with and without 10 
ng/μL plasminogen per well (Lot#FF0125 HCPG-0130, Haematologic Technologies Inc., Essex 
Junction, VT, USA). Plasminogen, a serine protease, can be activated by a serine protease specific 
substrate (Fluorogenic Peptide Substrate, R & D systems, Cat# ES011, Minneapolis, Minnesota). 
Plasmin was used as a positive control (10 ng/μL per positive control well, Lot#EE1120, HCPM-
0140, Haematologic Technologies Inc., Essex Junction, VT, USA). Activation from venoms was 
measured by adding 90 μL quenched fluorescent substrate per well (total volume 100 μL/well; 20 
μL/5mL enzyme buffer - 150 mM NaCl and 50 mM Tri-HCl (pH 7.3), Fluorogenic Peptide Substrate, 
R & D systems, Cat#ES011, Minneapolis, Minnesota). Fluorescence was monitored by a Fluoroskan 
Ascent™ Microplate Fluorometer (Cat#1506450, Thermo Scientific, Vantaa, Finland) at excitation 
390 nm and emission at 460 nm over 150 min or until activity had ceased. Data was collected using 
Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). Experiments were conducted in 
triplicate. 
5.5.1.3 Prothrombin activation 
The ability for Protobothrops crude venom to directly activate prothrombin was investigated and 
measured by modifying the above protocol used for plasminogen activation. Plasminogen was 
replaced with prothrombin (Lot#EE0930, HCP-0010, Haematologic Technologies Inc., Essex 
Junction, VT, USA) and plasmin was replaced with thrombin (Lot#FF0315, HCT-0020, 
Haematologic Technologies Inc., Essex Junction, VT, USA) as a positive control (10 ng/μL per 
positive control well). Data was collected using Ascent® Software v2.6 (Thermo Scientific, Vantaa, 
Finland). Experiments were conducted in triplicate. 
5.5.1.4 Factor X activation 
The ability for Protobothrops crude venom to directly activate blood coagulation Factor X (FX) was 
investigated and measured by modifying the above protocol used for plasminogen activation using 
FX (Lot#FF0407, HCX-0050, Haematologic Technologies Inc., Essex Junction, VT, USA) as the 
experimental target and FXa (Lot#EE1102, HCXA-0060, Haematologic Technologies Inc., Essex 
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Junction, VT, USA) as the positive control (10 ng/μL per positive control well). Data was collected 
using Ascent® Software v2.6 (Thermo Scientific, Vantaa, Finland). Experiments were conducted in 
triplicate. 
5.5.1.5 Protein C activation 
The ability for Protobothrops crude venom to directly activate Protein C was investigated and 
measured by modifying the above protocol used for plasminogen activation. Plasminogen was 
replaced with Protein C (Lot#FF0802, HCPC-0070, Haematologic Technologies Inc., Essex Junction, 
VT, USA) and plasmin was replaced with activated Protein C (Lot#FF0325, HCAPC-0080, 
Haematologic Technologies Inc., Essex Junction, VT, USA) as a positive control (10 ng/μL per 
positive control well). Data was collected using Ascent® Software v2.6 (Thermo Scientific, Vantaa, 
Finland). Experiments were conducted in triplicate. 
5.5.2 Phylogenetic comparative analyses  
Observed venom activities of the different snake species were investigated in an evolutionary 
framework by mapping them on a taxonomical tree (phylogeny was adapted from (Alencar et al., 
2016)), generated using the Mestique software package and analyses  subsequently performed using 
the R package Phytools  using Phylogenetic Generalized Least Squares (PGLS) (Lister et al., 2017; 
Rogalski et al., 2017). Analyses were implemented in R v3.2.5 (Team, 2016) using the APE package 
for basic data manipulation (Paradis et al., 2004).  Ancestral states of each substrate functional trait 
(ES001, ES002, ES003, ES005, ES010, ES011, PLA2, coagulation) were estimated via maximum 
likelihood with the contMap function in phytools (Revell, 2012).   
 
5.5.3 Coagulation analysis  
5.5.3.1 Action upon plasma  
Plasma clotting and co-factor dependency of Ca2+ and phospholipid  
As per (Debono et al., 2017a), in order to investigate whole plasma clotting and co-factor dependency 
clotting, we  prepared healthy human plasma (citrate 3.2%, Lot#1690252, approval # 16-04QLD-10), 
obtained from the Australian Red Cross (44 Musk Street, Kelvin Grove, Queensland 4059). 
Coagulopathic toxin effects were measured by a modified procoagulant protocol on a Stago STA-R 
Max coagulation robot (France) using Stago Analyser software v0.00.04 (Stago, Asniéres sur Seine, 
France). Plasma clotting baseline parameters were determined by performing the standardised 
activated Partial Thromboplastin Time (aPTT) test (Stago Cat# T1203 TriniCLOT APTT HS). This 
was used as a control to determine the health of normal clotting plasma according to the universal 
standard range of between 27–35 sec. Plasma aliquots of 2 mL, which had been flash frozen in liquid 
nitrogen and stored in a -80°C freezer, were defrosted in an Arctic refrigerated circulator SC150-A40 
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at 37°C. In order to determine clotting times effected by the addition of varying venom 
concentrations, a modified aPTT test was developed. A starting volume of 50 μL of crude venom (5 
µg/50 μL) was diluted with STA Owren Koller Buffer (Stago Cat# 00360). An 8-dilution series of 1 
(20 µg/mL), 1/2 (10 µg/mL), 1/5 (4 µg/mL), 1/12 (1.6 µg/mL), 1/30 (0.66 µg/mL), 1/80 (0.25 µg/mL), 
1/160 (0.125 µg/mL), and 1/400 (0.05 µg/mL) was performed in triplicate. CaCl2 (50 μL; 25 mM 
stock solution Stago Cat# 00367 STA CaCl2 0.025M) was added with 50 μL phospholipid 
(solubilized in Owren Koller Buffer adapted from STA C.K Prest standard kit, Stago Cat# 00597). 
An additional 25 μL of Owren Koller Buffer was added to the cuvette and incubated for 120 sec at 
37°C before adding 75 μL of human plasma. Relative clotting was then monitored for 999 sec or until 
plasma clotted (whichever was sooner). Additional tests were run, both with and without CaCl2 and 
phospholipid, respectively, to test for CaCl2 or phospholipid dependency. STA Owren Koller Buffer 
was used as a substitute, using the same volumes to allow for consistency in the final volumes (250 
μL). 
Plasma anticoagulant inhibition – FXa and thrombin  
The ability for Protobothrops crude venom to directly prevent a fibrin clot from forming was 
investigated. Species were chosen based off the above described protocol and initial screening of 
which venoms were unable to clot plasma. FXa inhibition and thrombin inhibition were investigated 
as alternative targets. Clotting baseline parameters were established by performing FXa-initiated 
clotting in human plasma utilising liquid FXa from Stago Liquid Anti FXa kit (Stago Cat#250491 
Liquid Anti FXa kit). This was used as a control to determine the normal clotting of plasma caused 
by the activation of prothrombin via FXa under these specific conditions (between 12.5 ± 0.2 sec). A 
starting volume of 50 μL of crude venom (at 10 mg/mL) was diluted with STA Owren Koller Buffer 
(Stago Cat# 00360). An 8-dilution series of 1 (200 µg/mL), 1/2 (100 µg/mL), 1/4 (55 µg/mL), 1/6 
(30 µg/mL), 1/8 (25 µg/mL), 1/10 (20 µg/mL), 1/20 (10 µg/mL), and 1/50 (4 µg/mL) was performed 
in triplicate. Following, 50 μL CaCl2 (25mM stock solution Stago Cat# 00367 STA) was added to 50 
μL phospholipid (solubilized in Owren Koller Buffer adapted from STA C.K Prest standard kit, Stago 
Cat# 00597) and 50 μL Factor Xa (unknown concertation from supplier, Liquid Anti-Xa FXa 
Cat#253047, Stago) or 50 μL TCT thrombin kit (unknown concentration from supplier, Thrombin, 
Lot#252818, Stago) and incubated for 120 sec. Post incubation 50 μL of either human plasma for the 
FXa inhibition test (citrate 3.2%, Lot#1690252, approval # 16-04QLD-10, obtained from the 
Australian Red Cross (44 Musk Street, Kelvin Grove, Queensland 4059) (defrosted in an Arctic 
refrigerated circulator SC150-A40 at 37°C)) or human fibrinogen for the thrombin inhibition test (at 
4 mg/mL, (Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States, reconstituted in enzyme 
buffer (150 mM NaCl and 50 mM Tri-HCl (pH 7.3)) was added to the reaction and each test run in 
triplicate for each concentration. Relative clotting was then monitored for 999 sec or until plasma 
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clotted (whichever was sooner) on a Stago STA-R Max coagulation robot (France) using Stago 
Analyser software v0.00.04 (Stago, Asniéres sur Seine, France). Additional tests were run with 
increased incubation times of 300 sec and 600 sec. Venom dilutions in triplicates were mapped over 
time using GraphPad PRISM 7.0 (GraphPad Prism Inc., La Jolla, CA, USA) to produce concentration 
curves. 
5.5.3.2 Action upon fibrinogen  
Fibrinogen clotting and co-factor dependency of Ca2+ and phospholipid 
The ability for Protobothrops crude venom to directly clot human fibrinogen was investigated and 
measured by following that described by (Debono et al., 2017a) such that human fibrinogen (4 
mg/mL, Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States), was used in place of human 
plasma. Relative clotting was then monitored for 999 sec or until fibrinogen clotted (whichever was 
sooner). Experiments were conducted in triplicate. Venom dilutions in triplicates were mapped over 
time using GraphPad PRISM 7.0 (GraphPad Prism Inc., La Jolla, CA, USA) to produce concentration 
curves. 
Thromboelastography® 5000  
The clotting ability of Protobothrops venom using human fibrinogen (4 mg/mL) and human plasma 
was investigated using a Thrombelastogram® 5000 Haemostasis analyser (Haemonetics®, 
Haemonetics Australia Pty Ltd, North Rdye, Sydney 2113, Australia). Human fibrinogen (4 mg/mL, 
Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States) was reconstituted in enzyme buffer 
(150 mM NaCl and 50 mM Tri-HCl (pH 7.3)). Natural pins and cups (Lot# HMO3163, Haemonetics 
Australia Pty Ltd, North Rdye, Sydney 2113, Australia) were used with the following solution; 7 μL 
venom working stock (1 mg/mL outlined in (Debono et al., 2017a)) or 7 μL thrombin as a positive 
control (stable thrombin from Stago Liquid Fib kit, unknown concentration from supplier (Stago 
Cat#115081 Liquid Fib)), 72 μL CaCl2 (25mM stock solution Stago Cat# 00367 STA), 72 μL 
phospholipid (solubilized in Owren Koller Buffer adapted from STA C.K Prest standard kit, Stago 
Cat# 00597), and 20 μL Owren Koller Buffer (Stago Cat# 00360) was combined with 189 μL 
fibrinogen or human plasma and run immediately for 30 min to allow for ample time for clotting 
formation. An additional positive control of 7 μL Factor Xa (unknown concentration from supplier, 
Liquid Anti-Xa FXa Cat#253047, Stago) was also incorporated for plasma only. When no clot was 
formed from the effects of anticoagulant venoms, an additional 7 μL thrombin was added to the pin 
and cup to generate a clot and to determine the effects of fibrinogen degradation.  
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Fibrinogen gels  
To investigate fibrinogenolysis activity demonstrating α, β and γ chain cleavage, 1D SDS PAGE 12% 
acrylamide gels were cast, run and stained following the protocol described in (Ali et al., 2013b; 
Debono et al., 2017a) outlining 1D SDS PAGE preparation and running conditions. Human 
fibrinogen (Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States) was reconstituted to a 
concentration of 1 mg/mL in isotonic saline solution, flash frozen in liquid nitrogen and stored at 
−80ºC until use. Freeze-dried venom was reconstituted in deionised H2O and concentrations were 
measured using a Thermo Fisher Scientific™ NanoDrop 2000 (Waltham, MA, USA). Assay 
concentrations were a 1:10 ratio of venom:fibrinogen. Human fibrinogen (Lot#F3879, Sigma Aldrich, 
St. Louis, Missouri, United States) stock of 1 mg/mL was dispensed into ten 120 μL aliquots. 
Fibrinogen from each aliquot (10 μL) was added to 10 μL buffer dye (5 μL of 4× Laemmli sample 
buffer (Bio-Rad, Hercules, CA, USA), 5 μL deionised H2O, 100 mM DTT (Sigma-Aldrich, St. Louis, 
MO, USA)) as an untreated control lane. An additional fibrinogen aliquot (10 μL) was firstly 
incubated for 60 min at 37ºC before immediately adding 10 μL buffer dye. Venom stock (1 μL at 1 
mg/mL) was added to the remaining 100 μL fibrinogen aliquot and incubated over 60 min at 37ºC, 
taking out 10 μL at varying time points (1, 5, 10, 15, 20, 30, 45 and 60 min). This 10 μL was 
immediately added to an additional 10 μL buffer dye. Once all 8-time points including the two 
controls were added to the buffer dye these were incubated at 100oC for 4 minutes then immediately 
loaded into the precast 1D SDS-PAGE gel. The following set up within the gel was as follows: Lane 
1: untreated, unincubated fibrinogen, Lane 2: 1-min 37ºC incubation, Lane 3: 5 min 37ºC incubation, 
Lane 4: 10 min 37ºC incubation, Lane 5: 15 min 37ºC incubation, Lane 6: 20 min 37ºC incubation, 
Lane 7: 30 min 37ºC incubation, Lane 8: 45 min 37ºC incubation, Lane 9: 60 min 37ºC incubation, 
Lane 10: untreated fibrinogen that has been incubated for 60 min at 37ºC. Gels were prepared in 
triplicate under the described conditions per venom and were run in 1× gel running buffer (as 
described by (Debono et al., 2017a; Koludarov et al., 2017) at room temperature at 120 V (Mini 
Protean3 power-pack from Bio-Rad, Hercules, CA, USA) until the dye front neared the bottom of the 
gel. Gels were stained with colloidal coomassie brilliant blue G250 (34% methanol (VWR Chemicals, 
Tingalpa, QLD, Australia), 3% orthophosphoric acid (Merck, Darmstadt, Germany), 170 g/L 
ammonium sulfate (Bio-Rad, Hercules, CA, USA), 1 g/L Coomassie blue G250 (Bio-Rad, Hercules, 
CA, USA), and destained in deionised H2O. 
Fibrinogen gel analysis (ImageJ and PRISM) 
Using the publicly available software ImageJ (V1.51r, Java 1.6.0_24, National Institutes of Health, 
Bethesda, Maryland, USA) (Schneider et al., 2012), gels that had been scanned using a standard 
printer/scanner were loaded onto the software. Scans were changed to 32 bit to emphasise darken 
bands of fibrinogen chains so that the image could be manipulated to view individual peaks and 
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troughs representing the alpha, beta and gamma chains. The intensity represents the amount of protein 
within that particular band and as the chain degrades the intensity decreases. Using the ‘wand 
function’ each peak within the graph was selected automatically producing a quantity for the area 
under the curve. AUC was graphed using GraphPad PRISM 7.0 (GraphPad Prism Inc., La Jolla, CA, 
USA). This process was repeated for all three triplicates for each venom.  
 
Fibrinolysis ± tPA 
To investigate the fibrinolysis ability of Protobothrops venoms, varying concentrations of venom 
(100 ng/μL, 500 ng/μL and 1 µg/μL) were tested under varying conditions with the addition of tissue 
plasminogen activator (tPA, Sekisui Diagnostics, Lexington, MA, USA). Aliquots (100 μL) of normal 
pooled human plasma (Leiden University Medical Center (Leiden, NL)) stored at -80ºC were 
defrosted in a water bath at 37°C. A 96-well plate was prepared under the following conditions: 6 pM 
tissue factor (TF) (Innovin, Siemens, USA) was added to 10 µM phospholipid vesicles (PCPS, 75% 
phosphatidylcholine and 25% phosphatidylserine, Avanti Polar Lipids, Alabama, USA) in HEPES 
buffer (25 mM HEPES, 137mM NaCl, 3.5 mM KCl, 0.1% BSA (Bovine Serum Albumin A7030, 
Sigma Aldrich, St Louis, MD, USA)) and gently incubated at 37ºC for 1 hr in a water bath. 17 mM 
CaCl and 37.5 U/mL tPA (diluted in dilution buffer (20 mM HEPES, 150 mM NaCl, 0.1% PEG-8000 
(Polyethylene glycol 8000,1546605 USP, Sigma Aldrich, St Louis, MD, USA), pH 7.5)) was then 
added to the solution. A volume of 30 μL of this solution was added to each experimental well, along 
with 10 μL of venom at varying concentrations and an additional 10 μL of HEPES buffer, prepared 
on ice (total well volume of 100 μL). Normal pooled plasma (50 μL) was immediately added to each 
well (heated to 37ºC). Absorbance measuring commenced immediately and was measured every 30 
sec over 3 hr at 405 nm on a Spectra Max M2e (Molecular Devices, Sunnyvale, CA, USA) plate 
reader, heated to 37ºC. Measurements were captured on Softmax Pro software (V 5.2, Molecular 
Devices, Sunnyvale, CA, USA) and data points analysed using GraphPad PRISM 7.0 (GraphPad 
Prism Inc., La Jolla, CA, USA). All experimental conditions were repeated in triplicates and 
averaged.  
5.5.3.3 Platelet agglutination and inhibition 
The ability to aggregate platelets via the GP Ib/IX receptor was tested for both venoms at varying 
concentrations (1 µg/μL, 2 µg/μL and 5 µg/μL) using the ristocetin cofactor assay (Lot# H081032, 
Chrono-log™, Havertown, PA, USA) under modified conditions. For a control sample, in a modified 
glass cuvette with a rubber spacer and electrode stir bar, 200 μL of platelets (Lot# 1087-40) 
reconstituted in TRIS-buffer saline (Lot# 1091-35) was combined with 25 μL Ristocetin (10 mg/mL, 
Lot# 1088-33), reconstituted in Ultra-pure water. Prior to aggregation tracking performed on a 
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Chrono-log 700 multichannel system (Chrono-log, DKSH, Vic, Australia), 0% and 100% baselines 
were established. Agglutination of platelets was measured for 6 min under the following conditions: 
slope length 16, gain 0.05, mode optical. For experimental samples, 200 μL of reconstituted platelets 
was combined with an additional 40 μL TRIS-buffer saline and incubated at 37°C for 2 min. After 
incubation, 10 μL of crude venom/TRIS-buff saline solution at varying concentrations (100 ng/μL, 
200 ng/μL and 5 µg/μL) were injected into the cuvette and run for 6 min under the same conditions. 
Controls and experimental samples were run in triplicate.  
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Chapter 6:  Clinical implications of coagulotoxic variations in Mamushi 
(Viperidae: Gloydius) snake venoms  
 
6.1 Abstract  
Snake bite is currently one of the most neglected tropical diseases affecting much of the developing 
world. Asian pit vipers are responsible for a considerable amount of envenomations annually and 
bites can cause a multitude of clinical complications resulting from coagulopathic and neuropathic 
effects. While intense research has been undertaken for some species of Asian pit viper, functional 
coagulopathic effects have been neglected for others. We investigated their effects upon the human 
clotting cascade using venoms of four species of Gloydius and Ovophis okinavensis, a species closely 
to Gloydius. All species of included within this investigation displayed varying fibrinogenolytic 
effects, resulting in a net anticoagulant outcome. Gloydius saxatilis and Gloydius ussuriensis 
displayed the most variable effects from differing localities, sampled from Russia and Korea. As this 
Gloydius investigation includes some geographical variation, notable results indicate key variations 
of these species that point to possible limitations in antivenom cross-reactivities, which may have 
implications for the clinical care of victims envenomed by these snakes.  
6.2 Introduction  
Snake bite is currently a globally neglected tropical disease with many of the poorer regions of the 
world mostly effected as they live in extremely close proximity to highly venomous snakes (Fry, 
2018; Gutiérrez et al., 2017; Kasturiratne et al., 2008). Snake venoms are complex cocktails of toxins 
that exert effects on any part of the body reachable by the bloodstream (Casewell et al., 2013). These 
mixtures of toxins have evolved and diversified over millions of years primarily to facilitate predation 
(and defence in some cases (Panagides et al., 2017)), and the toxin combinations differ between snake 
families, genus and species with many varying clinical effects (Fry et al., 2008). Clinical effects range 
from wide spread neurotoxicity, myotoxicity, necrosis and coagulotoxicity through to debilitating 
permanent damages if bite victims survive (Casewell et al., 2013; Fry, 2018; Fry et al., 2008; 
Slagboom et al., 2017).  
Coagulotoxic venom components interfere with normal haemostasis and are capable of eliciting an 
immediate procoagulant or anticoagulant (i.e. haemorrhagic) response upon injection into the 
bloodstream. Procoagulant venoms are known to activate Factor X or prothrombin, resulting in the 
generation of endogenous thrombin and subsequent stable fibrin clots (Joseph and Kini, 2002; Kini, 
2005a, 2006; Kornalik and Blombäck, 1975; Lister et al., 2017; Oulion et al., 2018; Rogalski et al., 
2017; Rosing and Tans, 1991; Rosing and Tans, 1992; Rosing and Tans, 2010; Sousa et al., 2018; 
Tans and Rosing, 2002; Yamada et al., 1996; Zdenek et al., 2019). Anticoagulant effects can be 
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accomplished through the inhibition of clotting enzymes, such as Factors Xa, XIa, IXa or thrombin, 
or through fibrinogenolytic effects (Youngman et al., 2018). Fibrinogen cleavage occurs either in a 
non-clotting, destructive manner, or results in the formation of aberrant fibrin clots that are short lived 
and rapidly degraded (Coimbra et al., 2018; Debono et al., 2019c). Both types of fibrinogen cleavage 
have a net anticoagulant effect through a reduction in the amount of normal, intact fibrinogen 
available for cleavage by endogenous thrombin to form stable fibrin clots. 
Asian pit vipers are characterised by haemorrhagic venoms. Gloydius is a wide-spread Asian pit viper 
genus, spanning Japan, China, Mongolia and surrounding borders, Siberian Russia and Korea, 
occupying many distinct and variable climatic locations (Vogel, 2006). There has been little 
comparative research performed on species of this genus despite thousands of Mamushi (G. 
blomhoffi) bites (and related species) each year across Japan and surrounding areas (Hifumi et al., 
2015; Hifumi et al., 2011). Bite case reports describe classic haemorrhagic pit viper symptoms 
including wide spread bleeding which can be fatal (Okamoto et al., 2017; Toh Yoon et al., 2017). The 
mechanisms behind these widespread symptoms has been subjected to minimal investigation, with 
majority of the results illustrating fibrinogenolytic effects upon coagulation (Cho et al., 2001; Choi 
and Lee, 2013; Huang et al., 2011; Zhang et al., 2007). Most studies have focussed not on functional 
aspects but rather concentrated on proteomic isolation and purification from single species (Cho et 
al., 2001; Choi and Lee, 2013; Fujisawa et al., 2009; Huang et al., 2011; Sun et al., 2006; Yang et al., 
2015; Zhang et al., 2007).  
It has been established in the literature that venom composition between closely related species, or 
within different populations of a single species, may vary considerably due to differential pressures 
regarding prey availability and prey escape potential. This variation has direct implications for the 
relative clinical usefulness of antivenoms against species not included in the immunising mixture, or 
varying populations of the species used (Debono et al., 2017a; Dobson et al., 2018; Fry et al., 2003a; 
Lister et al., 2017; Rogalski et al., 2017; Sousa et al., 2018; Sunagar et al., 2014; Tan et al., 2016; Tan 
et al., 2017a; Yang et al., 2016; Zdenek et al., 2019). Many current antivenomic strategies are mostly 
limited to the immunoreactivity of the antivenom towards the venom components, these do not 
ascertain whether the antivenom is effective in neutralising venom pathological functions (Jones et 
al., 2019; Williams et al., 2011; Xu et al., 2017). Out of the ten commonly described Gloydius species, 
antivenom exists only for four (G. blomhoffii, G. brevicaudus, G. halys and G. ussuriensis) 
(Supplementary Table 6.1). With antivenom available for only a select few species, this creates 
potential life-threatening challenges for bite victims of other Gloydius species. In addition, localities 
for these species from which antivenom is made is restricted, resulting in unknown medical 
challenges if a bite victim is bitten by a species from an alternative geographical location.  
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In this study we investigated the effects on coagulation of the venoms from multiple species of 
Gloydius, and populations within some species, in addition to Ovophis okinavensis, which sits basal 
to Gloydius rather than being closely related to other species within the Ovophis genus, and therefore 
may be considered as part of an expanded Gloydius genus (Alencar et al., 2018; Malhotra and Thorpe, 
2004). We aimed to highlight coagulotoxic differences between the venoms and how this relates to 
potential clinical effects of the envenomed patient. This investigation will provide important insight 
into the key variations of these species which is fundamental for clinical care as well as snake bite 
management across varying localities within Japan and surrounding countries.  
 
Table 6.1 Species list 
Species list of samples from the genus Gloydius and Ovophis. Pooled samples are of an unknown 
number of species and unknown specific localities. 
Species Sample composition Sex  Origin 
Gloydius brevicaudus Individual  Female 
Hapcheon-gun, 
Gyeongsangnam-do, 
Korea 
Gloydius saxatilis Pooled NA Russia 
Gloydius saxatilis Individual  Male 
Yangsan-si, 
Gyeongsangnam-do, 
Korea 
Gloydius saxatilis Individual  Male 
Yangsan-si, 
Gyeongsangnam-do, 
Korea 
Gloydius 
tsushimaensis 
Pooled NA Tsushuma Island, Japan 
Gloydius ussuriensis Pooled  NA Russia 
Gloydius ussuriensis Individual  Male 
Wonju-si, Gangwon-do, 
Korea 
Gloydius ussuriensis Individual  Female 
Wonju-si, Gangwon-do, 
Korea 
Gloydius ussuriensis Individual  Female 
Wonju-si, Gangwon-do, 
Korea 
Ovophis okinavensis Pooled NA Ryukyu Islands, Japan 
 
6.3 Results  
6.3.1 Procoagulation and anticoagulation studies 
At the initial 20 μg/mL venom concentration, only G. tsushimaensis (35 ± 3.7 sec) and O. okinavensis 
(54.6 ± 1 sec) displayed the ability to clot plasma quicker than the negative control (spontaneous 
clotting of recalcified plasma) time of 350 ± 50 sec (Figure 6.1). All other venom species were equal 
or above the negative control (data not shown). An 8-point dilution series was undertaken with the 
two clotting venoms (G. tsushimaensis and O. okinavensis) under three experimental conditions: with 
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both cofactors (calcium and phospholipid), in the absence of phospholipids, and in the absence of 
calcium (Figure 6.1). Phospholipid was not a significant variable for either venom, shifting the 
clotting curve only 0.06 ± 0.01% for G. tsushimaensis and 0.004 ± 0.001 for O. okinavensis. However, 
for the calcium-dependence there was an area under the curve shift of 90 ± 4% for G. tsushimaensis 
(p = 0.0075 and therefore significant) and a shift of 65 ± 1% for O. okinavensis (p = 0.0004 and 
therefore significant) (Figure 6.1). An 8-point dilution series was also undertaken for G. 
tsushimaensis and O. okinavensis with fibrinogen under the same three experimental conditions 
(Figure 6.2). Gloydius tsushimaensis had an area under the curve shift of 52 ± 3% for phospholipid 
dependence (p = 0.07, and therefore only marginally insignificant), while O. okinavensis displayed a 
lower phospholipid dependence with a curve shift of 20 ± 5% (p = 0.25 and therefore insignificant). 
There was a significant dependency evident for calcium for G. tsushimaensis, with the area of the 
curve shifting 152 ± 5% (p = 0.007), while O. okinavensis displayed only lower calcium dependency 
with an area under the curve shift of 21 ± 2% (p = 0.25 and therefore insignificant) (Figure 6.2). As 
the clotting of plasma could be due to procoagulant functions through the generation of endogenous 
thrombin (producing strong fibrin clots), or pseudo-procoagulant functions by directly acting upon 
fibrinogen (producing weak clots), additional tests were conducted to ascertain the ability to activate 
Factor X or prothrombin, and also to determine the relative strength of fibrin clots in the plasma tests. 
None of the venoms, even the ones which produced clots in the above analyses, were able to activate 
FX or prothrombin, thus indicating pseudo-procoagulant actions directly upon fibrinogen. 
 
 
Figure 6.1 Cofactor dependency – plasma  
Concentration-response curves the ability of the venoms to clot human plasma in the presence of both 
calcium and phospholipid (red line), in the absence of phospholipids (blue line), or in the absence of 
calcium (black line) for A) G. tsushimaensis and B) O. okinavensis. Data points are N = 3 with 
standard deviations. 
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Figure 6.2 Cofactor dependency – fibrinogen  
Concentration-response curves the ability of the venoms to clot human fibrinogen in the presence of 
both calcium and phospholipid (red line), in the absence of phospholipids (blue line), or in the absence 
of calcium (black line) for A) G. tsushimaensis and B) O. okinavensis. Data points are N = 3 with 
standard deviations.  
 
Our study aimed to characterise the function and underlying haemorrhagic mechanisms of the 
Gloydius genus. Addition of the remaining venoms to recalcified human plasma extended the clotting 
time which exceeded the machine maximum reading time of 999 sec. Investigations to determine the 
site of action proceeded in a stepwise manner in order to ascertain specific sites of action (Table 6.2): 
i) incubation with FXa followed by addition of plasma to determine the ability to directly inhibit FXa; 
ii) incubation with plasma followed by addition of FXa to determine effects on prothrombinase 
complex formation (with the site of action determined by comparison with iii and iv, whereby if a 
strong effect was noted here but corresponding strong effects were not noted in iii or iv, then this 
indicated  inhibition of the formation of the prothrombinase complex, as previously validated by us 
(Youngman et al., 2018); iii) incubation with thrombin followed by addition of fibrinogen to 
determine direct inhibition of thrombin; and iv) incubation with fibrinogen followed by addition of 
thrombin to determine the ability to degrade fibrinogen. Results were as follows (Figure 6.3): i) intra-
specific and inter-specific variation in FXa inhibition was notable, with the Russian G. saxatilis 
population being potent in this regard, but the Korean  G. saxatilis were low in activity, with the other 
species showing activities levels approximately half of that of the Russian G. saxatilis (G. 
brevicaudus, G. tsushimaensis, and G. ussuriensis) or inactive in this assay (O. okinavensis) (Figure 
6.3A); ii) incubation with plasma followed by addition of FXa did not produce a relative strong effect 
for any of the venoms (Figure 6.3B); iii) incubation with thrombin also revealed negligible effects in 
this inhibitory function (Figure 6.3C); iv) incubation with fibrinogen revealed a very strong non-
clotting, destructive fibrinogenolytic effect for G. brevicaudus, a lower but still strong effect for on 
G. ussuriensis male venom sample, but only moderate to low for all other samples (Figure 6.3D).       
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Figure 6.3 Clotting factor inhibition 
Clotting factor inhibition showing the relative inhibitory effects of Gloydius and Ovophis venom on 
preventing the activation of: A) FXa, B) Prothrombin to thrombin (Prothombinase complex), C) 
Thrombin inhibition and D) destruction of fibrinogen. For A) and C) venom was incubated with FXa 
or thrombin for 2 min before adding plasma or fibrinogen, with clot time then immediately measured. 
For B) and D) venom was incubated with human plasma or fibrinogen for 2 min before adding Factor 
Xa or thrombin with clot time then immediately measured. Data points are N = 3 displayed as a shift 
away from the control with standard deviations (no shift from control values would be a zero value). 
Star icons represent values that could not be recorded due to premature clotting of plasma or 
fibringoen prior to addition of thrombin or FXa, thus no inhibition.   
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6.3.2 Fibrinolytic activity 
In order to determine the specific fibrinogen chains cleaved by the venoms, additional assays were 
undertaken to determine the time-dependent effects upon fibrinogen each chain (Figure 6.4 and 
Figure 6.5). A wide variation in pattern emerged, with many of the venoms displaying the ability to 
cleave the alpha chain (with the exception of G. saxatilis [Korea, male]). In most other samples, the 
alpha chain was initially quite rapidly degraded, quickly followed by the beta chain, and in some 
cases the gamma chain (O. okinavensis) displaying full cleavage of all three chains, with partial 
degradation of the gamma chain noted for G. ussuriensis and G. tsushimaensis. Ovophis okinavensis 
degraded all three chains the quickest, congruent with its ability to clot plasma. There was a 
geographical variation pattern emerging between Russian localities and Korean localities, with 
diversity in chain degradation shown among G. ussuriensis samples and G. saxatilis samples, with 
G. saxatilis being the most notable. For species with multiple samples (G. saxatilis Korea males and 
G. ussuriensis Korea male/females), representatives were chosen to be displayed as there was no 
differences between fibrinolytic actions and chain degradation within this assay (data not shown).  
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Figure 6.4 Fibrinogen chain cleavage - gel 
1D SDS PAGE time dependent fibrinogen chain degradation (α, β or γ) by venom at 0.1µg/μL 
concentration at 37ºC over 60 min. F = fibrinogen at 0 min or 60 min incubation controls, V = venom 
at 1, 5… 60 min incubation. 
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Figure 6.5 Fibrinogen chain cleavage - % intact  
Relative cleavage of alpha (blue), beta (green) or gamma (pink) chains of fibrinogen. X-axis is time 
(min), Y-axis is percentage of intact chain remaining. Error bars indicate standard deviation and N = 
3 means. 
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6.3.3 Thromboelastography 
Clot strength on plasma was investigated in the presence of Ca2+ and phospholipid using 
thromboelastography (Figure 6.6). There was a wide variation in ability to clot plasma, however these 
results coincided with additional above analysis on plasma. Plasma clotted faster than that of the 
negative control (SP = 8.5 ± 0.8, R = 9.9 ± 0.7, A = 15.4 ± 0.7, MRTGG 1.35 ± 0.09, TMRTG 11.8 
± 0.9 and TGG 90.7 ± 5.4), for G. ussuriensis (Russia) which formed a very small, weak clots (SP = 
2.5 ± 0.3, R = 18.5 ± 2.1, A = 2.9 ± 0.8, MRTGG = 0.17 ± 0.01, TMRTG = 2.86 ± 0.34 and TGG = 
14.2 ± 4.2); G. tsushimaensis which formed a very small, weak clot (SP = 1.9 ± 0.1, R = NA, A = 1.4 
± 0.05, MRTGG 0.27 ± 0.02, TMRTG 2.4 ± 0.2 and TGG 6.8 ± 0.3); O. okinavensis produced a more 
robust clot, albeit this being smaller than that of the controls (SP = 2.1 ± 0.1, R = 9.4 ± 2.5, A = 10.4 
± 0.5, MRTGG = 0.4 ± 0.08, TMRTG = 10.7 ± 4.5 and TGG = 57.3 ± 3.1). In contrast, G. saxatilis 
(Russia) delayed the formation of the clot, consistent with the FXa inhibition noted in Figure 6.3A, 
and decreased the clot strength consistent with destructive, non-clotting cleavage of fibrinogen. 
Gloydius brevicaudus, G. saxatilis (Korea, male), and G. ussuriensis all prevented plasma 
spontaneous clotting, indicative of destructive, non-clotting cleavage of fibrinogen. 
 
 
 
97 
 
 
Figure 6.6 Thromboelastography plasma traces 
Overlaid thromboelastography traces showing effects of venoms ability to clot plasma relative to 
spontaneous clot control where species cleave plasma in a clotting manner to form weak clots.  Blue 
traces = spontaneous clot controls, green traces = thrombin induced clot or Factor Xa induced clot, 
red traces = samples. SP = split point, time taken until clot begins to form (min). R = time to initial 
clot formation where formation is 2 mm+ (min). A = amplitude of detectable clot (mm). MRTGG = 
maximum rate of thrombus generation (dsc, dynes/cm2/sec). TMRTG = time to maximum rate of 
thrombus generation (min). TGG = total thrombus generation (dynes/cm2). Overlaid traces are N = 3 
for each set of control or experimental conditions. Values are N = 3 means and standard deviation. 
 
As the actions of G. ussuriensis (Russia), G. tsushimaensis, and O. okinavensis indicated pseudo-
procoagulant effects whereby fibrinogen was directly cleaved by the venom, to produce weak fibrin 
clots, additional thromboelastography studies were undertaken. In addition, these additional studies 
would determine if G. brevicaudus, G. saxatilis (Korea, male), and G. ussuriensis prevented plasma 
spontaneous clotting through the destructive, non-clotting cleavage of fibrinogen. In order to 
determine the strength of the clots formed by venom-dependent fibrinogen cleavage, we investigated 
the ability for the venoms to clot fibrinogen in the presence of Ca2+ and phospholipid using 
thromboelastography (Figure 6.7). Results revealed wide variation between the venoms. Consistent 
with the effects noted upon plasma, G. tsushimaensis, G. ussuriensis (Russian pooled sample) and O. 
okinavensis all clotted fibrinogen within the initial 30 min analysis in a pseudo-procoagulant manner 
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with a reduction in clot strength relative to the thrombin control. As the remainder of the samples did 
not display any ability to directly clot fibrinogen within the allocated 30 min, thrombin was added 
after 30 minutes to attempt to generate a clot and to determine if the venoms were destroying 
fibrinogen directly to impede a clot being formed (Figure 6.7). All fibrinogen samples which were 
not clotted by the venoms directly, displayed high level of destructive cleavage of fibrinogen after 
the addition of thrombin, whereby thrombin produced only weak clots for some venoms (G. 
brevicaudus, and G. ussuriensis female), consistent with substantial degradation of the fibrinogen by 
the venoms, yet was unable to produce clots at all for other venoms (G. ussuriensis male, and G. 
saxatilis) consistent with complete destruction of fibrinogen by the venoms. Diversification in 
fibrinogenolytic activity was shown between G. ussuriensis samples from Korea versus Russia.  For 
species with multiple samples (G. saxatilis Korea males and G. ussuriensis Korea females), 
representatives were chosen to be displayed as there was no differences in clot time, clot strength or 
clot output among them within these assays (data not shown). 
 
 
 
Figure 6.7 Thromboelastography fibrinogen traces 
Overlaid thromboelastography traces showing tests for A) ability to clot fibrinogen relative to 
thrombin control; or B) test for the ability to degrade fibrinogen for species which did not clot in (A) 
whereby thrombin was added at the end of the 30 min runs to test for intact fibrinogen. Blue traces = 
thrombin controls, red traces = samples. SP = split point, time taken until clot begins to form (min). 
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R = time to initial clot formation where formation is 2 mm+ (min). A = amplitude of detectable clot 
(mm). MRTGG = maximum rate of thrombus generation (dynes/cm2/sec). TMRTG = time to 
maximum rate of thrombus generation (min). TGG = total thrombus generation (dynes/cm2). Overlaid 
traces are N = 3 for each set of control or experimental conditions. Values are N = 3 means and 
standard deviation. 
 
6.3.4 Fibrinolysis assessment  
The ability for the venoms to actively lyse plasma clots was investigated with the presence and 
absence of tPA (tissue plasminogen activator) (Figure 6.8). Although plasma clots were unable to be 
lysed by any of the venoms, some species increased the ability for tPA to lyse clots. In the presence 
of tPA, some species (G. brevicaudus, G. tsushimaensis pooled) were able to decrease clot lyses time 
(CLT) as compared to the control (Figure 6.8).  This could be due to fibrinogen structure of the clot 
in the presence of venom whereby tPA is better able to lyse a particular structure. Albeit, coupled 
with thromboelastography clot strength outputs, the ability for these specific venoms to reduce clot 
strength was demonstrated by all. Due to venom availability at the time of assay completion, certain 
venoms were unable to be included in this assay.   
 
 
Figure 6.8 Fibrinolysis  
Clot Lysis Time (CLT) for each species within the basal clade in the presence of tPA at 0.1 µg, 0.5 
µg and 1 µg venom concentrations. The CLT of normal human plasma in the absence of venom is 
indicated in black. Columns are averages of triplicates and error bars given for each.  
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6.3.5 Snake venom serine protease contribution  
As Gloydius tsushimaensis and Ovophis okinavensis both displayed clotting ability in the above 
analysis, both species were subjected to additional inhibition studies. Fibrinogen clotting by Ovophis 
okinavensis venom was completely inhibited by 2 mM AEBSF (venom without inhibitor = 23.5 ± 
1.3, while venom + inhibitor = 999.99 ± 0 sec), while that of the G. tsushimaensis venom was only 
partially inhibited (venom without inhibitor = 59.0 ± 1.6, while venom + inhibitor 207.8 ± 27.6 sec) 
under these conditions (Figure 6.9), as clotting times for fibrinogen did not reach the maximum output 
of 999.99 sec for G. tsushimaensis. This indicates that the venom of O. okinavensis is heavily 
dominated by SVSP proteins actively responsible for fibrinogen-specific coagulation effects, as 
opposed to G. tsushimaensis, which may have a wider composition of coagulatoxic proteins including 
contribution by metalloproteases.  
 
Figure 6.9 SVSP inhibition  
Snake venom serine protease inhibition. Venom-induced fibrin clot formation of fibrinogen was 
analysed for G. tsushimaensis or O. okinavensis venom in the presence or absence of the serine 
protease inhibitor AEBSF (2 mM). The values represent the average  S.D. of three identical 
experiments.     
 
6.4 Discussion  
Our study aimed to investigate the differential coagulotoxic mechanisms within Gloydius venoms 
across majority of the genus, with the addition of O. okinavensis. Ovophis okinavensis was added as 
an additional species as it sits basal to Gloydius and is phylogenetically distinct from all other species 
currently placed in the Ovophis genus (Alencar et al., 2018; Malhotra and Thorpe, 2004) and therefore 
may be included in an expanded consideration of the Gloydius genus along with ‘Trimeresurus’ 
gracilis. Extensive functional and coagulotoxic variation was evident among all samples tested across 
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a myriad of assays, depicting variances across the genus and within a single species of differing 
geographical locations, with venoms falling into two broad anticoagulant functional categories in 
regards to their actions upon fibrinogen: directly anticoagulant through the destructive cleavage of 
fibrinogen (G. brevicaudus, G. saxatilis, G. ussuriensis [Korea population]); and pseudo-
procoagulant whereby fibrinogen levels are depleted by cleavage to form weak, unstable, short-lived 
fibrin clots (G. tsushimaensis, G. ussuriensis [Russia population], and O. okinavensis). Inhibition of 
clotting enzymes was not shown to be a major feature, with the exception of the potent FXa inhibition 
effect noted for the Russian population of G. saxatilis, and more moderate yet still considerable FXa 
inhibition by G. brevicaudus and G. ussuriensis. Inhibition of FXa would have a synergistic 
anticoagulant activity with the depletion of fibrinogen levels. Coagulotoxic effects from O. 
okinavensis can be directly attributed to its venom composition being dominated by SVSPs (Figure 
6.9) (Aird et al., 2013). Comparatively, G. tsushimaensis pseudo-procoagulant effects are due to a 
more complex venom composition, as fibrinogen clotting was only partially inhibited by the known 
serine protease inhibitor AEBSF (Kuniyoshi et al., 2017; Torres-Bonilla et al., 2018; Xin et al., 2009; 
Yamashita et al., 2014). This variation between two pseudo-procoagulant venoms with seemingly 
similar venom actions in vitro can have vast implications clinically as the variation in underlying 
venom biochemistry is indicative of differential toxins exerting the pathophysiological actions, which 
may therefore result in variations in antivenom efficacy. Future work is needed however to elucidate 
such variations in antivenom efficacy in order to fully ascertain such clinical implications.  
Variation in action upon fibrinogen was shared among the other species included within this study. 
Ecological niche partitioning and a shift in diet would contribute to venom evolution of the species 
across varying localities and habitats, with consequential impacts upon relative clinical effects 
(Casewell et al., 2013; Fry et al., 2008). Such wide variation depicted within a single genus has also 
been shown within many other groups of closely related snakes, each inhabiting slightly varied 
ecological niches (Debono et al., 2019a; Debono et al., 2019c; Debono et al., 2017a; Dobson et al., 
2018; Rogalski et al., 2017) as well as variation between localities of the same species (Sousa et al., 
2018). While some ontogenetic shift has been shown within one species of Gloydius (Gao et al., 
2013), due to lack of sample availability the impact upon relative coagulotoxicity was not investigated 
in the present study and should be the subject of future work.  
Variation in venom, dependent on its geographical location, can create many new challenges when 
seeking medical attention post envenomation. With antivenoms being reared among one or two 
species of a single locality, envenomation from another locality is not always effectively neutralised, 
as shown, for example, for the Bothrops genus of pit vipers of South America (Sousa et al., 2018), 
Crotalus (Dobson et al., 2018), and Echis genus of true vipers in Africa (Rogalski et al., 2017). Such 
complications must be taken into consideration by clinicians when treating an envenomated patient, 
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while differences in venom composition lead to differences in relative venom efficacy. Future work 
should investigate the variations in antivenom efficacy for the available antivenoms against these 
species (and others within this genus) in order to map out problematic species or localities.  
The variations exhibited by these species in this study highlight the importance of a combined 
evolutionary and clinical approach to snake venom research. While clinical biology can demonstrate 
physiological effects, evolutionary biology can communicate variations among a genus and infer 
possible explanations as seen with G. tsushimaensis and O. okinavensis, two species with similar in 
vitro effects occupying two extremely isolated habitats. Although this study included only a select 
few species and of geographical locations, the results are indicative of a large clinical and 
biodiscovery potential for future medical implications and bite case management. The substantial 
differences in fundamental venom biochemistry of these species indicate potential limitations in intra-
specific and inter-specific cross-reactivity for antivenoms which include Gloydius venoms in the 
immunizing mixtures. Future research should investigate such limitations in these life-saving 
medications. 
6.5 Material and methods  
6.5.1 Venoms 
Lyophilized venom from a total of nine venom samples from four adult Gloydius species (pooled or 
sourced from single specimen) and one sample from an adult O. okinavensis species were investigated 
for effects upon coagulation (Table 6.1) (Alencar et al., 2016; Malhotra and Thorpe, 2004). Venoms 
were resuspended in deionized H20 and protein concentrations (mg/mL) determined using a 
ThermoFisher Scientific Nanodrop™ 2000c Spectrophotometer. Working stocks of 50% deionized 
water/50% glycerol (> 99%, Sigma-Alrich) for all venoms were prepared at 1 mg/mL and stored at -
-20°C to preserve enzymatic activity and reduce enzyme degradation. Where possible, both pooled 
and individual samples were tested for maximum variation. Where results were the same, 
representatives were used to minimise redundancy. All venom work was undertaken under University 
of Queensland Biosafety Approval #IBC134BSBS2015. 
 
6.5.2 Coagulation analysis 
Venoms were ascertained for their ability to clot or inhibit the clotting of recalcified plasma, or to 
form fibrin clots in fibrinogen solutions using methods previously validated by us (Debono et al., 
2019a; Debono et al., 2019c; Debono et al., 2017a). Healthy human plasma (citrate 3.2%, 
Lot#1690252, approval #16-04QLD-10) was obtained from the Australian Red Cross (44 Musk 
Street, Kelvin Grove, Queensland 4059). Human fibrinogen (Lot#F3879, Sigma Aldrich, St. Louis, 
Missouri, United States) was reconstituted to a concentration of 1 mg/mL in isotonic saline solution, 
flash frozen in liquid nitrogen and stored at −80ºC until use. Coagulopathic toxin effects were 
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measured by a modified procoagulant protocol on a Stago STA-R Max coagulation robot using Stago 
Analyser software v0.00.04 (Stago, Asniéres sur Seine, France). Plasma clotting baseline parameters 
were determined by performing the standardised activated Partial Thromboplastin Time (aPTT) test 
(Stago Cat# T1203 TriniCLOT APTT HS). In order to determine clotting times effected by the 
addition of varying venom concentrations, a modified aPTT test was developed, in which 50 μL of 
venom (20 – 0.05 µg/mL) dilutions in STA Owren Koller Buffer (Stago Cat# 00360), 50 μLCaCl2 (5 
mM final, Stago Cat# 00367 STA CaCl2 0.025M), and 50 μL phospholipid (solubilized in Owren 
Koller Buffer adapted from STA C.K Prest standard kit, Stago Cat# 00597) in a final volume of 175 
μL in Owren Koller Buffer was incubated for 120 sec at 37°C before adding 75 μL of human plasma. 
Relative clotting was then monitored for 999 sec or until plasma clotted (whichever was sooner). 
Calcium or phospholipid dependency was assessed by replacing calcium or phospholipid for Owren 
Koller Buffer, respectively.  
Inhibition of venom serine protease activity was determined using 4-benzenesulfonyl fluoride 
hydrochloride (AEBSF), a known serine protease inhibitor (Kuniyoshi et al., 2017; Torres-Bonilla et 
al., 2018; Xin et al., 2009; Yamashita et al., 2014) in the modified aPTT assay. For this purpose, 25 
μL of (diluted) venom, 50 μLCaCl2 (5 mM final), 50 μL phospholipid, and 50 μL AEBSF (2 mM 
final) were incubated for 2 min at 37°C before adding 75 μL of human fibrinogen (1.2 mg/mL final). 
Additional procoagulation (Factor X and prothrombin activation) or anticoagulation (inhibition of 
FXa, prothrombinase complex formation, thrombin, or fibrinogen cleavage, Table 6.2) assays were 
also conducted, using methods previously validated by us (Debono et al., 2019a; Debono et al., 2019c; 
Youngman et al., 2018). To identify the possible target in the clotting cascade which the venom was 
acting upon, inhibition assays were performed in which either plasma or individual clotting factors 
were incubated with the sample venom, as shown in (Youngman et al., 2018). Data was analysed 
using GraphPad PRISM 8.0 (GraphPad Prism Inc., La Jolla, CA, USA). 
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Table 6.2 Anticoagulation assay details 
 
FXa inhibition assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock 
diluted with OK buffer) + 50 μL 0.025 M calcium (Stago 
catalog # 00367 + 50 μL phospholipid (Stago catalog #00597) 
+ 25 μL FXa (Stago catalog # 00311). 
Step 2. 120 second incubation. 
Step 3. Addition of 75 μL plasma. 
Prothombinase 
complex inhibition 
assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock 
diluted with OK buffer) + 50 μL 0.025 M calcium + 50 μL 
phospholipid + 75 μL plasma 
Step 2. 120 second incubation. 
Step 3. Addition of 25 μL Factor Xa 
Fibrinogen 
destruction assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock 
diluted with OK buffer) + 50 μL 0.025 M calcium + 50 μL 
phospholipid + 75 μL 4 mg/mL fibrinogen. 
Step 2. 60 minute incubation. 
Step 3. Addition of 25 μL thrombin (Stago catalog #00673) 
Thrombin inhibition 
assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock 
diluted with OK buffer) + 50 μL 0.025 M calcium + 50 μL 
phospholipid + 25 μL thrombin (Stago catalog # 00611). 
Step 2. 120 second incubation. 
Step 3. Addition of 75 μL 4 mg/mL fibrinogen. 
 
6.5.3 Fibrinolytic activity  
Fibrinogenolytic activity was assessed as previously described (Debono et al., 2019a; Debono et al., 
2019c). In brief, fibrinogen (1 mg/mL final) was incubated with venom (10 µg/mL final) for 60 min 
at 37°C, and fibrinogen cleavage was assessed at several time points (1, 5, 10, 15, 20, 30, 45 and 60 
min) using SDS-PAGE analysis under reducing conditions followed by staining with Coomassie 
Brilliant Blue R-250. The visualized protein fragments were quantified using ImageJ software 
(V1.51r, Java 1.6.0_24, National Institutes of Health, Bethesda, Maryland, USA) and analysed using 
GraphPad PRISM 7.0 (GraphPad Prism Inc., La Jolla, CA, USA). 
 
6.5.4 Thromboelastography (fibrinogen and plasma)  
Venoms were investigated for clot strength ability on fibrinogen and plasma employing 
thromboelastography using a Thrombelastogram® 5000 Haemostasis analyser (Haemonetics®, 
Haemonetics Australia Pty Ltd, North Rdye, Sydney 2113, Australia) as described (Debono et al., 
2019a; Debono et al., 2019c). Human fibrinogen was reconstituted in enzyme buffer (150 mM NaCl 
and 50 mM Tri-HCl (pH 7.3)). Briefly, 7 μL venom working stock (1 mg/mL outlined in (Debono et 
al., 2017a)) or 7 μL thrombin as a positive control (stable thrombin from Stago Liquid Fib kit, Stago 
Cat#115081 Liquid Fib), 72 μL CaCl2 (25mM stock solution Stago Cat# 00367 STA), 72 μL 
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phospholipid (solubilized in Owren Koller Buffer adapted from STA C.K Prest standard kit, Stago 
Cat# 00597), and 20 μL Owren Koller Buffer (Stago Cat# 00360) were combined with 189 μL 
fibrinogen or human plasma and run immediately for 30 min to allow for ample time for clotting 
formation. An additional positive control of 7 μL Factor Xa (Liquid Anti-Xa FXa Cat#253047, Stago) 
was also incorporated for plasma only. When no clot was formed from the effects of anticoagulant 
venoms, an additional 7 μL thrombin was added to the pin and cup to generate a clot and to determine 
the effects of fibrinogen degradation.  
 
6.5.5 Fibrinolysis 
The ability for venoms of the Gloydius and Ovophis genus to actively lyse fibrin clots was 
investigated following methods described previously (Debono et al., 2019a; Debono et al., 2019c). 
Varying concentrations of crude venom (1 – 0.1 µg/μL) were tested either with or without the addition 
of tissue plasminogen activator (tPA, Sekisui Diagnostics, Lexington, MA, USA). Briefly, tissue 
factor (TF) (Innovin, Siemens, USA) and phospholipid vesicles (PCPS, 75% phosphatidylcholine and 
25% phosphatidylserine, Avanti Polar Lipids, Alabama, USA) were incubated at 37°C for 1 hour in 
HEPES buffer (25 mM HEPES, 137mM NaCl, 3.5 mM KCl, 0.1% BSA (Bovine Serum Albumin 
A7030, Sigma Aldrich, St Louis, MD, USA), pH 7.4). To the TF/PCPS mixture (1.8 pM/3 μM final), 
CaCl2 (17 mM final), tPA (37.5 U/mL final, diluted in 20 mM HEPES, 150 mM NaCl, 0.1% PEG-
8000, pH 7.5), venom (50% v/v), and plasma (50% v/v, prewarmed at 37°C) were added. The fibrin 
clot formation and the subsequent lysis was monitored by measuring the absorbance at 405 nm for 
every 30 sec during 3 hr at 37°C in a SpectraMax M2e microplate reader. The onset of clot formation 
was defined as the time point at which the turbidity increased (delta absorbance > 0.04); the clotting 
time was the time from the start of the assay to the onset of clot formation. The clot lysis time was 
the interval between the clear to turbid transition (defined as the midpoint between the onset of clot 
formation and the maximum turbidity) and the turbid to clear transition; the latter was determined by 
a sigmoidal fit of the turbidity plots using GraphPad Prism 8.0.  
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Chapter 7: Clinical implications of differential antivenom efficacy in neutralising 
coagulotoxicity produced by venoms from species within the arboreal viperid 
snake genus Trimeresurus  
 
7.1 Abstract 
Snake envenomation globally is attributed to an ever-increasing human population encroaching into 
snake territories. Responsible for many bites in Asia is the widespread genus Trimeresurus. While 
bites lead to haemorrhage, only a few species have had their venoms examined in detail. We found 
that Trimeresurus venom causes haemorrhaging by cleaving fibrinogen in a pseudo-procoagulation 
manner to produce weak, unstable, short-lived fibrin clots ultimately resulting in an overall 
anticoagulant effect due to fibrinogen depletion. The monovalent antivenom ‘Thai Red Cross Green 
Pit Viper antivenin’, varied in efficacy ranging from excellent neutralisation of T. albolabris venom 
through to T. gumprechti and T. mcgregori being poorly neutralised and T. hageni being unrecognised 
by the antivenom. While the results showing excellent neutralisation of some non-T. albolabris 
venoms (such as T. flavomaculaturs, T. fucatus, and T. macrops) needs to be confirmed with in vivo 
tests, conversely the antivenom failure T. hageni, and the very poor results against T. gumprechti and 
T. mcgregori, despite being conducted in the ideal scenario of preincubation of antivenom:venom, 
indicates that the likelihood of clinically relevant cross-reactivity for these species is low (T. 
gumprechti and T. mcgregori) to non-existent (T. hageni). These same latter three species were also 
not inhibited by the serine protease inhibitor AEBSF, suggesting that the toxins leading to a 
coagulotoxic effect in these species are non-serine proteases while in contrast T. albolabris 
coagulotoxicity was completely impeded by AEBSF, and thus driven by kallikrein-type serine 
proteases.  There was a conspicuous lack of phylogenetic pattern in venom variation, with the most 
potent venoms (T. albolabris and T. hageni) being distant to each other on the organismal tree, and 
with the three most divergent and poorly neutralised venoms (T. gumprechti, T. hageni    and T. 
mcgregori) were also not each other’s closest relatives. This reinforces the paradigm that the 
fundamental dynamic evolution of venom results in organismal phylogeny being a poor predictor of 
venom potency or antivenom efficacy. This study provides a robust investigation on the differential 
venom effects from a wide range of Trimeresurus species on coagulation, highlighting differential 
fibrinogenolytic effects, while also investigating the relative antivenom neutralisation capabilities of 
the widely available Thai Red Cross Green Pit Viper antivenom. These results therefore have 
immediate, real-world implications for patients envenomed by Trimeresurus species.  
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7.2 Introduction 
Effective treatment for snake envenomation is becoming increasingly important, with a rise in 
reported snake bites worldwide (Fry, 2018; Gutiérrez et al., 2017; Gutiérrez et al., 2006; Kasturiratne 
et al., 2008). Human-snake conflicts are increasing due to a myriad of factors including human 
population expansion and urban development encroaching into snake territories, and an increase in 
snake activity periods due to climate change (Fry, 2018). In addition, the increase in exotic pets 
outside of zoological facilities also increases the risk of bites from exotic species of snake, which 
means that the issue of snakebite is no longer restricted to the developing world (Fry, 2018; Gutiérrez 
et al., 2017; Kasturiratne et al., 2008). Across Asia there are many species of highly venomous snakes, 
and populations of humans existing in close contact with these species is ever increasing. Pit vipers 
are responsible for a major proportion of envenomation due to large population densities of people 
that bring increased agriculture to regions overlapping with the pit viper habitat, coupled with poor 
snakebite management and education (Alirol et al., 2010; Chippaux, 1998).  
Trimeresurus is a genus of pit viper that is widespread across much of Asia. Trimeresurus albolabris 
is a particularly commonly encountered species, and envenomations are considered medically 
significant with effects ranging from local blistering and necrosis, shock, to spontaneous systemic 
bleeding, defibrinogenation, thrombocytopenia and leucocytosis (Hutton et al., 1990). As a result, T. 
albolabris envenomation and venom composition has been the centre of much research focus 
(Chotenimitkhun and Rojnuckarin, 2008; Greene et al., 2017; Hutton et al., 1990; Lin et al., 2009; 
Muanpasitporn and Rojnuckarin, 2007; Peng et al., 1992; Pradniwat and Rojnuckarin, 2015; 
Rojnuckarin et al., 1999; Tan et al., 2017a; Tan et al., 2012) and is the main Trimeresurus species 
targeted by available antivenoms, such as the monovalent Green Pit Viper Antivenin produced by the 
Thai Red Cross. However, in many of the regions where Trimeresurus species exist, a specific 
antivenom is lacking (Tan et al., 2017a). Moreover, the venom composition and function of most 
other species within the genus have been comparably neglected, with a few exceptions such as T. 
flavomaculatus, T. insularis, T. macrops, T. purpureomaculatus, and T. stejnegeri (Clark and 
Davidson, 1997; Jones et al., 2019; Mitrakul, 1973; Rojnuckarin et al., 1999; Tai et al., 2004; Tan et 
al., 2017a; Tan, 2010; Tan et al., 1994; Visudhiphan et al., 1989; Witharana et al., 2019; 
Wongtongkam et al., 2005).  
Correct treatment for envenomation is crucial for patient care, to reduce both morbidity and mortality 
rates (Fry, 2018). Having a better understanding of the effects of such species’ venom on the 
coagulation cascade can aid in this knowledge and improve current treatments available. 
Coagulotoxicity from Trimeresurus envenomations results in anticoagulant effects which clinically 
manifests into haemorrhaging, most commonly attributed to fibrinogenolytic activity, as seen for 
many pit-vipers (Bell, 1997; Debono et al., 2019a; Debono et al., 2019b; Debono et al., 2019c; Kolev 
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and Longstaff, 2016; Longstaff and Kolev, 2015; Mosesson, 2005; Visudhiphan et al., 1989; 
Wolberg, 2007; Wolberg and Campbell, 2008). Fibrinogenolytic enzymes may act upon fibrinogen 
either directly induce an anticoagulant effect by destructive cleavage of fibrinogen, or indirectly by 
aberrant cleavage of fibrinogen, resulting in short-lived, weak clots in a pseudo-procoagulant manner, 
with both actions leading to a net anticoagulant state due to depletion of the levels of intact fibrinogen 
(Coimbra et al., 2018; Debono et al., 2019a; Debono et al., 2019b; Debono et al., 2019c; Dobson et 
al., 2018; Esnouf and Tunnah, 1967; Huang et al., 1992; Levy and Del Zoppo, 2006; Nielsen, 2016a; 
Premawardena et al., 1998; Trookman et al., 2009; Zulys et al., 1989). This effect has been 
demonstrated in many other species of Asian pit viper (Dambisya et al., 1994; Debono et al., 2019a; 
Debono et al., 2019b; Debono et al., 2019c; Levy and Del Zoppo, 2006; Liu et al., 2011; Nielsen, 
2016a; Nolan et al., 1976; Zulys et al., 1989).  
Understanding exactly how these anticoagulant effects arise and persist can drastically improve 
patient care and thus positive outcomes. Here we investigated the differential coagulotoxic effects of 
a total of 13 of the 37 known and described Trimeresurus species (Alencar et al., 2018; Alencar et 
al., 2016) and ascertained the relative effectiveness of available monovalent Green Pit Viper 
antivenom in neutralising fibrinogenolytic actions for each species. Note: we follow Alencar et al., 
2016 in considering Trimeresurus as the genus name for all species and do not subscribe to proposed 
division into several genera as proposed by Malhotra and Thorpe, 2004, as the more inclusive 
definition of Trimeresurus renders these snakes as a well-defined monophyletic clade sharing 
ecological, evolutionary, and morphological features distinctive of these speices relative to all other 
Asian pit vipers. These venoms are evolving under unique selection pressures due to the species being 
unique amongst Asian pit vipers in being arboreal specialists and thus there is a high chance of prey 
escape. These venoms may also be diversification hot spots due to limited gene flow as a consequence 
of arboreality. Thus there may be real world implications of such venom variation for the envenomed 
patient as a consequence of differential efficacy by available antivenoms. 
 
7.3 Results  
7.3.1 Coagulation analyses on plasma  
The ability of the Trimeresurus venoms to affect clot formation of human plasma was investigated. 
Using a final concentration of 20 µg/mL venom, five of the venoms displayed the ability to clot 
plasma quicker than the negative control (spontaneous clotting of recalcified plasma: 584 ± 35 sec): 
T. albolabris (62 ± 9 sec), T. borneensis (82 ± 8 sec), T. gumprechti (90 ± 1 sec), T. hageni (71 ± 2 
sec), and T. mcgregori (78 ± 1 sec) (Figure 7.1A). For these five procoagulant venoms (T. albolabris, 
T. borneensis, T. gumprechti, T. hageni and T. mcgregori), their cofactor-dependent clotting activity 
was assessed in further detail, with the cofactors being calcium and/or phospholipid. The absence of 
109 
 
phospholipid did not significantly affect the shift in AUC (AUC shift of 4 ± 2% for T. albolabris, 22 
± 1% for T. borneensis, 4 ± 2% for T. gumprechti, 5 ± 0% for T. hageni, and a shift of 6 ± 5 % for T. 
mcgregori; Figure 7.1B-F). In contrast, a pronounced shift in the AUC was observed for the clotting 
activity obtained in the absence of calcium (AUC shift of 172 ± 0% for T. albolabris, 75 ± 11% for 
T. borneensis, 102 ± 1% for T. gumprechti, 75 ± 0% for T. hageni, and 85 ± 1% for T. mcgregori). 
 
 
Figure 7.1 Cofactor dependency – plasma  
A) Initial 20 µg/mL venom concentration clotting times on human plasma for all species included in 
study. B) 8-point dose-response curves of human plasma clotting activity with both calcium and 
phospholipid (red line), with just calcium (blue line), and with just phospholipid (purple line) for T. 
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albolabris, T. borneensis, T. gumprechti, T. hageni and T. mcgregori. Y-axis = Clotting time (sec). 
Data points are N = 3 with standard deviations. 
 
7.3.2 Coagulation analyses on fibrinogen  
To gain further insight into the mechanism by which the five Trimeresurus venoms (T. albolabris, T. 
borneensis, T. gumprechti, T. hageni and T. mcgregori) induce fibrin clot formation in plasma, their 
clotting activity using purified fibrinogen as substrate was assessed. At a final concentration of 20 
µg/mL venom, T. albolabris (49 ± 13 sec), T. borneensis (63 ± 11 sec), T. gumprechti (77 ± 0 sec), 
T. hageni (42 ± 2 sec) and T. mcgregori (59 ± 6 sec) displayed the ability to directly clot fibrinogen 
(Figure 7.2A). Assessment of the cofactor-dependent fibrinogen clotting activity indicated that 
phospholipid was not a major contributing cofactor (AUC shift of 12 ± 7% for T. albolabris, 35 ± 2% 
for T. borneensis, 26 ± 1% for T. gumprechti, 38 ± 1% for T. hageni, and a shift of 30 ± 0% for T. 
mcgregori; Figure 7.2B-F), corroborating our findings obtained for plasma clotting (Figure 7.1B-F). 
While the venom-induced clotting of fibrinogen appeared to dependent on calcium as a cofactor, the 
shift in the AUC was lower than that observed for venom-induced plasma clotting in the absence of 
calcium (AUC shift of 32 ± 0% for T. albolabris, 104 ± 4% for T. borneensis, 89 ± 0% for T. 
gumprechti, 77 ± 0% for T. hageni and 92 ± 0% for T. mcgregori). 
Monovalent antivenom from T. albolabris (Thai Red Cross Green Pit viper antivenin) was tested 
against all 13 Trimeresurus species included in this study for its neutralising capabilities on fibrinogen 
clotting. Most species were eventually neutralised by the antivenom, except for T. gumprechti, T. 
hageni and T. mcgregori where the antivenom had negligible effects (Figure 7.3). In contrast, 
Trimeresurus albolabris was completely neutralised even at the highest venom concentrations, as too 
were T. flavomaculatus, T. fucatus, T. macrops and T. popeiorum. The remainder of the tested venom 
species reached complete neutralisation at lower concentrations of venom (Figure 7.3), indicating an 
intermediate effectiveness of the antivenom. There was no phylogenetic signal of antivenom efficacy, 
with the closest relative of T. albolabris only moderately neutralised while in other cases, such as T. 
flavomaculatus and T. mcgregori, two species who are each other’s closest relatives, were 
diametrically opposed in their relative neutralisation (Figure 7.4). 
To ascertain the relative contribution of snake venom serine proteases (SVSPs) to fibrinogen clotting, 
the effect of AEBSF (a well-characterised serine protease inhibitor (Torres-Bonilla et al., 2018; Xin 
et al., 2009; Yamashita et al., 2014)) was investigated. The fibrinogen clotting activity of both T. 
albolabris and T. borneensis venom was completely inhibited by incubation with 2 mM AEBSF, 
indicated by an undetectable fibrinogen clotting time in the presence of the inhibitor (>999 sec; Figure 
7.5). These observations suggest that SVSPs are responsible for the coagulotoxic effects upon 
fibrinogen for T. albolabris and T. borneensis venoms, On the other hand, the fibrinogen clotting 
activity of the T. gumprechti, T. hageni, and T. mcgregori venoms was only partially inhibited upon 
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AEBSF incubation (Figure 7.5). These observations suggest that SVSPs are only partially 
contributing to the coagulotoxic effects upon fibrinogen by the T. gumprechti, T. hageni, and  
T. mcgregori venoms and that metalloproteases are responsible for the majority of the fibrinogen 
clotting effects of these venoms. 
 
Figure 7.2 Cofactor dependency – fibrinogen  
A) Initial 20 µg/mL venom concentration clotting times on human fibrinogen for all species included 
in study. B) 8-point dose-response curves of human fibrinogen clotting activity with both calcium 
and phospholipid (red line), with just calcium (blue line), and with just phospholipid (purple line) for 
T. albolabris, T. borneensis, T. gumprechti, T. hageni and T. mcgregori. Y-axis = Clotting time (sec). 
Data points are N = 3 with standard deviations. 
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Figure 7.3 Antivenom neutralization  
Comparison of relative Thai Red Cross Green Pit Viper antivenom cross neutralisation across various species of Trimeresurus on fibrinogen (1.2 mg/mL 
final concentration). Fibrinogen+venom clotting curve = red line, venom+antivenom clotting curve = blue line. X axis: final venom concentration 
(µg/mL), Y axis: clotting time in seconds. Values are averages of triplicates (single dilution measured three times) and standard deviation error bars are 
shown for each, although for most the error range is smaller than the line icon. 
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Figure 7.4 Antivenom neutralization efficacy heat map 
Heat map of Green Pit Viper antivenom neutralisation efficacy against Trimeresurus venoms. 
Organismal phylogeny was based on Alencar et al. (2016) and Alencar et al. (2018).  
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Figure 7.5 SVSP Inhibition  
Inhibition of SVSPs by AEBSF (2 mM) against 20 µg venom from pseudo-procoagulant species 
performed on a Stago STA R Max. Clotting time was measured against 4 mg human fibrinogen with 
the addition of cofactors calcium and phospholipid. Red columns = venom without 2mM (end 
concentration) inhibitor, blue columns = venom with 2 mM (end concentration) inhibitor incubated 
together for 20 min at 37ºC. clot time was measured for a max reading time of 999.99 sec or until 
fibrinogen had clotted. Y axis = clot time (s), X axis = venom species. N = 3.     
 
7.3.3 Thromboelastography (plasma) 
The clot strength of venom-induced clotted plasma was investigated in the presence of calcium and 
phospholipid using thromboelastography (Figure 7.6). While the clotting activity of the tested 
Trimeresurus venoms on the plasma varied widely, as demonstrated by the variation in speed of 
action and in strength of fibrin clot formed, all clots produced were extremely small and weak relative 
to the control plasma clots, and therefore the action is pseudo-procoagulant, not a true procoagulant 
activity. However, T. popoeirum venom was the only species that did not clot the plasma directly, 
producing a trace very similar to that of the spontaneous control clot. 
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Figure 7.6 Thromboelastography Plasma traces  
Overlaid thromboelastography traces showing effects of venoms ability to clot plasma relative to spontaneous clot control where species cleave plasma 
in a clotting manner to form weak clots.  Blue traces = spontaneous clot controls, green traces = thrombin induced clot or Factor Xa induced clot, red 
traces = samples. SP = split point, time taken until clot begins to form (min). R = time to initial clot formation where formation is 2mm+ (min). 
A = amplitude of detectable clot (mm). MRTGG = maximum rate of thrombus generation (dsc, dynes/cm2/sec). TMRTG = time to maximum rate of 
thrombus generation (min). TGG = total thrombus generation (dynes/cm2). Overlaid traces are N = 3 for each set of control or experimental conditions. 
Values are N = 3 means and standard deviation. 
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7.3.4 Thromboelastography (fibrinogen)  
Next, the direct clotting effects of the Trimeresurus venoms upon fibrinogen were assessed, again 
using thromboelastography in the presence of calcium and phospholipid (Figure 7.7). As with the 
plasma tests, the results revealed wide variation between the venom-induced clots in both speed of 
action and the relative clot strength. Consistent with the previous observations on plasma clot 
strength, all clots formed were weak relative to the thrombin-induced control. All Trimeresurus 
species tested (with the exception of T. flavomaculatus) clotted fibrinogen within the initial 30 min 
in a pseudo-procoagulant manner indicated by a reduction in clot strength relative to the thrombin 
control. Trimeresurus popoeirum was very slow in the action upon fibrinogen, which is consistent 
with its inability to clot plasma before spontaneous clotting occurred (see section above).  In the case 
of T. flavomaculatus, which did not display any ability to directly clot fibrinogen within the initial 30 
min, thrombin was subsequently added with the aim of generating a clot to test for destructive 
cleavage of fibrinogen by the venom. Indeed, the thrombin-induced clot displayed a greatly reduced 
clot strength in comparison to the thrombin control in the absence of venom, which is consistent with 
destructive (non-clotting) cleavage of fibrinogen by T. flavomaculatus venom (Figure 7.7).  
Consistent with the extreme variance in speed of action and clot strength, Phylogenetic Generalized 
Least Squares PGLS analysis confirmed that there is no statistical correlation between the speed of 
reaction and the strength of the fibrin clot produced (t = 0.9240, p = 0.3753, df = 1) (Figure 7.8). 
This indicates that the strength of the clot (A) is independent of the time to maximum thrombus 
generation (TMRTG). Interestingly, T. mcgregori, which produced the strongest clot (A = 8 ± 1.8, 
TGG = 43.2 ± 10.4) registers at mid-range in terms of speed of clot formation (SP = 2.9 ± 0.2, 
MRTGG = 0.4 ± 0.02), while one of the fastest to produce a clot, T. trigonocephalus, (SP = 2.6 ± 0.4, 
MRTGG = 0.2 ± 0.02) produces one of the weakest clots (A = 1.8 ± 0.05, TGG = 8.8 ± 0.03). 
 
 
 
 
117 
 
 
Figure 7.7 Thromboelastography fibrinogen traces   
Overlaid thromboelastography traces showing effects of venoms A) ability to clot fibrinogen relative 
to thrombin control; or B) test for the ability to degrade fibrinogen for species which did not clot in 
(A) whereby thrombin was added at the end of the 30 min runs to test for intact fibrinogen. Blue 
traces = thrombin clot controls, red traces = samples. SP = split point, time taken until clot begins to 
form (min). R = time to initial clot formation where formation is 2 mm+ (min). A = amplitude of 
detectable clot (mm). MRTGG = maximum rate of thrombus generation (dsc, dynes/cm2/sec). 
TMRTG = time to maximum rate of thrombus generation (min). TGG = total thrombus generation 
(dynes/cm2). Overlaid traces are N = 3 for each set of control or experimental conditions. Values are 
N = 3 means and standard deviation. 
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Figure 7.8 Heat map overlay phylogeny fibrinogen thromboelastography  
Heat map overlay phylogeny of sampled Trimeresurus species tested for their ability to clot 
fibrinogen using a Thromboelastography (Figure 7).  Heat map illustrates the relationship between 
amplitude (A) of generated clot vs Time to Maximum Rate of Thrombus Generation (min) (TMRTG). 
Cooler colours are smaller amplitudes and longer time taken to generate thrombus, while warmer 
colours are larger amplitudes with a shorter time taken to generate thrombus. PGLS analysis showed 
no statistical correlation between speed of reaction and clot size formed on fibrinogen for any species 
(t = 0.9240, p = 0.3753, df = 1). Values are N = 3 means and standard deviation. Organismal 
phylogeny was based on (Alencar et al., 2016; Malhotra and Thorpe, 2004). T. flavomaculatus is in 
gray as it does not clot fibrinogen within the assay time period. 
  
7.3.5 Fibrinogen chain degradation  
In order to determine the specific fibrinogen chain cleavage by the various Trimeresurus venoms, 
time-dependent assays were conducted to illustrate effects upon each chain (Figure 7.9 and Figure 
7.10). A wide variation in pattern emerged, with many of the venoms displaying the ability to cleave 
the alpha chain (with the exception of T. gumprechti and T. popeiorum). In most venom samples, the 
alpha chain was initially quite rapidly degraded within the first 5 minutes, followed by the beta chain. 
Trimeresurus albolabris, T. borneensis, T. flavomaculatus, T. hageni, T. mcgregori, T. 
purpureomaculatus, T. trigonocephalus and T. vogeli also cleaved the gamma chain, thereby 
displaying the ability to cleave all three chains, with partial degradation of the gamma chain noted 
for T. puniceus. Some species (T. flavomaculatus and T. purpureomaculatus) degraded all three 
chains the quickest, however this ability was not congruent with their ability to clot plasma (Figure 
7.1 and Figure 7.6) or fibrinogen (Figure 7.2 and Figure 7.7), indicative of at least some cleavage 
being destructive rather than clot forming. Other species, however, which did display an ability to 
clot plasma in a timely manner did not necessarily cleave all three chains rapidly (T. albolabris), nor 
did they cleave both alpha and beta (T. gumprechti). This suggests notable variation in destructive 
chain degradation leading to versus systematic degradation of chains leading to clot formation (albeit 
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with weak and unstable fibrin structures), but both effects leading to a net depletion of fibrinogen 
levels. 
 
Figure 7.9 Fibrinogen chain cleavage - gel  
1D SDS PAGE time dependent fibrinogen chain degradation (α, β or γ) by venom at 0.1µg/μL 
concentration at 37ºC over 60 min. F = fibrinogen at 0 min or 60 min incubation controls, V = venom 
at 1, 5… 60 min incubation. 
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Figure 7.10 Fibrinogen chain cleavage - % intact  
Relative cleavage of alpha (blue), beta (green) or gamma (pink) chains of fibrinogen. X-axis is time 
(min), y-axis is percentage of intact chain remaining. Error bars indicate standard deviation and N = 
3 means. 
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7.3.6 Fibrinolysis  
The ability of the venoms to actively lyse plasma clots was investigated in the presence and absence 
of tPA (tissue plasminogen activator) (Figure 7.11). Although plasma clots were unable to be directly 
lysed by any of the venoms, some species increased the ability of tPA to induce fibrinolysis. These 
species (T. albolabris, T. borneensis, T. gumprechti, T. hageni, T. macrops, T. popeiorum, T. 
puniceus, T. purpureomaculatus, T. trigonocephalus and T. vogeli) were able to shorten the clot lysis 
time (CLT) as compared incubations in the absence of venom.  
 
Figure 7.11 Fibrinolysis  
Clot Lysis Time (CLT) for each species in the presence of tPA at 500 ng/μL venom concentrations 
(other concentrations not shown). Control is indicated in black. Columns are averages of triplicates 
and error bars given for each. Bars which are lower than the control lysed the plasma clot quicker 
than under normal tPA clot lyse conditions. 
 
7.3.7 FXa, thrombin and FIXa enzyme inhibition studies  
Investigations to determine the sites of potential venom-dependent enzyme inhibition proceeded in a 
stepwise manner in order to ascertain specific sites of action: i) incubation of venom with FIXa 
followed by the addition of plasma to determine the venom’s ability to directly inhibit FIXa; ii) 
incubation of venom with FXa followed by the addition of plasma to determine the ability of the 
venom to directly inhibit FXa; iii) incubation of venom with plasma followed by the addition of FXa 
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to determine the effects of the venom on prothrombinase complex formation; iv) incubation of venom 
with thrombin followed by the addition of fibrinogen to determine direct inhibition of thrombin.  
The results were as follows (Figure 7.12): i) incubation with FIXa revealed a wide variation in the 
level of inhibitory activity of the venoms with some species displaying stronger inhibitory effects 
than others (T. borneensis and T. mcgregori) (Figure 7.12A); ii) a wide variation in FXa inhibition 
was notable across the genus. (Figure 7.12B); iii) incubation of the venom with plasma followed by 
the addition of FXa did not result in a prolonged clotting time and thus potential inhibition of 
prothrombinase, with the exception of T. puniceus venom which also showed inhibition towards FXa 
(Figure 7.12C); iv) no substantial inhibition of thrombin-dependent fibrinogen cleavage was observed 
following incubation with Trimeresurus venom (Figure 7.12D). However, as these enzymes work as 
a cascade, the cumulative effect of the inhibition may strongly contribute to the anticoagulant actions 
of these venoms.   
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Figure 7.12 Clotting factor inhibition  
Clotting factor inhibition panel showing the relative inhibitory effects of Trimeresurus venom on 
preventing the activation of: A) FIXa, B) FXa, C) Prothrombin to thrombin (Prothombinase complex) 
and D) Thrombin inhibition. For A) venom was incubated with FIXa for 2 min before adding plasma, 
with clot time then immediately measured. For B) venom was incubated with human plasma for 2 min 
before adding Factor Xa with clot time then immediately measured. For C) and D) venom was 
incubated with FXa or thrombin for 2 min before adding plasma or fibrinogen, with clot time then 
immediately measured. Data points are N = 3 displayed as a shift away from the control with standard 
deviations (no shift from control values would be a zero value).  
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7.4 Discussion  
Species of Trimeresurus are wide spread throughout the Asian continent. As arboreal specialists, they 
are under extreme selection pressure due to high prey escape potential combined with prey variation. 
Arboreality also restricts gene flow, which in turn creates a diversification hot spot for many species 
to flourish and for venom to diverge. Such venom diversification within a genus can have real world 
implications for the treatment of envenomed patients due to differential coagulopathy and therefore 
a variable response to antivenom. 
Despite species Trimeresurus species being very similar ecologically and morphologically, this study 
has revealed that their venoms are extremely functionally diverse and therefore capable of producing 
divergent clinical effects that are variably neutralised by antivenom. We observed coagulotoxic 
effects of the venom on plasma and fibrinogen of pseudo-procoagulant cleavage of fibrinogen to 
produce weak, unstable, short-lived fibrin clots. Such venom-mediated proteolysis of fibrinogen 
results in a depletion of fibrinogen levels, thus leading to a net anticoagulant state. The 
anticoagulation was potentiated by inhibition of clotting enzymes. 
These laboratory findings are consistent with the haemorrhagic clinical manifestations of 
envenomation by Trimeresurus species (Chan et al., 1993; Chotenimitkhun and Rojnuckarin, 2008; 
Cockram et al., 1990; Greene et al., 2017; Hutton et al., 1990; Rojnuckarin et al., 2007; Rojnuckarin 
et al., 1999; Tan et al., 2017a; Visudhiphan et al., 1989; Witharana et al., 2019; Wongtongkam et al., 
2005). In particular, the venoms have been shown clinically to produce rapid and pronounced 
decrease in fibrinogen levels leading to a net anticoagulant state (Collet et al., 2000; Longstaff and 
Kolev, 2015; Ryan et al., 1999), which is consistent with the results presented here. These effects are 
similar to that produced by other Asian pit vipers (Debono et al., 2019a; Debono et al., 2019b; Debono 
et al., 2019c).  
Previous analysis of fibrinogen degradation on a very limited range of Trimeresurus species only 
provided qualitative, descriptive data and did not quantify the rates of fibrinogen chain cleavage 
(Jones et al., 2019). Further, this prior study did not attempt to determine the effect fibrinogen 
cleavage had upon clotting or the ability of antivenom to neutralise these pathological effects. In 
addition, prior studies also only measured antivenom binding through the use ELISA or Western Blot, 
which would reveal only simple antivenom binding to venom proteins, with no kinetic information, 
and, crucially prior studies did not ascertain whether the antivenom was effective in neutralising the 
venom’s pathological functions(Jones et al., 2019; Tan et al., 2017a). In contrast, in this study we not 
only quantified the effects upon fibrinogen but also investigated the ability of the Thai Red Cross 
Green Pit Viper Antivenin to neutralise the coagulotoxic effects of the 13 species of Trimeresurus 
investigated here. As expected, since the antivenom is made using T. albolabris venom, this species 
was completely neutralised even at the highest venom concentration. Trimeresurus borneensis, T. 
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flavomaculatus, T. macrops and T. popeiorum were also extremely well neutralised. Other venoms 
were differentially neutralised by the antivenom, with notably poor effects upon T. gumprechti, and 
T. mcgregori and no detectable effect upon T. hageni. There was not, however, a phylogenetic pattern 
in regards to which species were well neutralised or poorly neutralised, which is consistent with the 
rapid molecular evolution characteristic of predatory venoms (Casewell et al., 2013). 
In addition to investigating the effects upon fibrinogen by the venoms, this study also ascertained 
inhibition of clotting enzymes by the venoms. Trimeresurus trigonocephalus displayed the most 
pronounced inhibition of FXa, while T. borneensis displayed the largest inhibitory effect on FIXa. 
The inhibition of clotting enzymes would have a synergistic relationship with the depletion of 
fibrinogen levels, thereby potentiating the net anticoagulant effect. Indeed, anticoagulation is a major 
clinical feature in patients envenomated by Trimeresurus species (Chotenimitkhun and Rojnuckarin, 
2008; Cockram et al., 1990; Greene et al., 2017; Hutton et al., 1990; Rojnuckarin et al., 2007; 
Rojnuckarin et al., 1999; Rojnuckarin et al., 1998). Fibrinogenolytic effects have frequently been 
reported leading to swelling, excessive bleeding and defibrination. Antivenom has been reported as 
being effective for T. albolabris and T. macrops envenomations (Chan et al., 1993; Hutton et al., 
1990; Rojnuckarin et al., 2007; Yang et al., 2007), which is consistent with the results we obtained 
for both species in this study. Haemorrhagic shock would be further potentiated by the anticoagulant 
mechanisms we have identified in this study working synergistically with metalloprotease enzymes 
that damage the vascular wall (Escalante et al., 2011; Gutiérrez et al., 2011). 
Consistent the poor neutralisation from the tested antivenom on T. gumprechti, and T. mcgregori 
venoms, and the lack of effect upon T. hageni, these same three species were also not inhibited by 
the known serine protease inhibitor AEBSF, which was effective in neutralising the effects of the 
other species. Thus, while the actions upon fibrinogen for species such as T. albolabris and T. 
borneensis are due to serine proteases, the coagulotoxic effects from T. gumprechti, T. hageni and T. 
mcgregori are due to the other fibrinogenolytic enzyme class present in the venoms: metalloproteases. 
Interestingly, these three species are not closely related to each other and therefore this unique activity 
has been derived on three independent occasions. As antivenom is made using the venom of T. 
albolabris venom, which contains fibrinogenolytic serine proteases, this explains the poor 
performance against the venoms which are rich in fibrinogenolytic metalloproteases. As these three 
species were phylogenetically distinct from each other, and therefore convergently derived their 
venoms away from the plesiotypic serine protease driven actions upon fibrinogen with the consequent 
impact upon antivenom cross-neutralisation, this underscores the unreliability of organismal 
phylogeny as a predictor of antivenom efficacy. Similarly, organismal was a poor predictor of venom 
potency, with the two most potent venoms (T. albolabris and T. hageni) being distant to each other 
on the organismal tree. 
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These findings therefore have real world implications for the treatment of patients envenomed by 
Trimeresurus species using the widely available Thai Red Cross Green Pit Viper antivenom. An 
important caveat is that the positive cross-reactivity with T. flavomaculatus and T. fucatus requires in 
vivo confirmation before clinical recommendations can be made regarding treatment protocols. 
However, as T. macrops was also well neutralised, consistent with clinical reports, the congruent 
positive effects upon T. flavomaculatus and T. fucatus in the tests conducted in this study are strongly 
suggestive of clinical usefulness of the antivenom against these species. In contrast, the poor 
performance of the antivenom against T. gumprechti and T. mcgregori, and failure against T. hageni, 
is cause for significant concern, despite the ideal scenario of preincubation of antivenom:venom, is 
cause for significant concern and the likelihood of clinical usefulness for these species is low (T. 
gumprechti and T. mcgregori) to non-existent (T. hageni). Another important note to be made is that 
the antivenom efficacy in this paper is purely from the perspective fibrinogenolysis. Studies into other 
clinically relevant pathophysiological functions, such as myotoxicity, may produce differential 
antivenom efficacy patterns and should be the subject of future research. 
7.5 Materials and Methods  
7.5.1 Venoms  
A total of 13 venoms from the Asian pit viper genus Trimeresurus were investigated for their 
coagulotoxic effects (T. albolabris, T. borneensis, T. flavomaculatus, T. fucatus, T. gumprechti, T. 
hageni, T. macrops, T. mcgregori, T. popeiorum, T. puniceus, T. purpureomaculatus, T. 
trigonocephalus, T. vogeli), which were obtained from the long-term cryogenic collection of the 
Venom Evolution Lab. Pooled (N = 3 adult males for each), lyophilized venom samples were 
resuspended in deionized H2O and protein concentrations (mg/mL) were determined using a 
ThermoFisher Scientific Nanodrop™ 2000c Spectrophotometer. Working stocks of 50% deionized 
water/50% glycerol (>99%, Sigma-Alrich) for all venoms were prepared at 1 mg/mL and stored at  
-20°C to preserve enzymatic activity and reduce enzyme degradation. All venom and plasma work 
was undertaken under the University of Queensland Biosafety Approval #IBC134BSBS2015. 
 
7.5.2 Coagulation analyses on plasma and fibrinogen    
The ability of the Trimeresurus venoms to affect clotting of plasma and/or fibrinogen was 
investigated using a Stago STA-R Max coagulation analyser as previously described (Debono et al., 
2019a; Debono et al., 2019b; Debono et al., 2019c; Debono et al., 2017a). Human plasma (3.2% 
citrate) was supplied by the Red Cross Blood Service (under Research Supply Agreement 18-03QLD-
09), and all work was undertaken under University of Queensland Biosafety Approval 
#IBC134BSBS2015 (1/1/2015) and Human Ethics Approval # 2016000256 (1/6/2016). Human 
fibrinogen (4 mg/mL, Lot#F3879, Sigma Aldrich) was reconstituted to a concentration of 1 mg/mL 
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in 150 mM NaCl2, 50 mm Tris, pH 7.3, flash frozen in liquid nitrogen and stored at −80 ºC until 
further use. Coagulopathic toxin effects were measured by a modified procoagulant protocol on a 
Stago STA-R Max coagulation robot (France) using Stago Analyser software v0.00.04 (Stago, 
Asniéres sur Seine, France). Plasma clotting baseline parameters were determined by performing the 
standardised activated Partial Thromboplastin Time (aPTT) assay (TriniCLOT APTT HS, Stago). In 
order to determine clotting times effected by the addition of varying venom concentrations, a 
modified clotting test was developed, in which 50 μL of venom (20 – 0.05 µg/mL) dilutions in STA 
Owren Koller Buffer (Stago Cat# 00360), 50 μLCaCl2 (25mM stock solution Stago Cat# 00367 STA), 
and 50 μL phospholipid (solubilized in Owren Koller Buffer adapted from STA C.K Prest standard 
kit, Stago Cat# 00597) in a final volume of 175 μL in Owren Koller Buffer was incubated for 120 sec 
at 37°C before adding 75 μL of human plasma or human fibrinogen (1.2 mg/mL final). Relative 
clotting was then monitored for 999 sec or until plasma clotted (whichever was sooner). The calcium 
or phospholipid dependence was assessed by replacing calcium or phospholipid for Owren Koller 
Buffer, respectively. Inhibition of venom serine protease activity was determined using 4-
benzenesulfonyl fluoride hydrochloride (AEBSF), a known serine protease inhibitor (Kuniyoshi et 
al., 2017; Torres-Bonilla et al., 2018; Xin et al., 2009; Yamashita et al., 2014) in the modified clotting 
assay. For this purpose, 25 μL of (diluted) venom, 50 μL CaCl2 (5 mM final), 50 μL phospholipid, 
and 50 μL AEBSF (2 mM final) were incubated for 2 min at 37°C before adding 75 μL of human 
fibrinogen (1.2 mg/mL final). As a control, fibrinogen clotting was measured using thrombin (stable 
thrombin from Stago Liquid Fib kit, unknown concentration from supplier (Stago Cat#115081 Liquid 
Fib)). Change in Area Under the Curve (AUC) was used as a statistical representation to relative 
influence of cofactors (calcium or phospholipid) or the impact of antivenom. An increase in the AUC 
represents longer clotting times compared to the optimum conditions (control). AUC values were 
calculated using the program GraphPad PRISM 8.0 (GraphPad Prism Inc., La Jolla, CA, USA) using 
the following formula: ΔX*(Y1+Y2)/2. Each experimental condition AUC was divided by control 
AUC for each venom, and then 1 subtracted so that if there was no change, then this would have been 
a value of zero. The results were then multiplied by 100 in order to present them as % change.  
 
7.5.3 Inhibition of FIXa, FX or thrombin  
Additional studies in which the inhibition of serine proteases FXa, prothrombinase complex 
formation, thrombin, or FIXa (working stock of 0.17 mg/mL so that 5 µg/mL of FIXa is in end 
concentration, Haematological technologies Cat# HCIXA-0050, Essex Junction VT USA), Table 7.1) 
by Trimeresurus venoms were performed using previously validated methods  (Debono et al., 2019a; 
Debono et al., 2019b; Debono et al., 2019c; Youngman et al., 2018). All species were subjected to 
these assays. To identify the possible target in the clotting cascade which the venom was acting upon 
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to result in the anticoagulant activity, either plasma or individual factors of the clotting cascade were 
incubated with the sample venom as the incubation step allows venom to bind and inhibit its target. 
Data was analysed calculating a shift away from the control for each assay using GraphPad PRISM 
8.0 (GraphPad Prism Inc., La Jolla, CA, USA) as described above.   
 
Table 7.1 Anticoagulation assay details 
 
FXa inhibition assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock diluted 
with OK buffer) + 50 μL 0.025 M calcium (Stago catalog # 00367) + 
50 μL phospholipid (Stago catalog #00597) + 25 μL FXa (Stago 
catalog # 00311). 
Step 2. 120 second incubation. 
Step 3. Addition of 75 μL plasma. 
Prothombinase 
complex inhibition 
assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock diluted 
with OK buffer) + 50 μL 0.025 M calcium + 50 μL phospholipid + 
75 μL plasma 
Step 2. 120 second incubation. 
Step 3. Addition of 25 μL Factor Xa 
FIXa inhibition assay 
Step 1. 25 μL 0.1 μg/mL venom (2 mg/mL 50% glycerol stock diluted 
with OK buffer) + 75 μL 0.025 M calcium (2:1 ratio of CaCl2 + OK 
buffer) + 50 μL phospholipid + 25 μL FIXa (Haematological 
technologies Cat# HCIXA-0050)   
Step 2. 120 second incubation. 
Step 3. Addition of 75 μL plasma 
Thrombin inhibition 
assay 
Step 1. 50 μL 0.1 μg/mL venom (1 mg/mL 50% glycerol stock diluted 
with OK buffer) + 50 μL 0.025 M calcium + 50 μL phospholipid + 
25 μL thrombin (Stago catalog # 00611). 
Step 2. 120 second incubation. 
Step 3. Addition of 75 μL 4 mg/mL fibrinogen. 
 
 
7.5.4 Thromboelastography analyses on plasma and fibrinogen  
Venoms were investigated for their ability to clot or impede clotting of plasma and fibrinogen using 
a Thrombelastogram® 5000 Haemostasis analyser (Haemonetics®, Haemonetics Australia Pty Ltd, 
North Rdye, Sydney 2113, Australia) as previously described (Coimbra et al., 2018; Debono et al., 
2019a; Debono et al., 2019b; Debono et al., 2019c; Oulion et al., 2018). Human fibrinogen (4 
mg/mL,) was reconstituted in enzyme buffer (150 mM NaCl and 50 mM Tri-HCl (pH 7.3)). Briefly, 
7 μL venom working stock (1 mg/mL) or 7 μL thrombin as a positive control (stable thrombin from 
the Stago Liquid Fib kit, unknown concentration from supplier, (Stago Cat#115081 Liquid Fib)), 72 
μL CaCl2 (25mM stock solution, Stago Cat# 00367 STA), 72 μL phospholipid (solubilized in Owren 
Koller Buffer adapted from STA C.K Prest standard kit, Stago Cat# 00597), and 20 μL Owren Koller 
Buffer (Stago Cat# 00360) was combined with 189 μL fibrinogen or human plasma and run 
immediately for 30 min to allow for ample time for clot formation. An additional positive control of 
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7 μL Factor Xa (unknown concentration from supplier, Liquid Anti-Xa FXa Cat#253047, Stago) was 
also incorporated for plasma only. If no clot was formed for a venom in the fibrinogen assay by 30 
minutes, 7 μL thrombin (stable thrombin from Stago Liquid Fib kit, unknown concentration from 
supplier (Stago Cat#115081 Liquid Fib)) was added to ascertain if destructive cleavage of fibrinogen 
had occurred due to the venom.  
Parameters obtained from thromboelastography analysis were: SP = split point, time taken until clot 
begins to form (min); R = time to initial clot formation where formation is 2 mm+ (min); 
A = amplitude of detectable clot (mm); MRTGG = maximum rate of thrombus generation (dsc, 
dynes/cm2/sec); TMRTG = time to maximum rate of thrombus generation (min); and TGG = total 
thrombus generation (dynes/cm2). Statistical analysis of speed of reaction and the clot size formed 
was conducted using Phylogenetic Generalized Least Squares (PGLS), including the parameters p = 
p value, probability, df = degrees of freedom and t = t value, calculated difference of standard error. 
 
7.5.5 Fibrinogenolysis analysis  
Fibrinogenolytic activity was assessed as previously described (Debono et al., 2019a; Debono et al., 
2019b; Debono et al., 2019c). In brief, fibrinogen (1 mg/mL reaction concentration, 150 mM NaCl / 
50 mM Tri-HCl (pH 7.3), Lot#F3879, Sigma Aldrich, St. Louis, Missouri, United States) was 
incubated with venom (10 µg/mL reaction concentration) for 60 min at 37ºC, and fibrinogen cleavage 
was assessed at several time points (1, 5, 10, 15, 20, 30, 45 and 60 min) using SDS-PAGE analysis 
under reducing conditions followed by staining with Coomassie Brilliant Blue R-250. The visualized 
protein fragments were quantified using ImageJ software (V1.51r, Java 1.6.0_24, National Institutes 
of Health, Bethesda, Maryland, USA) and analysed using GraphPad PRISM 7.0 (GraphPad Prism 
Inc., La Jolla, CA, USA). 
 
7.5.6 Fibrinolysis  
The ability of venoms to actively lyse clots was investigated following methods described previously 
(Debono et al., 2019a; Debono et al., 2019b; Debono et al., 2019c). Varying concentrations of venom 
(1 – 0.1 µg/μL) were tested either with or without the addition of tissue plasminogen activator (tPA, 
Sekisui Diagnostics, Lexington, MA, USA). Briefly, tissue factor (TF, Innovin, Siemens, USA) and 
phospholipid vesicles (PCPS, 75% phosphatidylcholine and 25% phosphatidylserine, Avanti Polar 
Lipids, Alabama, USA) were incubated at 37°C for 1 hour in HEPES buffer (25 mM HEPES, 137mM 
NaCl, 3.5 mM KCl, 0.1% BSA (Bovine Serum Albumin). To the TF/PCPS mixture (1.8 pM/3 μM 
final), CaCl2 (17 mM final), tPA (37.5 units/mL reaction concentration, diluted in 20 mM HEPES, 
150 mM NaCl, 0.1% PEG-8000, pH 7.5), venom (50% v/v), and plasma (50% v/v, prewarmed at 
37°C) were added. The fibrin clot formation and the subsequent lysis was monitored by measuring 
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the absorbance at 405 nm for every 30 sec during 3 hr at 37°C in a SpectraMax M2e microplate 
reader. The onset of clot formation was defined as the time point at which the turbidity increased 
(delta absorbance > 0.04); the clotting time was the time from the start of the assay to the onset of 
clot formation. The clot lysis time was the interval between the clear to turbid transition (defined as 
the midpoint between the onset of clot formation and the maximum turbidity) and the turbid to clear 
transition; the latter was determined by a sigmoidal fit of the turbidity plots using GraphPad PRISM 
8.0 (GraphPad Prism Inc., La Jolla, CA, USA). 
 
7.5.7 Antivenom efficacy assessment  
The monovalent antivenom effects on all 13 Trimeresurus crude venoms was investigated using 
fibrinogen clotting assays as described above. The monovalent Green Pit Viper Antivenin 
(Trimeresurus albolabris) (Lot #TA00119, Expiry date: 15th Jan 2024) was purchased from Queen 
Saovabha Memorial Institute, The Thai Red Cross Society, Bangkok, Thailand. One vial of dry 
antivenom was reconstituted in 10 mL provided saline solution (using manufacturers guide) and 
centrifuged at 12000 rpm on an Allegra™ X-22R Centrifuge (Lot#982501, Beckman Coulter, Brea, 
CA, USA) for 10 min at 4°C, upon which the supernatant was removed, filtered (0.45 µm Econofltr 
PES, Agilent Technologies, Beijing, China), aliquoted, and stored at 4°C. For each experiment, a 
working stock of 5% antivenom and 95% Owren Koller Buffer was prepared, and the final antivenom 
concentration for each reaction was 0.5%. Briefly, 25 μL of antivenom diluted in STA Owren Koller 
Buffer, 50 μL of venom (20 – 0.05 µg/mL) dilutions in STA Owren Koller Buffer, 50 μL CaCl2 (5 
mM final), and 50 μL phospholipid in a final volume of 175 μL in Owren Koller Buffer was incubated 
for 120 sec at 37°C before adding 75 μL of human fibrinogen (1.2 mg/mL final). Relative clotting 
was then monitored for 999 sec or until plasma clotted (whichever was sooner). Note that antivenom 
does not clot fibrinogen and that a control was performed to rule out any additional effects antivenom 
has on fibrinogen, in which antivenom was substituted into the above outlined protocol in replacement 
of a venom sample. 
 
7.5.8 Phylogenetic comparative analyses  
The phylogenetic tree used was based upon a previously published species tree (Alencar et al., 2016; 
Malhotra and Thorpe, 2004).  and manually recreated using Mesquite software (version 3.2) and then 
imported to Rstudio using the APE package (Paradis et al., 2004). Ancestral states were estimated for 
all traits using maximum likelihood as implemented in the contMap function of the R package 
phytools (Revell, 2012). As in previous studies with these methods (Lister et al., 2017; Rogalski et 
al., 2017), we used the phytools script shown in Supplementary Figure 1.  
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Chapter 8: Viper venom botox: the molecular origin and evolution of the 
waglerin peptides used in anti-wrinkle skin cream 
 
8.1 Abstract 
The molecular origin of waglerin peptides has remained enigmatic despite their industrial application 
in skin cream products to paralyse facial muscles and thus reduce the incidence of wrinkles. Here we 
show that these neurotoxic peptides are the result of de novo evolution within the prepro region of 
the C-type natriuretic peptide gene, at a site distinct from the domain encoding for the natriuretic 
peptide. The precursor region for the molecular evolution is a biodiversity hotspot that has yielded 
other novel bioactive peptides with novel activities. We detail the diversity of components in this 
region in order to explore what characteristics enable it to be such a biodiscovery treasure trove. 
8.2 Introduction 
Tropidolaeumus (temple vipers) venoms are unusually neurotoxic for vipers, selectively blocking the 
post-synaptic nicotinic acetylcholine receptors (epsilon subunit) to produce rapid collapse, spasms, 
ocular proctosis and tachypnea in prey, with death resulting from respiratory failure (Fry et al., 2015b; 
Lin et al., 1995; McArdle et al., 1999; Schmidt and Weinstein, 1995; Schmidt et al., 1992). These 
effects are produced by short (21 amino acid) peptides which do not display any homology to any 
other known peptide type and thus the gene precursor identity is unknown (Fry, 2005; Fry et al., 
2015a).  
A skin-cream with the trade name Syn®-Ake has been developed using the tripeptide synthetic 
compound dipeptide diaminobutyroyl benzylamide diacetate (molecular formula of C23H37N5O7 and 
a molecular weight of 495.57 g/m) to mimic the action of the full length peptide (Balaev et al., 2014; 
Trookman et al., 2009). Similar to botox, it blocks signal transmission and relaxes the muscles at the 
area of application, in order to reduce the formation and appearance of wrinkles.  
Despite the industrial usefulness of these peptides, their molecular origin and evolution has remained 
unelucidated. It has previously been hypothesised that based on the proline-rich nature, that they share 
evolutionary relationships with the neurotoxic peptides from Azemiops feae (Brust et al., 2013; Fry, 
2005; Fry et al., 2003b). However, in the absence of a gene sequence, this link has remained 
speculative.  
8.3 Results and Discussion 
Sequence blasting revealed cDNA library ORFs containing regions with homology to waglerin 
peptides (Figure 8.1 and Figure 8.2). Like waglerins 2 and 4 from T. wagleri, the version from T. 
subannulatus contained a -CYPPC- motif instead of CHPPC as seen in waglerins 1/3 from T. wagleri, 
a change that slightly decreases activity (Schmidt et al., 1992). As toxins evolve under selection 
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pressure towards a more potent form, this indicates that the -CYPPC- motif is the plesiotypic form, 
with the change from Y to H as a structural derivation that impacts upon functionality.  
Blasting of the full length gene sequence identified the precursor as that which encodes for C-type 
natriuretic peptides. Sequence alignment (Figure 8.1) revealed that the wagerlin peptides evolved 
within the same proline-rich region of the prepro domain as did the Azemiopsin peptides from 
Azemiops feae (Brust et al., 2013) but in a region distinct from that encoding for the also de novo 
evolved bradykinin potentiating peptides such as Captopril (Fry et al., 2015a). Phylogenetic analysis 
showed the affinity of the waglerin peptides with the Azemiopsis peptides, confirming that the two 
types of post-synaptic nicotinic acetylcholine receptor binding peptides share a common molecular 
evolutionary history, with the cysteines of waglerin peptides representing a derived state. 
De novo evolution of novel proline-rich bioactive peptides within the propeptide region of natriuretic 
peptides has not only occurred in the snake venoms (Fry et al., 2015a), but also independently in the 
natriuretic peptide form (B-type) convergently evolved within lizard venoms (Fry et al., 2015d). This 
reinforces the dynamic nature of this region, which is distinct from that encoding the plesiotypic 
natriuretic peptide. Genes coding for the normal body form do not have such proline rich regions 
(Figure 8.1). Another example of de novo evolution of bioactive peptides within a propeptide region 
has occurred in Psammophis mossambicus which has a myriad of bioactive peptides (Brust et al., 
2013; Fry et al., 2008). These include novel neurotoxins which have explosively evolved within the 
propeptide region of the snake venom metallaprotease gene, accompanied by stop-codons, preventing 
expression of the metalloprotease enzyme that was the original function of this gene   
These variants underscore the dynamic nature of venom evolution, which not only accelerates the 
molecular evolution of the plesiotypic proteins, but may result in neofunctionalisation in gene regions 
not normally associated with a secreted product.  This study also reinforces the value of studying 
evolutionarily diverse lineages as sources of novel lead compounds for drug design and development.  
8.4 Methods  
Sequencing and phylogenetic analysis of Bicol, Philippines Tropidolaemus subannulatus cDNA 
library sequences were undertaken using methods previously described by us (Fry et al., 2008).  
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Figure 8.1 Waglerin’s natriuretic peptide  
1. P24335 (waglerin-1/3) Tropidolaeumus wagleri, 2. P58930 (waglerin-2/4) Tropidolaeumus 
wagleri 3. S9L004TR1742 Tropidolaeumus subannulatus, 4. K4IT20 Azemiops feae, 5. Q9PW56 
Bothrops jararaca, 6. A0A0B4SX88 Philodryas chamisso, 7. A8YPR6 Echis ocellatus, 8. P23582 
Homo sapiens. Post-translationally cleaved peptides are highlighted in gray, including the ancestral 
natriuretic gene, cysteines are underlined. 
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Figure 8.2 Bayesian reconstruction of C-type NP 
Bayesian reconstruction of venom CNP molecular evolution.   
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Chapter 9: Conclusions and future directions   
 
9.1 Research overview  
The venomous snake species chosen for this thesis are a representation of a wide array of coagulotoxic 
venoms targeting multiple aspects of the clotting cascade from a broad spectrum of genera and 
geographical locations. All species included within this thesis are medically important or significant, 
effect the coagulation cascade, have limited research and understanding of their venom or have been 
completely neglected from the literature. Both procoagulant and anticoagulant species were included 
in order to ascertain differential selection pressures acting upon either mechanisms. Each chapter is a 
piece of the puzzle into increasing our understanding of snake venom coagulotoxins and novel drug 
design. Chapters 2 and 3 explored the procoagulant venoms of the infamous colubrid species the 
boomslang and the twig snake of Africa, while chapters 4-8 explored the extreme diversification that 
is Asian pit viper venom which was broken up into genus or smaller clades for easier digestion of 
results. In doing so, the following key findings could be achieved over the course of this research.  
9.2 Key findings  
9.2.1 Procoagulation  
As mentioned previously, procoagulation in venom is the more derived mechanism for subjugation 
of prey, with anticoagulation being an ancestral characteristic of snake venoms. Procoagulation is the 
result of toxins activating either Factor X or prothrombin to generate endogenous thrombin, which in 
turn cleaves fibrinogen to form strong, stable fibrin clots The boomslang (D. typus) and the twig 
snake (T. mossambicanus) are two procoagulant species which produce hemorrhagic symptoms in 
human bite victims. This is due to the mass production of microscopic clot formations, which 
combined with unregulated clotting from check points such as tPA, antithrombin or activated protein 
C, causes mass hemorrhaging post-envenomation. Both species have evolved their venom to activate 
prothrombin producing endogenous thrombin in large amounts, ultimately leading to a stroke (in prey 
items) or hemorrhaging (in larger victims) via PIII-SVMPs. Interestingly, unlike well know 
procoagulant species such as Pseudonaja textilis, Oxyuranus scutellatus or Notechis scutatus, which 
all require (to varying degrees) calcium and phospholipid as co-factors, D. typus and T. 
mossambicanus do not require the additional co factors calcium or phospholipid to produce such 
striking procoagulation effects. This has only ever been previously described from Echis carinatus 
‘Ecarin’, which is routinely used in diagnostic tools. Furthermore, as these two species produce such 
extremely similar clinical symptoms and occupy the same habitat, it is interesting that antivenom 
exists and is only effective against one species, D. typus. As SVMPs are the driving force behind the 
prothrombin activation exhibited by both species, we hypothesized that the additional SVMP 
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identified and isolated from T. mossambicanus was why the D. typus antivenom was almost 
completely ineffective at cross neutralization due to differences in the surface geometry (antigenicity) 
driving down the effectiveness of the D. typus antivenom against T. mossambicanus.  
Procoagulation was also evident among the Asian pit vipers, with results indicating Calloselasma 
rhodostoma as a true procoagulant species in contrast to the anticoagulation displayed by other Asian 
pit vipers. Although this has been mentioned previously within the literature eg (Tang et al., 2016; 
Yamada et al., 1997), our investigation was able to distinguish that C. rhodostoma activates Factor X 
to produce endogenous thrombin, resulting in strong, stable clots. Deinagkistrodon actus and Hypnale 
hypnale also displayed the ability to clot plasma; however, H. hypnale only activated FX mildly, 
while D. actus did not activate FX. All three species were able to cleave fibrinogen as an alternative 
site of action; however, fibrinogen cleavage alone did not form strong, stable clots and therefore it 
was not concluded that H. hypnale or D. actus were also true procoagulant species but were pseudo-
procoagulant in that they produced weak, transient fibrin clots resulting in the depletion of fibrinogen 
levels. Additional activation sites using H. hypanle venom were also investigated however only 
negative results were obtained and so it remains a mystery as to the coagulation mechanism of H. 
hypnale venom.  
 
9.2.2 Anticoagulation  
As shown throughout this thesis, there are multiple ways to cause an anticoagulant effect. The main 
site of action for species investigated was fibrinogen. By disrupting fibrinogen either via destructive 
cleavage of fibrinogen so that no fibrin clot is formed, or via irregular cleavage of fibrinogen so that 
weak, transient clots are formed resulting in a pseudo-procoagulant effect (due to their inherent 
instability), depletion of available fibrinogen can be achieved resulting in an overall net anticoagulant 
effect. Effects on fibrinogen as a mode of action is evident across the entire Asian pit viper clade, and 
supports clinical manifestations and presentations of hemorrhaging. Surprisingly, a pseudo-
procoagulant mode of action was more common than direct anticoagulant effects, as exhibited by 
species Gloydius brevicaudus, G. saxatilis, G. ussuriensis, Protobothrops flavoviridis, P. 
mucrosquamatus and P. tokarensis. All of these species acted directly as anticoagulant venoms by 
effecting FXa inhibition in some capacity, whether potently or moderately, however destructive 
cleavage of fibrinogen was the main site of action. On the other hand, pseudo procoagulation 
dominated the remainder of the species within the Asian pit viper clade with varying effects on time-
to-clot and strength of clot. Some species exhibited procoagulant tendencies such as Gloydius 
tsushimaensis, Ovophis okinavensis, Protobothrops jerdonii, P. mangshanensis, Trimeresurus 
albolabris and T. borneensis, which all exhibited quick clotting times on plasma and fibrinogen (with 
varying degrees of co factor dependency). However, with further investigation into clot strength via 
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thromboelastography, the true nature of clots produced by these venoms could be determined as 
pseudo-procoagulant. In addition to these species (as well as others), the toxins which contribute to 
this effect differ and belong to either a venom dominated by metalloproteases or serine proteases. 
This in itself, along with mode of action, depicts the extreme diversification that is Asian pit viper 
venom, and the rapid radiation that has occurred since their divergence.  
 
9.2.3 Other toxins  
Not all species investigated within this thesis exhibited coagulotoxic affects. Members of the basal 
clade (Chapter 4), including Azemiops feae, Tropidolaemus subannulatus and T. wagleri, either had 
no effect on coagulation or only limited response to coagulation investigations. Thromboelastography 
studies illustrated that only T. wagleri displayed action upon fibrinogen, albeit only a moderate level 
resulting in a pseudo-procoagulant activity, while T. subannulatus (sister species) did not display 
such activity. Azemiops feae also did not display any coagulotoxic action. Both Azemiops and 
Tropidolaemus are known to have venom which contains novel neurotoxic peptides rather than the 
larger enzymes typical of viperid venoms (Schmidt and Weinstein, 1995; Shelukhina et al., 2018; 
Tan et al., 2017b), which is consistent with these findings. As shown in Chapter 8, the neurotoxic 
peptides emerged in the venoms from de novo evolution of novel bioactive peptides in the propeptide-
region of the venom forms of C-type natriuretic peptides (Brust et al., 2013; Debono et al., 2017b). 
However, as these genera are not sister and occupy very different ecological niches (semi-fossorial 
for Azemiopis and arboreal for Tropidolaemus), selection pressures for the molecular evolution of the 
peptides differ. These findings again point to the extreme diversification within Asian pit viper 
venom, and the need for thorough investigation into these amazing venoms.  
 
9.2.4 Therapeutic applications  
While our knowledge of venom evolution and venom composition increases, so does the avenues for 
novel therapeutic applications from these aforementioned venoms. The diversification within one 
genus, let alone a whole clade of venoms, highlights the importance of such research to improve 
current treatments available, improve antivenom cross neutralization and open doors for novel drug 
design for blood clotting disorders. Harnessing such naturally diverse modes of action upon the 
coagulation cascade can facilitate much improved drug design and application. For example, 
designing diagnostic applications utilizing the Group A Prothrombin activating PIII-SVMPs of T. 
mossambicanus, or preventative stroke medications based off the selective fibrinogen chain 
degradation of a multitude of species similar to that of Calloselasma rhodostoma (namely ‘Arvin’), 
or the FX procoagulant effects of Calloselasma rhodostoma for use in surgery are all potential 
therapeutic avenues. ‘Venoms to drugs’ is not a newly coined term, and has been the subject of much 
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investigation for the past 50+ years. However, as our understanding of the human body and the 
diseases that come with it increases, our need for more naturally derived products to combat such 
disorders rises. And so, venom and its use in therapeutic applications is now more important than 
ever, and the treasure trove that is venom is endless.  
9.3 Future directions  
The chapters in this thesis provide a comparative insight into a range of coagulotoxic venoms and 
modes of actions behind such a diverse group of snakes. However, it also introduces a large number 
of unanswered questions and ideas for future studies. Research into these venoms and their 
coagulotoxicity reveals areas of further investigation, especially into antivenom cross-neutralization 
and production. Many venoms within this thesis lack available antivenom, and in many cases the only 
available antivenom poorly neutralizes the venom in question (for example Thelotornis 
mossambicanus by the Boomslang antivenom, or Trimeresurus hageni by the Green pit viper 
antivenom). Ideally, every venom would have its own antivenom, however this is not feasible due to 
production issues and costs associated with production. In addition, access to proper medical 
facilitates is not always easy once envenomated, as well as access to proper education around what 
to do if bitten. Many of the species investigated within this thesis occupy habitats close to or within 
human populations, and in the some of the world’s poorest communities. If bitten, victims are 
burdened with the decisions to either ‘A’, travel to the hospital and possibly receive some sort of 
antivenom which then will cost the family their annual salary, or ‘B’, succumb to less than acceptable 
unproven and not clinically validated ‘medical’ practices. If the victim survives, they are usually 
almost always left with permanent, debilitating disabilities, a huge debt and loss of lively hood due 
to their inability to work. Future directions into either more affordable antivenom, better neutralizing 
antivenom or snake bite education surrounding these venomous species could lead to some surprising 
results.  
In addition to this, future directions could also be aimed at supplementary anticoagulant investigation 
into species such as Hypnale Hypnale, exploring both FIX and FXI as possible sites of action. 
Furthermore, directions should also be aimed at specific toxin investigations behind the modes of 
action and coagulotoxic mechanisms, which would open up therapeutic application specificities. And 
finally, investigating additional species of Trimeresurus and Gloydius, as well as their geographical 
range, for a more robust conclusion surrounding venom shift within a species.   
9.4 Conclusion  
Coagulation and coagulotoxins are extremely diverse in both type and mode of action. Coagulotoxins 
can affect any part of the coagulation cascade, and these sites of action can differ widely depending 
on the type of toxin, be it serine protease or metalloprotease, and the synergistic effects associated 
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with it. This thesis provides a broad outlook at coagulation effects from two distinct families of 
venomous snake, Colubridae and Viperidae, each with limited research having been conducted prior 
to this investigation. This thesis also provides the first in depth investigation into Thelotornis 
mossambicanus and the mechanisms behind its procoagulant venom, as well as the first in depth 
investigation into the entire clade of Asian pit vipers and their diverse modes of action. This thesis 
highlights the rapid and extreme venom evolution that has taken place within both families and the 
results of such selection pressures on their venom. These results also highlight the diversification of 
venom and substantial variation that exists between sister genera, which can provide valuable 
information about clinical effects as well as antivenom neutralization. The findings of this thesis 
provide an important stepping stone in increasing our knowledge of the pathological relationship 
between venom and the human coagulation cascade, as well as the diversity of components and 
characteristics which enable venom research to be such a biodiscovery treasure trove in the boundless 
diversity that exists, providing a firm foundation on which future research can be established. 
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Appendix 
Supplementary Table 6.1 Gloydius antivenom 
Current antivenom manufactured for Gloydius species. 
http://www.who.int/bloodproducts/snakeantivenoms/database (WHO, 2010). 
Antivenom 
name 
Manufacturer Country Gloydius species 
included in 
immunising 
mixture 
Additional species 
Freeze-dried 
Mamushi 
Antivenom, 
Equine "Takeda" 
(SAsTCI01) 
Takeda Chemical 
Industries Ltd. 
Japan G. blomhoffii  
G. brevicaudus 
None 
Freeze-dried 
Mamushi 
Antivenom 
"Kaketsuken" 
(SAsKKJ01) 
The Chemo-Sero-
Therapeutic 
Research Institute 
(Kaketsuken) 
Japan G. blomhoffii 
G. brevicaudus 
None 
Polyvalent Snake 
Antivenin 
(SAsRII02) 
Razi Serum and 
Vaccine Research 
Institute 
I.R. Iran Gloydius halys Echis carinatus, 
Macrovipera 
lebetina,  
Naja oxiana, 
Pseudocerastes 
persicus,  
Vipera albicornuta, 
Vipera raddei 
Purified 
Agkistrodon 
halys Antivenom 
(SAsSIC01) 
Shanghai Institute 
of Biological 
Products 
Peoples 
Republic 
of China 
G. halys None 
Agkistrodon 
(Salmusa) 
Antivenom 
Korea Vaccine 
Co. Ltd. 
Seoul - 
Republic 
of Korea 
G. brevicaudus 
G. intermedius 
G. ussuriensis  
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Phytools script 
>library(ape) 
>library(maps) 
>library(phytools) 
># senci.contMap is a slight modification of errorbar.contMap that trims 95% CIs 
of ancestral state reconstructions to a sensible range, e.g., for traits bound 
between 0 and 1 
# Example of code for implementing it would be as follows (lines separated 
by semicolons): pasr<-contMap(tree,mapdat,plot=F,lims=c(0,1)) ; 
plot(setMap(pasr,invert=T)); 
senci.contMap(setMap(pasr,invert=T),mini=0,maxi=1) 
senci.contMap<-function(obj,...){ 
if (hasArg(x))  
x <- list(...)$x 
else x <- setNames(sapply(1:Ntip(obj$tree), function(x, obj) { 
ii <- which(obj$tree$edge[, 2] == x) 
ss <- names(obj$tree$maps[[ii]][length(obj$tree$maps[[ii]])]) 
obj$lims[1 ] + as.numeric(ss)/(length(obj$cols) − 1) * 
diff(obj$lims) 
}, obj = obj), obj$tree$tip.label) 
if (hasArg(scale.by.ci)) 
scale.by.ci <- list(...)$scale.by.ci 
else scale.by.ci <- TRUE 
if (hasArg(lwd)) 
lwd <- list(...)$lwd 
else lwd <- 14 
tree <- obj$tree 
aa <- fastAnc(tree, x, CI = TRUE) 
if (hasArg(min))#added lines here 
for (i in 1:length(aa$CI95[,1])){ #added lines here 
aa$CI95[i,1]<-ifelse(aa$CI95[i,1]<list(...)$min,list(...)$min,aa$CI95[i,1]) 
#added lines here 
} #added lines here 
else aa$CI95[,1]<-aa$CI95[,1] #added lines here 
if (hasArg(max)) #added lines here 
for (i in 1:length(aa$CI95[,2])){ #added lines here 
aa$CI95[i,2]<-ifelse(aa$CI95[i,2]>list(...)$max,list(...)$max,aa$CI95[i,2]) 
# added lines here 
} #added lines here 
else aa$CI95[,2]<-aa$CI95[,2] #added lines here 
xlim <- range(aa$CI95) 
if (xlim[2] > obj$lims[2] || xlim[1] < obj$lims[1]) { 
cat(paste(“ -----\n The range of the contMap object, presently (“, 
round(obj$lims[1], 4), “,”, round(obj$lims[2], 4), 
“), should be equal to\n or greater than the range of the CIs on ancestral 
states: (“, 
round(xlim[1], 4), “,”, round(xlim[2], 4), “).\n”, 
sep = ““)) 
cat(paste(“ To ensure that your error bars are correctly plotted, please 
recompute your\n”, 
“ contMap object and increase lims.\n -----\n”, 
sep = ““)) 
} 
d <- diff(obj$lims) 
if (scale.by.ci) { 
v <- aa$CI95[, 2] - aa$CI95[, 1] 
v <- v/max(v) 
} 
else v <- rep(0.5, tree$Nnode) 
n <- length(obj$cols) - 1 
lastPP <- get(“last_plot.phylo”, envir = .PlotPhyloEnv) 
h <- max(nodeHeights(tree)) 
for (i in 1:tree$Nnode) { 
ii <- round((aa$CI95[i, 1] - obj$lims[1])/d * n) 
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jj <- round((aa$CI95[i, 2] - obj$lims[1])/d * (n + 1)) 
cols <- obj$cols[ii:jj] 
add.color.bar(leg = 0.1 * h * v[i], cols = cols, prompt = FALSE, 
x = lastPP$xx[i + Ntip(tree)] - 0.05 * h * v[i], 
y = lastPP$yy[i + Ntip(tree)], title = ““, subtitle = ““, 
lims = NULL, lwd = lwd) 
} 
} 
>data<-read.csv(file.choose()) 
>dat<-data 
>mapvar<-dat$var 
>names(mapvar)<-dat$species 
>tree<-read.tree(file.choose()) 
>tree<-chronos(tree) 
>asr<-contMap(tree,mapvar,plot=F) 
 
To have the red (warmer) zone for the higher numbers (eg antivenom) we then used 
the below.  
>plot(setMap(asr,col=c(1,4,5,3,7,2,6)),lwd=10) 
>senci.contMap(setMap(asr,col=c(1,4,5,3,7,2,6)),lwd=20,min=[minimum value from 
the dataset],max=[minimum value from the dataset]) 
 
To have the red (warmer) zone for smaller numbers (eg clotting time) we then 
used the below 
>plot(setMap(asr,col=c(6,2,7,3,5,4,1)),lwd=10) 
>senci.contMap(setMap(asr,col=c(6,2,7,3,5,4,1)),lwd=20,min=[minimum value from 
the dataset],max=[minimum value from the dataset]) 
 
Supplementary Figure 1: R Phytools script 
R script phytools used for phylogenetic comparative analysis throughout thesis.    
 
